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ABSTRACT
Growth hormone transgenic (GHTg) Atlantic salmon have enhanced growth when
compared to their non-transgenic counterparts, and this trait is beneficial for aquaculture
production. However, there are concerns regarding the potential impacts of transgenic
fish on wild populations. The culture of sterile triploid GH transgenic (3NGHTg) Atlantic
salmon would prevent interbreeding of transgenic fish and wild stocks, thus minimizing
environmental impacts. Generally, the growth performance of triploid salmon relative to
diploid siblings remains an area of investigation. Growth rate of 3NGHTg Atlantic
salmon families were found to significantly vary between families in a breeding program.
In order to identify gene expression correlates of enhanced growth in 3NGHTg Atlantic
salmon, a functional genomics approach (32K cDNA microarrays followed by QPCR)
was used to identify and validate liver transcripts that are differentially expressed between
two fast-growing 3NGHTg Atlantic salmon families (ASII, AS26) and one slow-
growing 3NGHTg Atlantic salmon family (AS25). Of 687 reproducibly informative
microarray features, 143 features (116 more highly expressed in fast-growing, and 27
more highly expressed in slow-growing) were identified in the AS II vs. AS25 microarray
study, while 544 features (442 more highly expressed in fast-growing and 102 more
highly expressed in slow-growing) were identified in the AS26 vs. AS25 microarray
study. In order to identify growth-relevant transcripts that were consistently differentially
expressed between fast-growing and slow-growing 3NGHTg families, the AS II vs. AS25
and AS26 vs. AS25 microarray gene lists were further analyzed using Venn diagrams.
Forty microarray features (39 associated with fast growth and I associated with slow
growth) were present in both microarray comparisons. The expression levels of 15
microarray-identified transcripts were studied using QPCR with individual RNA samples
to validate the microarray results and to study biological variability of transcript
expression. The QPCR results agreed with the microarray results for 12 of 13 putative
fast-growth associated transcripts, but QPCR did not validate the microarray results for 2
putative slow-growth associated transcripts. Many of the 39 microarray features that were
consistently associated with fast-growing 3NGHTg salmon (including ACBP, APOA1,
APOA1V, B2M, D5DP, FTM, GAPDH, and NUPRI) were involved in carbohydrate,
lipid, and amino acid metabolism, iron homeostasis and oxygen transport, and immune-
or stress-related responses. The results of this study increase our knowledge of family-
specific impacts on growth rate and hepatic gene expression in 3NGHTg Atlantic salmon.
In addition, this study provides a suite of rapid growth rate associated transcripts that may
lead to the development of molecular markers (e.g. intronic, exonic or regulatory region
SNPs) for the selection of GHTg Atlantic salmon broodstock that will give rise to sterile
triploids of desired growth performance for future commercial applications.
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1. INTRODUCTION
1.1 Growth hormone (GH) transgenesis of fish
1.1.1 Impact ofGH transgenes on fish growth performance
In the past few years, due to continually decreasing wild fish stocks (Myers et aI.,
1997; Myers and Worm, 2003) and increasing demand of fish for human consumption,
there has been a large expansion of the aquaculture industry (Bostock et aI., 20 I0; Liu
and Sumaila, 2008; Naylor and Burke, 2005). However, the demand continues to grow as
human population increases. For this industry to meet the increased demand, it is
important to develop technologies that can enhance aquaculture production. Transgenesis
is a gene transfer technology that results in the integration of gene(s) of interest into an
organism's genome, changing its genotype and phenotype for desired purposes (e.g.
enhanced growth, increased freeze resistance or disease resistance of fish) (Hew and
Fletcher, 2001; Hew et aI., 1995; Zbikowska, 2003). For example, growth hormone (GH)
transgenes are able to improve the growth rate of various commercially important fish
species, such as Atlantic salmon (Salmo salar) and coho salmon (Oncorhynchus kisutch)
(Devlin et aI., 1994; Du et aI., 1992). The current study involved GH transgenic (GHTg)
Atlantic salmon (AquAdvantage@ salmon) that were previously generated using a gene
construct that contained regulatory sequences from an ocean pout (Macrozoarces
americanus) antifreeze protein (AFP) gene and coding sequence from Chinook salmon
(Oncorhynchus Ishawytscha) growth hormone gene (Butler and Fletcher, 2009). The AFP
gene promoter drives expression of the GH gene in the GH transgene construct, and this
promoter can be regulated (i.e. switched on) by common transcription factors in most fish
species (Hew and Fletcher, 200 I). Moreover, this promoter can be detected in a host by
PCR with ease since most commercially important fish (e.g. salmon, carp, catfish and
tilapia) lack AFP gene in their genomes (Hew and Fletcher, 2001). The average weight of
the GH transgenic Atlantic salmon was 2-4 times higher than non-transgenic siblings in
their first year and they reach market size one year earlier, thereby significantly
shortening the production cycle (Du et aI., 1992; Fletcher et aI., 2004).
In GHTg salmonids, elevated GH expression modifies a number of pathways
mostly through GH-mediated signaling, resulting in changes in feeding behavior (e.g.
Abrahams and Sutterlin, 1999; Devlin et aI., 1999), metabolism (e.g. Cook et aI., 2000;
Leggatt et aI., 2009; Rise et aI., 2006), and development (e.g. Devlin et aI., 2000). The
effects ofGH transgenesis on growth rate are thought to be largely determined by genetic
background, as a study in rainbow trout (Oncorhynchus mykiss) showed that GH
transgenesis (construct OnMTGHl) enhanced the growth rate in slow-growing wild
strains while having very little impact on the growth rate of fast-growing domesticated
(direct selected) strains (Devlin et aI., 2001). Furthermore, a recent transcriptomic study
showed that both domestication and GH-transgenesis modified a set of common pathways
involved in growth-related regulation (e.g. protein synthesis, cell/tissue structure, energy
production, metabolism) in coho salmon muscle and liver tissues (Devlin et aI., 2009).
Given the consistency in molecular mechanisms underlying fast growth observed between
GH transgenic and domesticated coho salmon strains, it is likely that at least one of these
pathways may also play important roles in regulation of growth in triploid salmon.
1.1.2 Obstacles to large-scale commercial aquaculture
GHTg fish are potentially attractive technology products for the development of
the aquaculture industry. However, there are important issues to be addressed for GHTg
fish to become commercially viable. For example, it is necessary to assess the potential
safety issues related to the development and use of this technology and its potential
environmental impacts (Fletcher et aI., 2004). There is a concern that transgenic fish may
accidentally escape from rearing cages and interbreed with wild fish populations, thus
potentially posing threats to the natural environment (Moreau et aI., 2011; Muir, 2004).
To predict the risk, interactions between transgenic fish and cultured/wild non-transgenic
fish have been investigated in a mimic natural environment. Such studies have shown that
GHTg coho salmon exhibited reduced survival and growth rate when food was scarce
(Sundstrom et aI., 2004), and had limited reproductive opportunities and abilities when
compared with wild coho salmon (Fitzpatrick et aI., 2011). Although these findings
suggest a low impact of GHTg escapees on the wild fish populations, it is beneficial to
have a reliable and controllable approach that can minimize or eliminate any possible
interactions between transgenic fish and wild populations and be used for large-scale
application ofGH transgenic fish in the future.
1.2 Triploidization of fish
1.2.1 Induction of triploidization
In past years, there has been concern and speculation regarding the potential
genetic impacts of escaped farmed fish on the fitness of native populations (Hindar et aI.,
2006; McGinnity et aI., 1997; Moreau et aI., 20 11). A land-based culture of domesticated
fish (including transgenics) would be advantageous to reduce the impacts, but it cannot
prevent unlicensed breeding of commercial breeds. Therefore, it would be preferable for
domesticated fish (including transgenics) reared either in land-based facilities or in sea
cages to be reproductively sterile. Among the efforts that have been made in confinement
of transgenic fish, triploidization technology, which renders the fish reproductively
sterile, is approved to be a practical and effective approach to not only reduce negative
effects of sexual maturation on fish production (e.g. weight loss, less desirable flesh
quality) (Felip et aI., 2001; Thorgaard and Gall, 1979), but also effectively minimize
genetic interactions between gene-modified fish and wild populations (Cotter et aI.,
2000).
Triploidization results in the retention of the second polar body of fertilized eggs
during meiosis II division and thus adds an extra set of chromosomes to the fish genome
(Swarup, 1959). With an extra set of chromosomes, triploids have nucleus and cell sizes
that are proportionally increased to approximately 1.5 times larger than the corresponding
cells in diploids; however, the sizes oftriploids' organs remain similar to the diploids as a
result of compensated cell number (Aliah et aI., 1990; Small and Benfey, 1987).
Triploidization can be achieved by applying a thermal shock, hydrostatic pressure,
or chemical shock to diploid fish eggs shortly after fertilization (Benfey and Sutterlin,
1984; Chourrout, 1980; Johnstone, 1985; Solar et aI., 1984). Among these methods, heat
treatment is slightly more effective than cold treatment for coldwater species such as
salmonids, while hydrostatic pressure shock generally shows the most consistent results
for Atlantic salmon and rainbow trout (Reviewed in Ihssen et aI., 1990). Various methods
have been developed to determine triploidy (Maxime, 2008) as triploids and diploids are
mostly indistinguishable in external appearance (Aliah et aI., 1990; Thorgaard and Gall,
1979). Flow cytometry methods employed in the current study allow rapid and accurate
determination of ploidy by analyzing the DNA content in fish red blood cells (Maxime,
2008; Thorgaard et aI., 1982).
1.2.2. Growth performance of triploid fish
The impact of triploidization on the growth performance of teleost fish has been
intensively investigated (Reviewed in Tiwary et aI., 2004). It has been hypothesized that
somatic growth of reproductively sterile triploid fish is increased as their energy
contribution to gonadal development is greatly reduced (Felip et aI., 200 I; Piferrer et aI.,
2009). However, in Atlantic salmon, studies on growth performance of triploids are
equivocal regarding the impact of triploidization on growth. For example, lower survival
and growth rate (McGeachy et aI., 1995) and higher incidence of deformity (Benfey,
200 I; O'Flynn et aI., 1997) have been observed in triploid Atlantic salmon in comparison
to their diploid counterparts, while accelerated growth rate in triploid Atlantic salmon has
also been reported (Gal breath et aI., 1994). The previously published growth performance
response of Atlantic salmon to triploidization may partially be affected by different
rearing conditions (e.g. separated or co-existed rearing of diploids and triploids), but is
also likely to have been influenced by genetic background of fish strains; evidence from
rainbow trout, brown trout (Salmo trutta), and chinook salmon shows a significant
correlation between genetic background and growth performance (Bonnet et aI., 1999;
Johnson et aI., 2004). In addition, other studies have shown that variability in growth
performance is consistently higher among triploid Atlantic salmon families than among
their diploid counterparts (Friars et aI., 200 I; Johnson et aI., 2007). In the current study,
growth data suggested that growth performance of the diploid Atlantic salmon during 45
days did not necessarily correlate with their triploid counterparts. These observations
suggest that triploidization may be an additional source of variability added to genetic
diversity that further complicates the study of the genetic/molecular basis of growth rates
in these fish. It is therefore of great interest to select diploid broodstock that are optimal
for triploid production based on the performance of their triploid offspring. In the current
study, I used a functional genomics approach to identify candidate enhanced growth-
associated transcripts and pathways that may be valuable in the future development of
molecular markers for the selection of GHTg broodstock that will produce rapidly
growing 3NGHTg families.
It is important to note that, due to a putative genome duplication event and
subsequent partial re-diploidization in the salmonid lineage, modem salmonid genomes
are considered to be pseudotetraploid (Davidson et aI., 20 I0); however, to improve
readability of this thesis, the Atlantic salmon genome is referred to as diploid.
1.3 Functional genomics tools and techniques
1.3.1 DNA microarrays
D A microarrays are global gene expression profiling tools. D A microarrays
allow researchers to determine transcript (mRNA) expression levels of thousands of
genes simultaneously, and lead us to a thorough understanding of gene activities involved
in various biological processes that are vital for aquaculture development. For salmonids,
DNA microarray platforms have been developed since 2004. For example, an
approximately 3,500 gene (3.5K) salmonid cDNA microarray (Rise et aI., 2004b) and a
16K salmonid cDNA microarray (von Schalburg et aI., 2005) were produced by the
Genomic Research on Atlantic Salmon Project (GRASP). They were employed in
published studies to characterize gene expression that was involved in salmonid growth
(e.g. Gahr et aI., 2008; Rise et aI., 2006; Tymchuk et aI., 2009), immune response to
pathogens (e.g. Morrison et aI., 2006; Rise et aI., 2004a; Workenhe et aI., 2009), and
exposure to chemicals (e.g. Gallagher et aI., 2008; Gunnarsson et aI., 2007). The current
study utilized a 32K salmonid cDNA microarray platform for gene expression profiling
experiments; this 32K microarray, developed by the consortium for Genomic Research on
All Salmon Project (cGRASP), contains 27,917 Atlantic salmon and 4,065 rainbow trout
cDNA features as well as control features (e.g. Alien oligonucleotide from Stratagene
SpotReport Alien cDNA Array Validation system) (Koop et aI., 2008). Recently, a 44K
salmon id oligonucleotide (oligo) microarray was produced from cGRASP based on
~500K Atlantic salmon ESTs and ~250K rainbow trout ESTs (Koop et aI., 2008).
One of the goals of the cGRASP project was to create tools such as DNA
microarrays for functional genomics studies involving Atlantic salmon, rainbow trout and
other salmonids; these resources were used extensively in my M.Sc. project. By
employing the 32K cGRASP cDNA microarray platform in concert with publicly
available nucleotide and amino acid sequence databases (e.g. National Centre for
Biotechnology Information (NCBI): http://www.ncbi.nlll1.nihYov. Swiss-Prot Protein
Knowledgebase: hltp://www.uniprot.org), expression profiles of growth-related genes in
fast-growing and slow-growing 3NGHTg Atlantic salmon families were studied and
differentially expressed genes were annotated. The genes that I identified in microarray
experiments as differentially expressed in fast-growing and slow-growing 3NGHTg
families may indicate altered molecular pathways involved in various growth-related
biological processes. These results will therefore improve our understanding of the
genetic basis of variable growth rates in 3NGHTg Atlantic salmon. In addition,
identifying genes associated with enhanced growth at the transcript expression level may
lead to the development of markers (e.g. single nucleotide polymorphisms (SNPs) in
introns, exons, and regulatory regions) for marker assisted selection. The next phase of
this research (beyond the scope of this M.Sc. project) will involve mining RNA-
sequencing (R A-seq) data for SNPs in growth-relevant cDNA sequences that may be
suitable molecular biomarkers for the selection of GHTg broodstock that will produce
rapidly growing 3NGHTg families.
1.3.2. QPCR
Quantitative reverse transcription - polymerase chain reaction (QPCR) is a
functional genomics technique that quantifies mRNA expression levels of genes of
interest with high sensitivity and accuracy. It involves the conversion ofmRNA to cDNA
(reverse transcription) and quantification of the level of the mRNA in the sample through
exponential amplification by PCR. QPCR has been used to study expression of genes that
are important for various biological processes in fish and can allow the researcher to
verify the expression levels of genes that have been identified in microarray studies (e.g.
Goetz et aI., 2009; Morais et aI., 20 11; Rise et aI., 2006; Workenhe et aI., 2009). In this
study, I utilized QPCR to determine the relative expression levels of microarray-identified
transcripts of interest (TOIs) in liver from individual fish to assess biological variability
of expression and to validate a subset of the microarray-identified genes.
lA Objectives of study
Previous studies of teleost fish have identified several biological processes and
pathways that can be affected by GH transgenes (Devlin et aI., 2009; Leggatt et aI., 2009;
Rise et aI., 2006); these effects are thought to be influenced by genetic background of the
fish strain (Devlin et aI., 2001). Given that growth rate is a heritable trait for Atlantic
salmon (Reviewed in Garcia de Leaniz et aI., 2007), I hypothesize that growth
performance of 3NGHTg Atlantic salmon is associated with their genetic
backgrounds, which have strong influences on expression levels of growth-relevant
genes in various molecular pathways.
[n this study, six passive integrated transponder (P[T)-tagged 3NGHTg Atlantic
salmon families were assessed for weight and length at initial and final time points
(approximate[y 45 days apart). The weight-specific growth rate (SGRw) and [ength-
specific growth rate (SGRL) indicated significant variability of growth performance
between families. A functional genomics approach was used to identify and validate
hepatic transcripts that are associated with growth performance in 3NGHTg Atlantic
salmon. The constitutive hepatic transcriptome of two families of fast-growing 3NGHTg
Atlantic salmon were compared to that of a family of slow-growing 3NGHTg At[antic
salmon in two independent microarray comparisons using the 32K cGRASP cDNA
microarray platform (Koop et aI., 2008). Fifteen microarray-identified genes with growth-
relevant functional annotations were selected for QPCR study to validate the microarray
results and to assess the biological variability of transcript expression.
I.S Hepatic transcript expression studies in 2N and 3N GHTg At[antic salmon
While the primary focus of my M.Sc. research was on hepatic gene expression
correlates of differential growth rate among 3NGHTg Atlantic salmon families, [ also
used microarrays and QPCR to investigate the impact of trip[oidization on hepatic
transcript expression in GHTg Atlantic salmon. G[oba[ transcript expression in liver
tissues of three diploid GHTg salmon families (AS[ [, AS25, and AS29) was compared to
that of the corresponding triploid families using the 32K cDNA microarray platform
following the same procedures used for the primary growth-related study. The
triploidization microarray experimental design and overview of results are shown in
[0
Appendix XIV. Families AS 11, AS25, and AS29 were selected for the triploid versus
diploid gene expression analyses due to enhanced or depressed growth performances
post-triploidization (Appendix XIII). This research will not only help us to understand the
underlying mechanisms of the impact of triploidization on GHTg Atlantic salmon
families, but will also offer an opportunity to test correlation in growth performance
between diploids and triploids. As a result, hepatic transcripts up-regulated or down-
regulated by triploidization, and biological processes associated with these transcripts,
were identified (Appendix VII-XII). Some of the informative transcripts identified in the
triploid vs. diploid microarray experiment were further studied using QPCR with
individual liver samples to validate microarray results and to assess the biological
variability in different GHTg families (Appendix XV). The microarray and QPCR data
related to the impact of triploidization on the hepatic constitutive transcriptome will
contribute to a manuscript (for submission to a peer-viewed journal) on which I am the
second author. The authorship and contributions to this research are clarified in the Co-
authorship statement.
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2. MATERIALS AND METHODS
2. t Fish husbandry and family selection
All experiments were conducted following the Canadian Council on Animal Care
(CCAC) guidelines and were approved by Institutional Animal Care Committees (IACC)
of both AquaBounty and Memorial University of Newfoundland.
In this study, each of 19 families of GHTg Atlantic salmon was obtained by
fertilization of eggs from a non-transgenic female Atlantic salmon with milt from a
hemizygous (i.e. having one copy of the growth hormone transgene) AquAdvantage@
(Aqua Bounty Canada, Fortune, Souris, PE) male. For each family, one-half volume of the
fertilized eggs was treated with hydrostatic-pressure (9500 pounds per square inch (psi)
for a period of five minutes at 300 degree minutes (deg-min) post-fertilization) to induce
triploids. The eggs were incubated in stacked incubation trays (10 L) until hatch when the
yolk-sac fry were transferred to individual tanks in the early rearing area. The yolk-sac
fry were first cultured in a flow-through system and then moved to a recirculation system
when they reached -I g in weight. Fish of different ploidy were cultured separately in
combi-tanks (500 L for early sac-fry or 1500 L for later stages). Density in the tanks was
maintained at < I kg m-3. Fish were reared with 24 hours light and fed to satiation with a
commercial salmon diet of appropriate composition and pellet size at different
developmental stages (e.g. Skretting Nutra ST, Nutra Fry, & Optiline (1.0 - 4.0 mm),
Vancouver, BC). The water temperature was maintained at l3°C and dissolved oxygen
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was kept >90% of air saturation. Approximately 95 days after first feeding (May 20-26,
2009), 50 fish from each family were assessed for weight, length, and visible deformities.
Based on this assessment, three families with larger body size and three families with
smaller body size were selected from the 19 families. At the initial time point (tl; July 27-
29, 2009), 18 fish selected from each of these six families were PIT-tagged. These fish
were then assessed for weight, length, and visible deformities before being evenly
distributed into three 500 L tanks (6 fish/family/tank; a total of 36 fish per tank).
Approximately 45 days later at the final time point (t2; September 9-10, 2009; tissue
sampling for functional genomics study), nine fish were arbitrarily selected from each of
the six families, with three fish from each of the triplicate tanks, had their PIT tags read
and were assessed for weight, length, and visible deformities followed by tissue sampling.
For family AS29, AS26, and AS33, one additional fish (for a total of 10 fish) was
assessed and sampled to ensure a minimum of three females and three males (based on
gross gonad morphology) within each family. To quantitatively analyze the growth
performance of these six families, length-specific growth rate (SGRL) and weight-specific
growth rate (SGRw) were calculated using the following equation:
SGR = In;:~/I~') x 100
In the above equation, Xl and X2 represent weight or length obtained at time point tl and
t2, respectively. One-way analysis of variance (ANOVA) followed by Tukey's post-hoc
test (Systat Software Inc., San Jose, CA) was utilized to identify significant (p < 0.05)
differences in growth parameters (initial weight or length, final weight or length, SGRL
and SGRw) among the six PIT-tagged families. In a functional genomic study aimed to
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identify transcriptomic differences between families with different growth rates, it is
important to select families that show significant differences in SGRL and SGRw, while
showing no significant differences (p ~ 0.05) in both weight and length at the sampling
time point. This is because significant differences between families in fish body size at
sampling time (for gene expression) may indicate differences in developmental stages
that could influence gene expression. Therefore, for microarray- and QPCR-based
transcript expression analyses, we selected three triploid families that collectively
represented differences in growth performance (two fast-growing families AS 11 and
AS26 and one slow-growing family AS25) while showing no significant differences in
body size at tissue sampling time (t2). All of the fish in this study were cultured at
AquaBounty's hatchery facility (Fortune, Souris, PE). Technicians from the facility
collected the growth data and conducted tissue sampling. All of the data and crude RNA
samples were sent to Ocean Sciences Centre for further data analysis and later functional
genomics studies.
2.2 Detection of the GH transgene and confirmation of triploidization
To assess for the presence of the integrated GH transgene, polymerase chain
reactions (PCRs) were performed by personnel at the AquaBounty facility according to
standard operating procedures developed by AquaBounty Canada.
Ploidy of each individual was determined by personnel at the AquaBounty facility
using flow cytotometry on a Becton Dickinson (BD) FACSCalibur flow cytometer.
Instrument quality control for DNA quantitation was performed using CellQuest Pro
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software and DNA QC particles (BD #349523) to assess resolution and linearity. For each
individual, two drops of heparinized blood from a syringe were mixed with 500 III of
sheath fluid (Biosure # I0 19). Eighty III of the blood-sheath fluid mixture were mixed
with 500 III of propidium iodide (PI) solution (Biosure # I021) along with 40 III of
chicken red blood cells (Biosure # I005) as an internal staining control. Samples were
incubated in PI solution in the dark for 10 min prior to analysis. The determination of
ploidy for individual blood samples was performed through comparison with diploid
control samples (animals not subjected to pressure shock) prepared in the manner
described above. When the mean peak channel of fluorescence for the pressure-shocked
treated sample fell to within 10% of the mean peak channel of the diploid control, the
sample was scored as diploid. If the mean peak channel of the treated sample fell within
10% of a 1.5 times multiple of that of the diploid control, the sample was scored as
triploid. Ten thousand events were collected for each sample analyzed. Any individuals
lacking the OH transgene and/or having unanticipated ploidy were removed from the
study.
2.3 Liver tissue sampling and RNA preparation
At the sampling time point, fish were euthanized using a sharp blow to the head.
The liver tissues harvested from each individual using standard molecular biology aseptic
techniques were immediately flash-frozen in liquid nitrogen and stored at -70°C until use.
Total RNA was extracted using the TRlzol reagent (Invitrogen, Burlington, ON)
following the manufacturer's instructions. Personnel in AquaBounty facility perfornled
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the liver tissue sampling and TRlzol RNA extraction. However, due to unsuccessful
column-purification of TRIzol-prepared RNA samples (i.e. failure of RNA to bind to the
column), the RNA was re-extracted using a phenol-chloroform method. The TRlzol-
prepared RNA was firstly separated from organic materials by centrifugation with an
equal volume of 50% Tris-buffered phenol (pH=8; Sigma-Aldrich, St. Louis, MO), 48%
chloroform (Sigma-Aldrich), and 2% isoamyl alcohol (Fisher Scientific, Whitby, ON)
(25: 24: I) mixture at 20817 x g at 4°C for 20 min. The RNA was then recovered from the
aqueous layer from the previous step by precipitating in 0.1 volume of 3M sodium acetate
(pH5.2; Ambion, Burlington, ON) and 2.2 volumes of 95% ethanol (Greenfield, Toronto,
ON) at -80°C for an hour, followed by centrifugation at 20817 xg at 4°C for 30 min. The
resulting RNA pellet was washed in five volumes of 70% ethanol by centrifugation at
20817 xg at 4°C for 20 min, air-dried at room temperature for 5-10 min, and dissolved in
0.3 volume of nuclease-free water.
To degrade any residual genomic DNA, the individual total RNA samples were
treated with 6.8 Kunitz units DNase-I (RNase-Free DNase Set, QIAGEN Inc.,
Mississauga, ON) at room temperature for 10 min, followed by column purification using
RNeasy Mini kit (QIAGEN) following the manufacturer's instructions. The quantity and
quality of cleaned RNA samples were assessed by Nanodrop (Thermo Fisher Scientific,
Waltham, MA) spectrophotometry and 1% agarose gel electrophoresis, respectively. The
quality of RNA samples was also calculated using a 2100 BioAnalyzer (Agilent
Technologies, Mississauga, ON) and associated RNA 6000 Nano and Pico LabChip kits
following the manufacturer's protocols.
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2.4 Microarray experimental design and procedures
The 32K cGRASP cONA microarray platform (Koop et aI., 2008)
(http://web.uvic.ca/grasp/microarray/array.html) was utilized in this study to identify
changes in transcript expression associated with growth rate in 3NGHTg Atlantic salmon.
The microarray study was comprised of two independent direct comparisons of 4
replicate microarrays including two dye-swaps (a total of 8 slides) using three 3NGHTg
families of Atlantic salmon with varying growth rate. These comparisons were used to
identify reproducibly differentially expressed hepatic transcripts between fast-growing
salmon families (AS II and AS26) and a slow-growing salmon family (AS25).
The microarray target syntheses and hybridizations were performed using the
30NA Array900 kit (Genisphere, Hatfield, PA) following the manufacturer's instructions
with minor modifications. Briefly, 1 !!g of pooled RNA containing equal contribution of
individuals (n ?: 6) from one family was reverse transcribed in a DNA Engine Tetrad 2
Peltier thermal cycler (Bio-Rad Laboratories, Hertfordshire, England, UK) at 42°C with a
heated lid for 2.5 hours in a final volume of 10.5 III containing Superscript Il (10 U Ilr l ,
Invitrogen), unlabeled dNTPs (0.5 mM), IX SuperScript Il first strand buffer, 0.01 M
OTT, and Oligo(dT) RT primers (0.1 pmole !!r l ) with anchored Cy3 or Cy5 capture
sequences. The reactions were terminated by incubating samples with 2 III of 0.5 M
NaOH/50 mM EOTA (Ambion) in the thermal cycler at 65°C with a heated lid for 10 min
and subsequently neutralized with 2.4 III of I M Tris-HCI (pH=7.5). Prior to
hybridization, microarrays (printing batch JL002) were washed twice for 10 min in 0.1 %
SOS (Ambion) and 5 times for I min in nuclease-free water (Fisher Scientific) with
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gentle agitation at room temperature and then dried by centrifugation in 50 ml conical
tubes (BD Scientific, Mississauga, ON) for 5 min at 800 rpm at room temperature. The
synthesized cDNA samples anchored with Cy3 or Cy5 capture sequences were hybridized
to microarrays using LifterSlip hybridization covers (Thermo Fisher Scientific) with pre-
warmed (hybridization temperature 50°C) formamide based hybridization buffer and
L A-dT blocker (included in the 3DNA Array900 kit). The microarrays were placed in
hybridization chambers (Coming, Lowell, MA) and incubated at 50°C in a covered water-
filled plastic container placed inside a hybridization oven for 16 hours. After the first
hybridization, LifterSlip covers were floated-off in 0.2% SDS/2X SSC buffer (Ambion)
at 50°C and the cDNA-hybridized microarrays were subjected to the following wash
steps with gentle agitation at room temperature to remove unbound cDNAs: 0.2%
SDS/2X SSC buffer for 15 min, 2X SSC for 15 min, 0.2X SSC for 15 min and 0.2X SSC
for 5 min. After washing, microarrays were dried by centrifugation as described above
prior to the second hybridization. In the second hybridization, Cy3 and Cy5 capture
reagents were hybridized to the microarrays for four hours in hybridization chambers in a
covered water-filled plastic container placed inside a hybridization oven at 50°C. The
second hybridization and subsequence procedures were conducted under dim light to
prevent quenching of the fluorescent dyes. The removal of LifterSlip covers and array
wash procedures were repeated as described for the first hybridization.
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2.5 Microarray data acquisition and analysis
Tagged image file (TIF) images containing fluorescent data were obtained using a
ScanArray GX Plus microarray scanner and ScanArray Express software v4.0
(PerkinElmer, Wellesley, MA) at 10 llm resolution and 90% laser power. Raw fluorescent
signal of microarray spots in a given area (e.g. one circle containing approximately four
sub-grids) was used to determine signal strength in Cy3 and Cy5 channels of a given
microarray. The differences in signal strength between Cy3 and Cy5 channels from a
given microarray were balanced through adjustment of photomultiplier tube (PMT)
values. As a result, in comparison AS 1I vs. AS25, PMTs were set to 70 in Cy5 channel
and 80 or 81 in Cy3 channel; in comparison AS26 vs. AS25, PMTs ranged from 54 to 58
in Cy5 channel and from 57 to 61 in Cy3 channel. The fluorescent intensity data was
extracted from TIF images using ImaGene v7.5 (BioDiscovery, El Segundo, CA).
Background correction and Lowess normalization (BCLN), and identification of
reproducibly differentially expressed features between fast-growing and slow-growing
families, were performed in GeneSpring GX v7.3 (Agilent Technologies). In order to
remove microarray features with fluorescent signal close to background from informative
gene lists, thresholds were calculated per channel and per array as the median background
signal of all salmonid features in the 32K microarray plus 2 standard deviations. In this
microarray study, a feature was only considered informative if it: I) exhibited more than
two-fold difference in BCLN expression between fast-growing and slow-growing
3NGHTg Atlantic salmon families in any three out of four technical replicate microarrays
(including at least one dye-swap); 2) showed the same direction of expression change in
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the fourth technical replicate; and 3) passed threshold in all four technical replicate
microarrays in the dominant channel (the dominant channel in the AS II > AS25 gene list
is AS I I, i.e. the higher expressing sample or channel).
The majority of the informative transcripts from the microarray study were re-
annotated using the best BLASTx or BLASTn hit (lowest E-value < 10.5 with an
informative gene name) of the expressed sequence tag (EST) representing a given
informative microarray feature. For those microarray feature ESTs with significant (E-
value < 10-5) BLASTn hits but no informative gene names, BLASTx alignment was
performed on the best BLASTn hits, and the first informative name for the resulting best
(lowest E-value < 10-5) BLASTx hits were used to re-annotate these transcripts. To
functionally annotate microarray-identified transcripts, best informative BLASTx or
BLASTn hits were used to obtain gene ontology (GO) terms from Swiss-Prot Protein
Knowledgebase (htto://www.uniproLora ) if the GO terms were available. Otherwise, GO
terms were gathered using best BLASTx or BLASTn hits (lowest E-value <10-5) from
Homo sapiens, Mus musculus or Danio rerio selected from the BLAST results. For a
given informative feature, all of the GO terms from the molecular function (MF) category
(if available) were selected for gene functional annotation. If GO terms from the MF
category were not available, then all of the GO terms from the cellular component (CC)
category were used for gene functional annotation. Lastly, if MF or CC category had no
available GO terms, then all of the GO terms from the biological process (BP) category
were used for functional annotation.
Multiple microarray informative features with same gene name within a given
gene list could potentially represent one or more genes (e.g. paralogues). For example,
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multiple informative microarray features were BLAST-identified as Glyceraldehyde-3-
phosphate dehydrogenase. Therefore, in order to determine if these informative features
represented a single gene or multiple paralogues, ESTs representing Atlantic salmon
microarray features were used to query the NCBI non-redundant nucleotide database by
BLASTn; all same-named Atlantic salmon nucleotide sequences were collected from the
list of BLASTn hits. These sequences were then subjected to multiple alignment analysis
using the MegAlign function of the Lasergene v8.0 software (DNASTAR Inc., Madison,
WI). Based on the similarity between microarray features and these nucleotide sequences
obtained from the nr database using BLASTn, a given microarray feature was deemed to
represent a NCBI nucleotide sequence if the percent identity was greater than or equal to
95% at the nucleotide level. Otherwise, the microarray feature was considered to be
paralogous to a given Atlantic salmon nucleotide sequence.
2.6 Gene ontology analysis
In order to identify the biological processes that were significantly differently
represented between gene differentially expressed in 3NGHTg Atlantic salmon families
with varying growth performance, the GO enrichment analyses for all hierarchies were
carried out for each of the two microarray comparisons using the BLAST2GO suite
(Conesa and Gotz, 2008; Conesa et aI., 2005; Gotz et aI., 2008). Collaborator Charles Y.
Feng performed this analysis. All 31,982 salmonid cDNA features from the 32K cGRASP
cDNA microarray were re-annotated using the high throughput BLASTx function with E-
value cut-off set at 10-3, and only the 20 best BLASTx hits were retained for GO
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mapping. The GO mapping and annotation were also carried out using BLAST2GO suite
with all parameters at default settings. Using the distribution of GO terms associated with
the salmonid cDNA features of the 32K cGRASP cDNA microarray as the reference,
Fisher's exact test was used to determine if a given GO term was significantly (p < 0.05;
2: 3 times) associated at a higher frequency with the transcripts of a pooled list of genes
that were differentially expressed in a fast-growing vs. slow-growing 3NGHTg Atlantic
salmon families microarray comparison.
2.7 QPCR
QPCR studies were conducted using individual liver RNA samples from the three
3NGHTg Atlantic salmon families involved in the microarray experiment. For each RNA
sample, template cDNA was synthesized from I ~Lg of DNase I-treated and column-
purified total RNA using random primers and SuperScript [[ reverse transcriptase
(SuperScript™ [[ RT) (Invitrogen) following the manufacturer's instructions. Briefly, a
mixture of I !Ag total RNA, dNTPs (0.5 mM each), and random primers (12.5 ng !Arl)
were incubated in the thermal cycler at 65°C with a heated lid for 5 min and then chilled
on ice for 2 min. Following the snap cool, IX first strand buffer, 0.01 M DTT, and
SuperScript [[ reverse transcriptase (10 units !Ar') were added to the mixture and the total
20 !AI of reaction was mixed gently by pipette and then incubated in the thermal cycler
following the thermal profile (25°e for 10 min, 42°e for 50 min, 700 e for 15 min) with
the lid heated. The resulting cDNAs were diluted 1:9 with nuclease-free H20 (Invitrogen)
and stored at -2oo e until QPeR amplification.
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The QPCR primers for the normalizer and TOls were designed based on the
cDNA sequences representing the selected informative features using the PrimerJ
program (http://frodo.wi.miLedu/primerJ/) (Rozen and Skaletsky, 2000). Each primer
pair was quality-checked before use, which included calculation of amplification
efficiency (E = 10rol/'IOpe]) (Pfaffl, 200 I) using five 1:5 serial dilutions of pooled cDNA
(starting with cDNA corresponding to 10 ng of input total RNA) with equal contributions
by all individuals involved in the QPCR study. For a given primer pair, quality control
was performed in triplicates to establish technical replicates. In addition, dissociation
(melt) curves were also performed and analyzed to ensure that there was a single peak at
the expected melting temperature of the amplicon, and no-template controls (NTCs) were
performed to ensure the absence of non-specific amplification. In order to validate
microarray results with QPCR, polyadenylate-binding protein I (PABPI) was selected as
a normalizer because it is stably expressed (0.9 < fold change < lA) between fast-
growing 3NGHTg Atlantic salmon families (AS II and AS26) and a slow-growing
3NGHTg Atlantic salmon family (AS25) in 7 out of 8 microarrays (data not shown). To
validate PABPI suitability as a normalizer in this study, QPCR expression analysis using
individual cDNA samples was performed in the three 3NGHTg Atlantic salmon families
(ASII, AS25 and AS26) and the difference of CT (cycle threshold) across all tested
samples in the same study was within a range of 1.5 cycles.
To quantify mRNA expression levels of TOls, 13 !!l amplification reactions that
contained 2 !!l of diluted cDNA (representing lOng of input total RNA), 50 nM each of
forward and reverse primer, and I X Power SYBR Green PCR Master Mix (Applied
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Biosystems, Foster City, CA) were performed on a 7500 Real Time PCR System
(Applied Biosystems) with the following cycling conditions: 50°C for 20 s, 95°C for 10
min, and 40 cycles of (95°C for 15 s and 60°C for I min) with the fluorescent signal
measured at the end of each 60°C step. The fluorescence thresholds and baseline were
determined automatically using the 7500 Fast Software Relative Quantification Study
Application (Version 2.0; Applied Biosystems). Three TOls were included in each of the
multi-plate studies that consisted of four 96-well format plates. A linker cDNA sample
made of equal contribution from randomly selected cDNA samples involved in the QPCR
study was run on every plate in triplicate to control for plate variability (CT value varied
less than 0.5 among plates in the same study). In addition, the samples were also
randomly distributed among plates in a multi-plate study to further eliminate possible
biases as a result of plate variability. For any given sample, the TOls and normalizer were
run in triplicates (technical replicates) on the same plate, and NTCs were performed in
each plate to ensure the absence of primer dimers and template contamination. Amplicons
for each Tor were run on a 2% agarose gel stained with ethidium bromide alongside a
100 bp DNA ladder (Invitrogen) to confirm the correct sizes of amplified products.
The relative quantity (RQ) of each QPCR target transcript for every studied
individual was calculated in the 7500 Real Time PCR System using the r MCT
quantification method including the calculated amplification efficiencies for Tors and the
normalizer (Livak and Schmittgen, 2001). The RQ values for each target for each sample
were calibrated to the individual with the lowest normalized expression for a given TOI.
To determine if there were significant (p < 0.05) differences in transcript expression
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between fast-growing and slow-growing families, two-sample t-tests were performed on
RQ values using Minitab v15.1 (Minitab Inc., State College, PA.).
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3. RESULTS
3.1 Growth performance of3 GHTg Atlantic salmon
Growth performance of the experimental 3NGHTg Atlantic salmon families was
calculated over a period of approximately 45 days. Three families with larger body size
(AS29, AS33 and AS25) and three families with smaller body size (AS 11, AS48 and
AS26) were selected from 19 experimental families based on their weight and length
measurements (data not shown). The six families were PIT tagged and subjected to
growth rate evaluation (Fig. I). At the initial time point (tl) in the growth study, the
weight of family AS29 (mean 92.1 g) was significantly (p < 0.05) higher than that of
families AS33 (mean 71.3 g), AS25 (mean 64.5 g), and AS48 (mean 57.3 g); families
AS 1I (mean 39.1 g) and AS26 (mean 46.1 g) had smaller initial body weights, and these
were significantly lower than the initial body weights of the other four experimental
families (Fig. lA). At the final time point (t2; when samples were taken for gene
expression analyses), no significant differences were observed in either weight or length
in families AS 11, AS48, AS26, and AS25 (Fig. IB); the final weight of AS29 was
significantly higher than the final weight of ASII, AS48, AS26, and AS25, and the final
length of AS29 was significantly higher than the final lengths of AS II and AS26 (Fig. I
A and B). In terms of specific growth rate during the period of approximately 45 days,
both SGRw and SGRL for families ASII, AS48, and AS26 were significantly higher than
family AS25, and no significant differences (p ~ 0.05) were detected in growth rate
among families AS 11, AS48, and AS26 (Fig. 1 C and D). Therefore, family AS 11,
26
Fig. t. Growth performance data of six PIT-tagged 3NGHTg Atlantic salmon
families (AS 11, AS29, AS48, AS26, AS33, and AS25) during a period of
approximately 45 days. A. Initial and final weight (g); B. Initial and final length
(cm); C. Weight-specific growth rate (SGRw); D. Length-specific growth rate
(SGRt}. All data are presented as means (± SEM). For all growth parameters
presented in panel A-D, different letters identify significant (p < 0.05) differences
among the six families enrolled in this study. In panels A and B, significant
differences in both initial weight and length among families were identified by
different lower case letters, and significant differences in both final weight and
length among families were identified by different upper case letters. In panels C
and D, significant differences in SGRw and SGRL among families were identified by
different upper case letters. See Section 2.1 for calculations of SG R and significance.
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AS25, and AS26 were selected for the functional genomic study based on the following
two criteria: I) the absence of any differences in either final weight or length among these
families reduces the possibility of comparing families at different developmental stages);
and 2) the presence of significant differences in both SGRw and SGRL among these
families, with ASII and AS26 having the highest and second highest SGRw and SGRL
and AS25 having the second lowest SGRw and SGRL (enabling comparisons between
fast-growing and slow-growing families) (Fig. 2; see Appendix I for complete data).
3.2 RNA quality control
We sampled liver tissue from nine individual fish from each family for RNA-
based studies (ten fish were sampled for family AS26, see Section 2.1 for details).
However, one individual from family ASII was determined to be non-transgenic and it
was excluded from the study (data not shown; see Section 2.2 for transgene detection).
The quality of RNA samples used in the microarray and QPCR studies were
checked using a Nanodrop spectrophotometer and gel electrophoresis. The optical density
(OD) 260/280 and 260/230 ratios were used to determine the purity of RNA samples as
nucleic acids have highest ultraviolet light absorption at 260 nm. The 260/280 ratio of
RNA samples contributing to microarray and QPCR studies ranged from 1.92 to 2.17,
indicating no or very low protein contaminants in these samples, and the 260/230 ratio
ranged from 1.83 to 2.39, indicating no or very low detectable solvents, salt and other
contaminants in these samples (Table I). Ethidium bromide stained 1% agarose gel
electrophoresis was performed on RNA samples involved in the study to check RNA
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Fig. 2. Growth performance data of three PIT-tagged 3NGHTg Atlantic salmon
families (AS25, ASH, and AS26) during a period of approximately 45 days. A.
Initial and final weight (g); B. Initial and final length (cm); C. Weight-specific
growth rate (SGRw); D. Length-specific growth rate (SGRd. All data are presented
as means (± SEM), and the complete growth data on all individuals are listed in
Appendix I. For all growth parameters presented in panels A-D, different letters
identify significant (p < 0.05) differences between the three families enrolled in this
study. In panels A and B, significant differences in both initial weight and length
among families were identified by different lower case letters, and significant
differences in both final weight and length among families were identified by
different upper case letters. In panels C and D, significant differences in SGRw and
SGRL among families were identified by different upper case letters. These three
families were selected from the six PIT-tagged 3NGHTg Atlantic salmon families
based on their comparable sizes at sampling point (i.e. no significant differences (p ~
0.05) in final weight and length) and significantly different specific growth rates (i.e.
significantly differences (p < 0.05) in SGRw and SGRL over approximately 45 days).
See Section 2.1 for additional information on the selection of families for the gene
expression analyses. The growth performance of the six PIT-tagged families is
shown in Fig. 1.
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Table 1. Quality of purified liver RNA samples from triploid CH transgenic
(3 CHTg) Atlantic salmon families AS11, AS25 and AS26.
Nanodrop2 Bioanalyzer
QPCR normalizer CT by multi-plate
Sample'
RIN3
studl
260/280 260/230
ASll (n=8)
151-F 2.17 2.27 6.8 19.3 21.6 21.7 21.4 21.1 22.0
155-F 2.13 2.33 8.8 19.1 21.5 20.8 20.3 20.0 21.3
156-M 2.15 2.34 9.2 18.8 21.2 20.8 20.4 20.1 20.9
160-F 2.13 2.34 8.0 19.5 21.4 21.4 20.7 20.5 21.3
161-M 2.11 2.12 9.6 19.3 21.2 21.6 21.0 20.8 21.1
162-F 2.14 1.90 9.6 18.9 21.0 20.9 20.5 20.2 21.4
166-M 2.12 2.39 8.1 19.4 21.2 21.0 21.0 20.7 21.5
168-M* 2.19 2.08 8.2 N/A N/A N/A N/A N/A N/A
AS25 (n=9)
153-F 2.08 2.17 6.9 N/A N/A N/A N/A N/A N/A
154-F 2.10 2.35 7.3 19.5 21.9 21.5 21.1 20.9 21.7
155-F 2.03 2.28 8.3 19.2 21.6 20.9 20.4 20.1 21.2
156-M* 2.05 1.83 6.3 19.8 21.9 21.7 21.0 20.9 21.9
157-M 2.14 2.34 7.7 19.2 21.1 21.5 21.4 21.2 22.0
159-F 2.14 2.32 7.6 19.3 21.3 21.0 20.7 20.4 21.2
160-M 2.14 2.29 5.3 19.6 21.1 21.6 21.0 20.8 21.7
164-F* 1.92 2.25 5.8 19.3 21.3 21.1 20.7 20.5 21.2
167-F* 2.04 1.89 5.9 19.4 21.1 21.0 20.8 20.5 21.7
AS26 (n=lO)
252-F 2.15 2.33 8.3 N/A N/A N/A N/A N/A N/A
253-F* 2.06 2.34 N/A 18.9 21.6 21.0 20.6 20.3 21.0
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254-F 2.17 2.30 8.9 18.9 21.4 21.0 20.6 2004 20.9
256-M 2.16 2.36 9.1 18.9 21.3 21.0 20.6 20.0 20.9
257-F 2.16 2.37 9.1 18.9 20.7 21.0 20.5 20.2 21.0
260-M 2.06 2.11 8.5 18.9 20.7 20.8 20.1 20.1 20.7
261-M 2.07 2.34 7.2 19.3 21.1 21.5 20.7 20.2 21.1
263-F 2.15 2.26 7.6 19.0 20.9 21.0 20.3 20.1 20.9
264-F* 2.15 2.34 8.0 N/A N/A N/A N/A N/A N/A
265-F* 2.17 2.33 6.7 18.9 20.8 21.1 2004 20.2 21.0
iSamples are ethanol-precipitated, DNase treated, and column-purified liver RNA samples.
RNA samples of insufficient quantity (indicated with an asterisk) were excluded from the
microarray study. The remainder of the samples contributed equally to the formation of RNA
pools that were used in microarray studies (AS II vs. AS25 and AS26 vs. AS25). "F"
indicates RNA samples that were extracted from female 3NGHTg Atlantic salmon, and "M"
indicates RNA samples that were extracted from male 3NGHTg Atlantic salmon.
20ptical density (OD) 260/280 ratio, and OD 260/230 ratios were taken using a NanoDrop
N0-1000 spectrophotometer.
3RNA quality was evaluated using an Agilent 2100 Bioanalyzer and associated RNA 6000
Nano and Pico LabChip kits. RNA integrity numbers (RINs) were calculated by Agilent2100
Expert software with a range of I to 10, with I being the most degraded profile and 10 being
the most intact. The Bioanalyzer was unable to determine RIN for sample AS26_3N_253_F
possibly due to the presence of RNA secondary structure.
The target transcripts involved in each of the multi-plate studies are as follows: study I:
APOAI, APOA2, D5DP; study 2: B2MI, B2M2, SEPPI; study 3: NUPRI, FTM, AA5; study
4: GADPHI, GADPH2, ACBP; study 5: APOAIV, SEPP2; study 6: ADAMTS-1. N/A
denotes samples that were not included in this QPCR study due to outlier normalizer Cr
values (i.e. AS25: 153-F) in a separate QPCR study on the impact oftriploidization on hepatic
gene expression (see Section 1.5) or insufficient RNA quantity (i.e. ASII: 168-M; AS26:
252-F,264-F).
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quality. A gel image of electrophoretically separated purified RNA samples from
3NGHTg family AS25 is shown as an example (Fig. 3). The image shows that the RNA
samples were of high quality; the agarose gel image showed the presence of visible 18S
and 28S rRNA bands and mRNA (smear in the background), and the absence of a high
molecular weight genomic DNA in these samples (Fig. 3). The RNA integrity numbers
(R1Ns) calculated by Agilent21 00 Expert software are within a range of I to 10, with I
being the most degraded profile and 10 being the most intact. RIN number of the tested
samples varied from 5.3 to 9.6 (Table I). There was no observed correlation between RIN
values and normalizer CT values, suggesting that all RNA samples involved in this work
were of acceptable quality for microarray and QPCR studies.
For each family, equal amounts of DNase-treated, column-cleaned total RNA
samples contributed to a pool (AS I I pool: n=7; AS25 pool: n=6; AS26 pool: n=7) for
microarray study. One individual from family AS 1I and three individuals from each of
families AS25 and AS26 were excluded from the microarray study due to insufficient
RNA quantity (Table I). For the QPCR study, one individual from AS25 (153-F) was
removed from the study due to outlier normalizer CT values, where outlier was defined as
CT that differ by more than 1.5 cycles from others in the same study; one individual from
AS 1I and two individuals from AS26 were removed from QPCR study due to insufficient
RNA quantity (Table I).
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Fig. 3. Image of an ethidium bromide stained 1% agarose gel showing
electrophoretically separated, DNase-treated purified liver RNA samples (n=6) from
triploid GH transgenic (3NGHTg) Atlantic salmon family AS25. The IKb plus DNA
ladder (Invitrogen) was electrophoretically separated in lane 1. The numbers above
lanes 2 through 7 represent fish individuals from family AS25 that contributed liver
RNA to the microarray study (see Table I for RNA quality). The visible bands in
lanes 2 through 7 indicate the presence of 18S and 28S ribosomal RNA (rRNA), and
the background smear in these lanes indicates the presence of messenger RNA
(mRNA). No visible band of high molecular weight near the wells of lanes 2 through
7 indicates the absence of genomic DNA in these RNA samples.
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3.3 Family-specific differences in hepatic transcript expression
To identify differences in gene transcription that are associated with enhanced
growth performance in 3NGHTg Atlantic salmon families, I compared two fast-growing
families (ASII and AS26) with one slow-growing family (AS25) using the 32K cGRASP
cDNA microarray platform (Fig. 4A). In total, the microarray study identified 143
differentially expressed features (116 more highly expressed in AS 11 and 27 more highly
expressed in AS25) in the comparison of AS I1 and AS25 pools, and 544 differentially
expressed features (442 more highly expressed in AS26 and 102 more highly expressed in
AS25) in the comparison of AS26 and AS25 pools (Fig. 4A). All informative microarray
features are shown in Appendices (i.e. ASII vs. AS25: Appendices 11 and Ill; AS26 vs.
AS25: Appendices IV and V) along with identification information of best BLASTx or
BLASTn hit from NCBI and cGRASP databases and associated GO terms from Swiss-
Prot Protein Knowledgebase (see Section 2.5 for details).
In order to identify putative growth-relevant transcripts that were reproducibly
expressed at a higher level in fast-growing families, informative features with higher
expression level in ASII (116 features; Appendix 11) and AS26 (442 features; Appendix
IV) were compared using Venn diagrams with GeneSpring software. The intersection of
these gene lists consisted of 39 informative microarray features that were consistently
expressed at a higher level in fast-growing families (AS I1 and AS26) compared to the
slow-growing family (AS25) (Fig. 4B; Table 2). Within the list of 39 potential enhanced
growth-associated microarray features, four features had BLAST identification and
37
Fig. 4. Microarray study to identify differentially expressed hepatic transcripts
between two fast-growing 3NGHTg Atlantic salmon families (ASII and AS26) and a
slow-growing 3NGHTg family (AS25). A. Microarray experimental design and
results summary. Within each comparison, microarray features were considered
informative if they: I) presented more than two-fold higher background-corrected,
Lowess-normalized (BCLN) expression in a given comparison (ASII vs. AS25 or
AS26 vs. AS25) in any three arrays (including at least one dye-swap) out of four
technical replicate arrays; 2) showed the same direction of expression change in the
fourth array; and 3) passed threshold in all four technical replicate microarrays. See
Section 2.5 for details on microarray data analysis, and Appendices I1-V for
complete gene lists. The base of each arrow represents the Cy3-labeled target, and
the head of each arrow represents the Cy5-labeled target. B. Venn diagram analysis
was used to identify the putative growth-relevant features (listed in Table 2) that
were consistently expressed at a higher level in the two fast-growing families relative
to the slow-growing family. C. Venn diagram analysis was used to identify the
putative growth-relevant transcript (listed in Table 2) that was consistently
expressed at a higher level in the slow-growing family compared to the two fast-
growing families.
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ASllpool(n=7)
Fast-growing
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Fast" Slow:AS26> AS25
(442 microarray reatures; Appendix IV)
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Table 2. Forty microarray features identified in both microarray comparisons between fast-growing 3NGHTg Atlantic
salmon families (ASH and AS26) and a slow-growing 3NGHTg family (AS25).
Functional Annotation (Gene
______________-- Ontology)ofBestBLASTXor
Length(% E-value BLASTN(N) Hit'
identify)
Expressed at higher levels in fast-growing families
Mean Fold Change (SEM)' Overall Fold Change'
6-phosphofructokinase, liver type
[AAI26579;Boslallrlls]
0Iyceraldehyde-3-phosphate
dehydrogenase [ACI33883;Solmo
salar](GAPDHOllcorhynchusmykiss
0Iyceraldehyde-3-phosphate
dehydrogenase [ACI66269;Salma
salar](GAPDHOncorhynchusmykiss
0Iyceraldehyde-3-phosphate
dehydrogenase [ACI69846;Salma
salarJ (Salmasalartype 2)
146(99%)
6·phosphofructokinaseactivity;
ATPbinding; Metal ion binding
(00:0003872;00:0005524;
00:0046872) [AIA4J1]
NADbinding;0Iyceraldehyde-3-
phosphate dehydrogenase
(phosphorylating) activity
(00:0051287;00:0004365)
[B5X3K2]
NAD binding; 0Iyceraldehyde-3-
phosphate dehydrogenase
(phosphorylating) activity
(00:0051287;00:0004365)
[B5X5Z9j
NADbinding;0Iyceraldehyde-3- 3.57(0.61) 26.56(14.65)
phosphate dehydrogenase
(phosphorylating) activity
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Kifl-bindingprotein[ABW89743;
Pre-mRNA-splicingfactor 18
Binding (GO:0005488)
[A8WE67]
Spliceosornalcomplex 2.63(0.50)
[AC009138; Osmerus (55%)/513 8613E- (GO:0005681) [CIBJD5]'
mordax]/[EZ871571;Oncorhynchlls (88%) 161
mykiss](BJ
Reverse transcriptase [AAS83200;
Fundlllusheteroclitus]
Toxin-I [AAM21198IAF363273;
Oncorhynchusmykiss]
Unknown (no significant BLAST hits)
Expressed at a higher level in the slow-growing
family (AS25)
CK990279 ADAMTS-Iprotein[BAEI6358;
Oryzioslalipes] (ADAMTSI, Fig
RNA binding; RNA-directed
DNA polymerase activity
(GO:0003723;GO:0003964)
[Q641X6j
lE-58 Metalloendopeptidaseactivity;
Zinc ion binding (GO:0004222;
3.89(1.07)
'Expressed sequence tags (ESTs) were identified by gene name of best BLASTX or BLASTN hit (lowest E-value; E-value < le-OS) from GenBank
nucleotide or protein database.
2 The length of aligned region, percent identity over aligned region and associated E-valuearepresented.
(N)lndicates best BLASTN hit with an informative gene name;
(B1lndicates BLASTX result of the best BLASTN hit from NCBI if the best BLASTN hit was not informative, and is presented in "gene name [BLASTX
result]/[BLASTN result]" format;
(Gllndicates BLAST result from cGRASP (http://web.uvic.calgrasp) EST database;
(X)lndicates best BLASTX hit from Homo sapiens, Mus musculus or Danio rerio, which was only listed if functional annotations (GO terms) of best
BLASTX hit were not available.
Features with same-named BLAST results were analyzed in the MegAlign software and manually assigned as "Salmo salar type #" (if more than one
paralogous sequence was identified; similarities < 95%) or "Salmo salar feature" (if sequence similarity 2: 95%). The same rules were applied to
Oncorhynchus mykiss features. The figure numbers are in parentheses for transcripts that were studied using QPCR.
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functional annotation showing involvement in carbohydrate metabolism, five features
were involved in lipid metabolism, seven features were involved in protein metabolism,
seven features were involved in iron homeostasis, seven features were involved in
immune- or stress-related responses, and the remaining nine features were involved in
other biological processes (Table 2). Informative features with higher expression level in
AS25 over AS 1I (27 features; Appendix I1I) and in AS25 over AS26 (102 features;
Appendix V) were compared using Venn diagrams. Only one microarray feature
(representing a transcript encoding an ADAMTS-l-Iike protein) was identified as
reproducibly more highly expressed in the slow-growing family compared with the fast-
growing families in both microarray comparisons (Fig. 4C; Table 2).
To investigate the biological processes that may be associated with fast-growing
families versus slow-growing family microarray gene lists, the proportion of GO terms
associated with each pooled gene list (all of the genes differentially expressed in ASll vs.
AS25 or AS26 vs. AS25) in this study was compared to the overall proportion of GO
terms associated with all cDNAs in the 32K microarray using Fisher's exact test. As a
result, 9 and 26 biological process terms were found to be significantly (p < 0.05; 2: 3
times) enriched in the list of differentially expressed transcripts that were identified in
AS \\ vs. AS25 and AS26 vs. AS25 comparisons, respectively (Table 3). Of these
biological processes, six GO terms were significantly enriched in both comparisons
(Table 3). All 35 enriched GO terms (including the six overlapping GO terms duplicated
in Table 3 since they were enriched in both comparisons) were categorized into seven
groups (biological regulation, cellular component organization or biogenesis, cellular
process, developmental process, localization, metabolic process, and response to
47
Table 3. Gene ontology (GO) terms over-represented in differentially expressed
transcripts between two fast-growing 3NGHTg Atlantic salmon families (ASll and
AS26) and a slow-growing 3NGHTg family (AS25).
GOTerm!
Biological regulation
Regulation of viral genome replication
Cellular component organization or biogenesis
Ribosomal small subunitassembly
Ribosomal1argesubunitbiogcncsis
ScqucstcringofactinmonomCTS
Cellular process
Neuronapoptosis
Endocrinepancrcasdevclopmcnl
Organ regeneration
Myoblastdim:rcntiation
Platclctdegnmulation
Iron ion transport
Iron ion transport
Oxygenlransport
Oxygcnlransport
Gluconeogenesis
Glycolysis
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% Tese p_Value5 Comparison'
Glycolysis
Malate mctabolic process
rRNAproccssing
Translational elongation
L-phenylalanine catabolic process
Cholestcrol mctabolic process
ATP synthesis coupled proton transport
Pcptidy)·cyslcincS-nitrosylation
Peptidyl-cystcincS-nitrosylation
Provirus integral ion
Viraltranscriplion
LipoprotcinmClabolicproccss
Lipoprotein mctabolic process
Response to stimulus
Dcfcnsc response to bacterium
'GO-ID and -GO identifiers of biological process terms that were associated three or more times with
transcripts present in the pooled list of genes that were differentially expressed in the microarray
comparison (i.e. ASII vs. AS25 or AS26 vs. AS25). All GO terms enriched in pooled gene lists were
categorized into seven groups based on biological processes at ancestral level (broadest category) in
Swiss-Prot Protein Knowledgebase.
Jpercentageoftranscriptsinthepooledgenelist(i.e.allofthe genes that were differentially expressed
between families in one comparison) that are associated with the GO term.
·Percentage of transcripts in the 32K cGRASP cDNA microarray (i.e. 11520 annotated microarray
features) that are associated with the GO term.
5Stat isticalenrichmentforGOterm.
6Pooled gene lists for which GO terms were significantly (i.e. associated three or more times with
differentially expressed transcripts that were identified in one microarray comparison; p < 0.05)
enriched. "I" represents pooled list of genes that were differentially expressed in microarray
comparison ASII vs. AS25, and "2" represents pooled list of genes that were differentiallyexpressed
in microarraycomparison AS26 vs. AS25.
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stimulus) based on their high-level parent terms in Swiss-Prot Protein Knowledgebase.
Fourteen different biological processes related to metabolic process were among the GO
terms that were significantly over-represented in fast-growing vs. slow-growing 3NGHTg
microarray gene lists (Table 3).
3.4 QPCR validations of microarray results
A total of 15 microarray-identified, candidate growth-relevant TOls were selected
for QPCR studies involving individual fish templates to validate the microarray results
and assess the biological variability in their mRNA expression.
3.4.1 QPCR primer design and quality control
The QPCR primers for the 15 TOls were designed based on the alignment of
informative microarray feature ESTs and available homologous nucleotide sequences in
GenBank (Table 4). Specifically, QPCR primers for apolipoprotein A-IV (APOAIV),
delta5-desaturase-like protein (D5DP), and nuclear protein I (NUPRI) were designed
using Atlantic salmon sequences that are putatively orthologues to microarray features
represented by rainbow trout ESTs; QPCR primers for acyl-CoA-binding protein (ACBP)
and annexin 5 (AA5) were designed using Atlantic salmon sequences; QPCR primers for
ferritin middle subunit (FTM) were designed using a consensus sequence since several
FTM microarray features representing at least three putative paralogous FTM nucleotide
sequences were identified (see Table 4 footnote for details); QPCR primers for a
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Table 4. Primers for 15 QPCR transcripts of interest identified in microarray studies as being differentially expressed
between fast-growing 3NGHTg Atlantic salmon families (ASH and AS26) and a slow-growing 3NGHTg salmon family
(AS25) in microarray studies and 1 normalizer gene.
Microarraygene
F 5'CAGTGTGAGAGCCAGTGGAA3'
R 5'TGTCTCTGGCTGTTGCTACG3'
F 5'TCGGGGCAAAGTAGCTGTAT3'
R 5'AACGGCGACTACAAGCTGAT3'
F 5'GAGGTATGTGCAGGGTGGTT3'
R 5'CGGCTTGTTGGTCCTGTATT3'
F 5' AGGTGAAGTTGACTGCACAGAG 3'
R 5' AGGTGGAATCAGCAAACTGC 3'
F 5' ACATGGCTCAGGTGAAGGAG 3'
R 5' AGTCAACTGAGCGCCGAAG 3'
F 5' CGCTCTGGCTGTATTCACTG 3'
R 5'TTGCCTTGGCAACGTAGT3'
F 5' TCCGTGCCAGCCTTAAACTA 3'
R 5' TCAGAAGCTGTGCCATTTGT3'
primerdesign2
Consensussequence6
efficiency (0/0) size (bp)3 panel
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microarrayfeatures"
CB500803
CB500982

2The accession numbers for Atlantic salmon NCBI nucleotide database entries that were used to design QPCR primers are listed. For APOAI, B2M,
GAPDH, and SEPP, paralogue-specific primers were designed based on nucleotide sequence alignments at the nucleotide level (see Fig. 5-8 for sequence
alignment results and primer locations).
3QPCR products amplified with each primer pair were electrophoretically separated on an ethidium bromide-stained agarose gel (2%) alongside a 100 bp
ladder (Invitrogen) to confirm that amplified products were of the expected size (Fig. 10).
4Microarray features (Atlantic salmon ESTs) more than 95% identical to the nucleotide sequences that were used to design QPCR primers are listed in
regular font. Microarray features represented by rainbow trout ESTs are in italics; their putative Atlantic salmon orthologues (best BLASTn hit from
Atlantic salmon) were used for the design ofQPCR primers.
5Although nucleotide BT060178 is the closest nucleotide sequence to the microarray feature CB509241, multiple alignment analysis suggests that
CB509241 represents a putative splice variant ofBT060178.
6Five sets of primer pairs were designed for ADAMTSl (CK990279), but none of them passed quality testing for QPCR study (e.g. due to low
amplification efficiency or multiple peaks in melt curve). Nucleotide sequence representing Atlantic salmon ADAMTS-I is not available in the NCBI
nucleotide database. Therefore, its QPCR primers were designed based on a consensus sequence (greater than 96.8% identity between any two
contributing sequences) among homologous ESTs (i.e. BLASTn against NCBI EST database) with the following GenBank ID: CK990279, DW546792,
DW549716, DW563041, DY696604, DY711996.
'Several FTM-like microarray features possibly representing at least 3 putative paralogous FTM nucleotide sequences were identified. In order to avoid
biased QPCR result towards a certain set of paralogues, generic QPCR primers were designed (GenBank ID: BT045310, BT046912, BT049618,
CB502663) to amplify these putative FTM paralogues.
8QPCR primer ofPABPI was designed from microarray feature CA052954 as this feature was stably (0.9 < fold-change < 1.4) expressed in seven out of
eightarraysinmicroarraystudy.
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disintegrin and metalloprotease with thrombospondin motifs-I (ADAMTS I) were
designed using consensus sequences since the primers designed from the informative
microarray feature did not pass quality testing for QPCR study (see Table 4 footnotes for
details). Additionally, paralogue-specific primers were designed for four microarray-
identified genes (apolipoprotein A-I (APOAI), beta2-microglobulin (B2M),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and selenoprotein Pa (SEPP))
since microarray features encoding these potentially growth-relevant genes were
reproducibly associated with fast-growing families and were represented by divergent
sequences that suggested the possibility of paralogues. The QPCR primers for the four
putative paralogous pairs were designed from Atlantic salmon sequences that were
greater than 95% identical to Atlantic salmon microarray features (APOAI-2, B2M,
GAPDH, and SEPP) or rainbow trout microarray features (APOAI-I) (Table 4).
Nucleotide sequences used for paralogue-specific QPCR primer design were aligned in
MegAlign software using the Clustal W program, giving the following results: APOAI-I
(GenBank ID: BT049771) was 89% identical to APOAI-2 (GenBank ID: BT048392)
with 15% nucleotide differences in both forward primers and APOAI-2 reverse primer,
and 25% nucleotide differences in APOAI-I reverse primer (Fig. 5; Table 5); B2MI
(GenBank ID: BT04645I) was 68% identical to B2M2 (GenBank ID: AF180483) with at
least 65% nucleotide differences in both forward and reverse primers (Fig. 6; Table 5);
GAPDH I (GenBank ID: BT046468) was 91 % identical to GAPDH2 (GenBank ID:
BT050045) with 10% and 25% nucleotide differences in GAPDH I and GAPDH2
forward primers, respectively, and 15% nucleotide differences in both reverse primers
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Table 5. Percent identities of four sets of paralogues at nucleotide and hypothetical
amino acid levels.
Gene Name Sequence used for
primer design
Percentidentity(%)
Nucleotide level I Hypothetical amino acid level'
APOAI-I BT04977I
BT048392
AFI80483
GAPDHI BT046468
BT050045
91
ipercent identity of each paralogue set at the nucleotide level was determined by Clustal W method in
MegAiign software (DNASTAR). See sequence alignments in Figures 5-8.
2Percent identity of each paralogue set at the hypothetical amino acid level was determined by BLASTp two
sequences (NCBI).
lThe protein entry for Salmo salar SEPP is not available in NCBI protein database (see Section 3.1 for
details).
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Fig. 5. Sequence alignment of Atlantic salmon nucleotide sequences of putative
paralogues apolipoprotein A-I type I (APOAI-I) and apolipoprotein A-I type 2
(APOAI-2). This alignment report was generated from MegAlign software
(DNASTAR) using the Clustal W program. The paralogue-specific QPCR primers
are shaded in grey. Nucleotide differences between sequences in the primer-design
region are indicated by arrows.
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Fig. 6. Sequence alignment of Atlantic salmon nucleotide sequences of putative
paralogues beta-2 microglobulin type 1 (B2Ml) and beta-2 microglobulin type 2
(B2M2). This alignment report was generated from MegAlign software (DNASTAR)
using the Clustal W program. The paralogue-specific QPCR primers are shaded in
grey. Nucleotide differences between sequences in the primer-design region are
indicated by arrows.
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(Fig. 7; Table 5); SEPPI (GenBank ID: BT072678) was 83% identical to SEPP2
(GenBank ID: BT07222I ) with 30% and 20% nucleotide differences in SEPP I forward
and reverse primers, respectively, and 10% nucleotide differences in both SEPP2 forward
and reverse primers (Fig. 8; Table 5).
The similarities of the four paralogue pairs at the hypothetical amino acid level
were also determined in the current study. Nucleotide sequences were firstly translated to
hypothetical amino acid sequences using translate tool of Swiss-Prot., and the correct
hypothetical amino acid sequences was then selected by searching the translations against
non-redundant (nr) protein database using BLASTp. The similarities of paralogues at the
amino acid level were determined by aligning two hypothetical amino acid sequences that
were translated from Tors using BLASTp (Table 5). As a result, APOAI-I was 83%
identical to APOAI-2 at the hypothetical amino acid level over 242 aligned amino acid
residues (E-value: 2e-148); B2MI was 91% identical to B2M2 at the hypothetical amino
acid level over 93 aligned amino acid residues (E-value: 4e-66); GAPDH I was 99%
identical to GAPDH2 at the hypothetical amino acid level over 334 aligned amino acid
residues (E-value: 0). The data mining of SEPP paralogue pair suggested they were
putative pseudogenes. Their best BLASTx hits were zebrafish selenoprotein P protein
(accession number: AAI55822). SEPPI was 58% identical to this best hit at the
hypothetical amino acid level over 169 aligned amino acid residues (E-value: le-54), and
SEPP2 was 62% identical to this best hit at the hypothetical amino acid level over 174
aligned amino acid residues (E-value: 2e-58).
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Fig. 7. Sequence alignment of Atlantic salmon nucleotide sequences of putative
paralogues glyceraldehyde-3-phosphate dehydrogenase type 1 (GAPDHl) and
glyceraldehyde-3-phosphate dehydrogenase type 2 (GAPDH2). This alignment
report was generated from MegAlign software (DNASTAR) using the Clustal W
program. The paralogue-specific QPCR primers are shaded in grey. Nucleotide
differences between sequences in the primer-design region are indicated by arrows.
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Fig. 8. Sequence alignment of Atlantic salmon nucleotide sequences of putative
paralogues selenoprotein Pa type 1 (SEPPl) and selenoprotein Pa type 2 (SEPP2).
This alignment report was generated from MegAlign software (DNASTAR) using
the Clustal W program. The paralogue-specific QPCR primers are shaded in grey.
Nucleotide differences between sequences in the primer-design region are indicated
by arrows.
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Quality control (QC) testing was conducted for each QPCR primer pair. The
results of primer QC for the D5DP primer pair are shown as an example (Fig. 9A). D5DP
QPCR primer QC results indicated 98.31 % amplification efficiency (r2 = 0.998) (Fig. 9A.
11; see Section 2.7 for details). A single sharp peak at the expected melting temperature
observed in the D5DP amplicon melt curve indicated high specificity of the amplification
and the absence of primer dimers (Fig. 9A. Ill). Similarly, the melt curve of the
normalizer PA8PI primer pair had a single sharp peak at the expected melting
temperature and the amplification efficiency for this primer was 101.78% (r2 = 0.999)
(Fig. 98). The QPCR primer QC testing results for all TOIs and the normalizer gene are
listed in Table 4. Furthermore, the QPCR amplicon size for each primer pair was
demonstrated by 2% agarose gel electrophoresis to show sharp, single bands at the
expected size (Fig. 10; Table 4).
3.4.2 Comparison of QPCR and microarray results
Of the 15 transcripts subjected to QPCR, 13 were determined to be associated
with fast-growing 3NGHTg salmon families in the microarray study (Appendices II and
IV). These were: AC8P, APOAI-I, APOAI-2, APOAIV, 82MI, 82M2, D5DP, FTM,
GAPDHI, GAPDH2, NUPRI, SEPPI, and SEPP2. The remaining two transcripts, AA5
and ADAMTS I, were determined to be associated with slow-growing 3NGHTg salmon
family in the microarray study (Appendices III and V).
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Fig. 9. Examples of QPCR primer quality control (A. Oelta5-desaturase-like protein,
050P; B. Polyadenylate-binding protein, PARPI). l. Amplification plots for five 1:5
serial dilutions of pooled cDNA (starting with cONA corresponding to 10 ng of input
total RNA) with equal contributions by all individuals involved in the QPCR study.
11. Standard curves for the five 1:5 serial dilutions of pooled cONA, indicating
efficiency of amplification. For 050P, efficiency E = 98.31 %, r2 = 0.998. For PARPI,
efficiency E = 101.78%, r2 = 0.999. Ill. Melt curves for detecting primer-dimers or
non-specific amplification. The single peak of melt curve at the expected melting
temperature of the amplicon indicates high specificity of this amplification.
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Fig. 10. Image of an ethidium bromide-stained agarose gel showing
electrophoretically separated QPCR amplicons generated from QPCR assay of a
liver cDNA sample (fish number 155) from 3NGHTg Atlantic salmon family ASl 1.
The resulting QPCR products were electrophoretically separated on a 2% agarose
gel stained with ethidium bromide to confirm the correct sizes of amplified products
(see Table 4 for amplicon sizes). Size marker (tOO bp DNA ladder; Invitrogen) and
abbreviations of gene names that associated with primer pairs are indicated above
each gel lane.
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100 bp DNA
ladder DSDP
'\"'~\ S",\\'),
v~ v' NURPl SEPPl SEPP2 PABPl
2.072 bp_
1.500 bp_
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Many of the transcripts selected for these QPCR studies have functional
annotations suggesting involvement in metabolism, iron homeostasis, cellular process,
and immune- or stress-related biological processes (Table 2). For each TOI, the QPCR
study was conducted using templates reverse transcribed from individual liver total RNA
samples (biological replicate) from all three 3NGHTg Atlantic salmon families (ASII,
AS26, and AS25). Expression levels of a given transcript in the different studied families
were shown as mean relative quantities (RQs) ± SEM (see Section 2.7 for details on
calculation; see Appendix VI for individual RQ values). The overall fold change values in
Table 2 and Figures 11-15 refer to ratios between average RQs from a fast-growing
family (AS 11 or AS26) and the slow-growing family (AS25).
The QPCR results largely agreed with the microarray results as 12 of the 13
microarray-identified, putative enhanced growth-related transcripts had higher expression
(though not always significantly higher, see Figures 11-15) in both fast-growing 3NGHTg
salmon families in the QPCR study (AS II and AS26) in comparison to the slow-growing
family (AS25). Although identified by the microarray study as more highly expressed in
both fast-growing families, QPCR results for NUPRl showed no difference in expression
between AS 11 (fast-growing) and AS25 (slow-growing), and 2.2-fold non-significantly
(p = 0.074) higher expression in AS26 (fast-growing) compared with both AS II and
AS25 (Fig. II E).
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Fig. 11. QPCR results for transcripts of interest (TOIs) selected from the 32K cDNA
microarray study. Mean relative quantities (RQs) with associated standard error of
the mean (SEM) values are shown for three 3NGHTg Atlantic salmon families:
AS25 (slow-growing), ASll (fast-growing), and AS26 (fast-growing). Significant
differences (p < 0.05) of expression level (RQ) between families for a single TOI are
indicated by asterisks; non-significant differences (p ~ 0.05) are indicated as values.
Overall fold change values for each TOI in families ASll and AS26 were calculated
relative to its expression level (mean RQ) in family AS25; fold change values in
black font on a white background represent fold higher expression in ASll or AS26
compared with AS25. If overall fold change values were less than 1.0, then the
inverse of the fold change was calculated; fold change values in white font on a black
background represent fold lower expression in ASll or AS26 compared with AS25.
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Fig. 12. QPCR results for apolipoprotein A-I type I (APOAI-I) and apolipoprotein
A-I type 2 (APOAI-2) selected from the 32K cDNA microarray study. Mean relative
quantities (RQs) with associated standard error of the mean (SEM) values are
shown for three 3NGHTg Atlantic salmon families: AS25 (slow-growing), ASll
(fast-growing), and AS26 (fast-growing). Significant differences (p < 0.05) of
expression level (RQ) between families for APOAI-l or APOAI-2 are indicated by
asterisks; non-significant differences (p 2: 0.05) are indicated as values. Overall fold
change values for each TOI in families AS 11 and AS26 were calculated relative to
expression level (mean RQ) in family AS25; fold change values in black font on a
white background represent fold higher expression in ASH or AS26 compared with
AS25.
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Fig. 13. QPCR results for glyceraldehyde-3-phosphate dehydrogenase type 1
(GAPDHl) and glyceraldehyde-3-phosphate dehydrogenase type 2 (GAPDH2)
selected from the 32K cDNA microarray study. Mean relative quantities (RQs) with
associated standard error of the mean (SEM) values are shown for three 3NGHTg
Atlantic salmon families: AS25 (slow-growing), ASll (fast-growing), and AS26 (fast-
growing). Significant differences (p < 0.05) of expression level (RQ) between families
for GAPDHl 0.' GAPDH2 are indicated by asterisks; non-significant differences (p ~
0.05) are indicated as values. Overall fold change values for each TOI in families
ASll and AS26 were calculated relative to its expression level (mean RQ) in family
AS25; fold change values in black font on a white background represent fold higher
expression in AS 11 or AS26 compared with AS25.
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Fig. 14. QPCR results for beta-2 microglobulin type I (B2MI) and beta-2
microglobulin type 2 (B2M2) selected from the 32K cDNA microarray study. Mean
relative quantities (RQs) with associated standard error of the mean (SEM) values
are shown for three 3NGHTg Atlantic salmon families: AS25 (slow-growing), ASII
(fast-growing), and AS26 (fast-growing). Significant differences (p < 0.05) of
expression level (RQ) between families for B2M I or B2M2 are indicated by
asterisks; non-significant differences (p ~ 0.05) are indicated as values. Overall fold
change values for each TOI in families ASH and AS26 were calculated relative to its
expression level (mean RQ) in family AS25; fold change values in black font on a
white background represent fold higher expression in ASH or AS26 compared with
AS25.
78
!-=-,=--,---r--r---r-........-r---r-,----,--.--,----,---.--l ~~
~ ~:e ~ ~ ~ ~ ~ ~ ~ ~ co CD" N Q £;
£0 IS9MOI 941 41!~~~~S~~~;~1 ~~;II~leI9J Al!Iueno ~ ~
~
:;
f
E~
~i~~ ~~
o ~.B
uo!ss9Jdx9 U"lZ8 it
« IS9MoI 941 41!M lenp!"lpu! 01 911!le19J A\llueno
Fig. 15. QPCR results for selenoprotein Pa type I (SEPPI) and selenoprotein Pa
type 2 (SEPP2) selected from the 32K cONA microarray study. Mean relative
quantities (RQs) with associated standard error of the mean (SEM) values are
shown for three 3NGHTg Atlantic salmon families: AS25 (slow-growing), ASH
(fast-growing), and AS26 (fast-growing). Significant differences (p < 0.05) of
expression level (RQ) between families for SEPPI or SEPP2 are indicated by
asterisks; non-significant differences (p 2: 0.05) are indicated as values. Overall fold
change values for each TOI in families ASII and AS26 were calculated relative to its
expression level (mean RQ) in family AS25; fold change values in black font on a
white background represent fold higher expression in ASIl or AS26 compared with
AS25.
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Seven of the QPCR confinned transcripts that were more highly expressed
(though not always significantly higher, see Figures 11-15) in fast-growing families
compared with a slow-growing family were associated with the GO tenn "metabolic
process" (Appendices 11 and IV). ACBP (GO:0000062, Fatty-acyl-CoA binding) was lA
and 1.7 fold more highly expressed in AS 1I (p = 0.156) and AS26 (p = 0.263),
respectively, compared with AS25 (Fig. IIA); APOAIV (GO:0008289, Lipid binding)
was 3.7 and 5.1 fold more highly expressed in AS II (p = 0.078) and AS26 (p < 0.05),
respectively, compared with AS25 (Fig. liB); and D5DP (GO:0020037, Heme binding;
GO:0016717, Oxidoreductase activity) was 2.7 and 5.9 fold more highly expressed in
AS II (p = 0.060) and AS26 (p < 0.05), respectively, compared with AS25, (Fig. It C).
Paralogues APOAI-I and APOAI-2 (GO:0008289, Lipid binding) were identified
in the microarray studies as being more highly expressed in at least one of the two fast-
growing 3NGHTg Atlantic salmon families (AS 1I and AS26) compared with the slow-
growing family (AS25) (Table 2; Appendices 11 and IV). QPCR showed that mRNA
expression levels of APOAI-I and APOAI-2 were lowest in AS25, highest in AS26 (2-
fold higher than AS25), and intennediate in ASII (1.3-fold higher than AS25) (Fig. 12).
The QPCR mRNA expression of APOAI- I in AS26 was significantly different from that
in AS25 and AS 11, but no significant difference (p = 0.119) was observed in expression
between AS25 and ASII (Fig. 12A). The QPCR mRNA expression of APOAI-2 in AS26
was significantly different from that in AS25, while expression of APOAI-2 in AS II was
110 significantly different (p = 0.343 between AS 11 and AS25; p = 0.057 between AS II
and AS26) from that of the other two families (Fig. 12B).
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GAPDH-like transcripts (GO:0004365, phosphorylating activity) were more
highly expressed in two fast-growing families when compared with the slow-growing
family in the microarray studies (Table 2; Appendices 11 and IV). In the QPCR study,
GAPDHI mRNA expression was lowest in AS25, highest in AS26 (6.7-fold significantly
higher than AS25), and intermediate in ASII (3.2-fold significantly higher than AS25);
mRNA expression of this GAPDH paralogue in each family was significantly different
from that of the other families (Fig. 13A). The QPCR expression profile ofGAPDH2 was
different from that of GAPDH I. GAPDH2 mRNA expression was lowest in AS25,
highest in AS II (5.0-fold significantly higher than AS25), and intermediate in AS26 (3.5-
fold significantly higher than AS25), and no significant difference (p = 0.345) was
observed between ASII and AS26 (Fig. 138).
Of the transcripts with immune- or stress-related annotations, QPCR mRNA
expression of82MI and its putative paralogue 82M2 (GO:00426 12, MHC class I protein
complex) confirmed the microarray results as they were both significantly more highly
expressed in fast-growing families (AS II and AS26) compared with the slow-growing
family (AS25) in the QPCR study (Fig. 14; Table 2; Appendices Il and IV). 82M I
mRNA expression was lowest in AS25, highest in AS26 (4.0-fold significantly higher
than AS25), and intermediate in AS I1 (2.2-fold significantly higher than AS25), and no
significant difference (p = 0.172) was observed in 82M I expression between AS 1I and
AS26 (Fig. 14A). Similar to QPCR mRNA expression profiles of paralogues GAPDH I
and GAPDH2, the mRNA expression profile of putative paralogue 82M2 was different
from that of 82MI, showing lowest expression in AS25, highest in AS!! (10.5-fold
significantly higher than AS25), and intermediate in AS26 (8.5-fold significantly higher
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than AS25), and no significant difference (p = 0.574) was observed in 82M2 expression
between AS II and AS26 (Fig. 148).
FTM-like transcripts (GO:0008199, Ferric iron binding; GO:0016491,
Oxidoreductase activity) were more highly expressed in two fast-growing Atlantic salmon
families when compared with the slow-growing family in the microarray studies (Table 2;
Appendices II and IV). QPCR mRNA expression of FTM in AS25 was significantly
different from ASII (2. I-fold higher than AS25) and AS26 (3.2-fold higher than AS25),
and no significant difference (p = 0.210) was observed between AS 11 and AS26 (Fig.
110).
The mRNA expression of two SEPP putative paralogues (GO:0008430, Selenium
binding) identified in GenBank as pseudogenes (SEPP I: 8T072678; SEPP2: 8T07222I )
was shown in the microarray study to be more highly expressed in at least one fast-
growing family compared with the slow-growing family (Appendices II or IV). In the
QPCR study, SEPPI had the lowest mRNA expression in AS25, the highest in AS26
(2.8-fold significantly higher than AS25), and the intermediate expression in ASII (1.7-
fold not significantly higher than AS25; p = 0.098); no significant difference was detected
between AS 11 and AS26 (p = 0.114) (Fig. 15A). SEPP2 had a similar expression profile
to SEPPI, showing the lowest mRNA expression level in family AS25, highest in AS26
(5.I-fold significantly higher than AS25), and intermediate expression in AS 11 (2.9-fold
significantly higher than AS25); no significant (p = 0.053) difference was observed
between ASII and AS26 (Fig. 158).
For the two slow-growth associated transcripts from the microarray study selected
for QPCR, AA5 (Appendix Ill) (GO:0005509, Calcium ion binding; GO:0005544,
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Calcium-dependent phospholipid binding) and ADAMTS I (Table 2; Appendices III and
V) (GO:0004222, Metalloendopeptidase activity; GO:0008270, Zinc ion binding), the
mRNA expression of neither transcript was validated as significantly more highly
expressed in slow-growing families compared to either fast-growing family in the QPCR
study (Fig. II F and G). In fact, ADAMTS-I mRNA expression was shown by QPCR to
be 2.4-fold significantly higher in fast-growing AS26 compared with slow-growing AS25
(Fig. IIF). AA5 showed non-significant slightly lower mRNA expression (I. I-fold) in
fast-growing family AS 11 compared with slow-growing family AS25 that agreed with
microarray results in direction of change (Fig. 11 G).
Since QPCR study was performed using biological replicates (i.e. RNA samples
from individual fish), the RQ values of TOIs were compared between females and males
in each family using two-sample t-test implemented in Minitab v 15.1; no significant (p >
0.05) effects of sex on gene expression were observed (data not shown).
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4. DISCUSSION
Triploid GH transgenic (3NGHTg) Atlantic salmon technology may enhance fish
production by reducing the time required for animals to reach market size. As it was
observed that growth performance of 3NGHTg Atlantic salmon varied among families
(Fig. I), the aim of this study was to identify and validate transcript expression correlates
of enhanced growth performance of 3NGHTg fish using a functional genomics approach.
Using the cGRASP 32K cDNA microarray platform (Koop et aI., 2008), two microarray
studies were carried out to compare the global constitutive hepatic transcript expression
of two fast-growing families (AS II and AS26) to a slow-growing family (AS25) of
3NGHTg Atlantic salmon (Fig. 4A). These two microarray studies gave rise to a total of
687 differentially expressed microarray informative features (more than two-fold
expression differences in any three out of four technical replicates, with the same
direction of change in the fourth technical replicate, and passing threshold in all four
technical replicates in a given comparison) between fast-growing and slow-growing
families of3NGHTg Atlantic salmon (Appendices II-V) including 39 microarray features
that were consistently expressed at higher levels in both fast-growing families and one
microarray feature that was consistently expressed at a higher level in the slow-growing
family compared with both fast-growing families (Fig. 4 Band C, Table 2). The GO term
enrichment analysis of differentially expressed microarray features identified 35 GO
terms significantly enriched in fast-growing or slow-growing 3NGHTg Atlantic salmon
families (Table 3). In addition, six of these GO terms (glycolysis, peptidyl-cysteine S-
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nitrosylation, lipoprotein metabolic process, oxygen transport, iron ion transport and
homeostasis) were more frequently represented in a given list than expected by chance in
fast-growing or slow-growing 3NGHTg salmon families in both comparisons (Table 3),
suggesting these physiological processes may be associated with growth performance.
QPCR validation using individual samples (to assess biological variability) was
conducted to analyze the expression of a subset of microarray-identified transcripts with
annotations (i.e. not unknowns) that were consistently associated with growth
performance. The QPCR results supported the microarray results in direction of change
for 12 out of 13 fast-growth associated transcripts analyzed. The exception was NUPRI,
where QPCR confirmed the microarray results in direction of change in the AS26 vs.
AS25 comparison (2.2-fold non-significantly higher expression in family AS26 compared
with AS25), but showed no difference in the comparison between AS 11 and AS25 in the
QPCR experiment (Fig. II E). The two microarray-identified transcripts associated with
slow growth (ADAMTS I and AA5) were not validated by QPCR (Fig. 1I F and G). This
discrepancy between microarray and QPCR results may be due to the presence of splice
variants (e.g. AA5, see Table 4 footnotes for details) or the presence of unidentified
paralogues or other related targets that could influence microarray results by non-specific
hybridization to microarray probes. The growth-related transcripts identified and
validated in the current study may guide the future development of genetic markers for
the selection of broodstock that can be used to generate rapidly growing and
reproductively sterile 3NGHTg Atlantic salmon. The emphasis of this study was placed
on transcripts that were consistently associated with fast-growth in 3NGHTg Atlantic
salmon (Table 2) as well as the biological processes (e.g. metabolism, iron homeostasis
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and oxygen transport, and immune- and stress-related response) that are associated with
these transcripts or their putative orthologues.
4.1 Carbohydrate metabolism
The liver is involved in a number of metabolic activities. Hepatocytes, which
make up the majority of liver tissue, have been reported to regulate the level of glucose
through several pathways (e.g. glycolysis and gluconeogenesis) in fish and mammals
indicating an important role in glucose homeostasis (Blouin et aI., 1977; Enes et aI., 2009;
Klover and Mooney, 2004). In a study of coho salmon, it was observed that GH
transgenesis affected growth performance as transgenic fish preferentially used
carbohydrate for energy production while shifting lipid and amino acid metabolism to
more anabolic roles (Leggatt et aI., 2009). Our analysis of the differences in the
constitutive hepatic transcriptome of 3NGHTg salmon with different growth rates also
revealed a number of fast-growth associated transcripts encoding key elements in various
energetic metabolic pathways (i.e. carbohydrate, amino acid and lipid metabolism) (Table
2). For example, four putative fast-growth associated transcripts identified in this study
encode enzymes involved in the glycolysis. They are three GAPDH paralogues and a
transcript encoding 6-phosphofructokinase (PFK) (Table 2; Appendices II and IV, Fig.
13). GAPDH is known as a major glycolytic enzyme that converts glyceraldehyde-3-
phosphate (G3P) to 1,3-diphosphoglycerate (1,3dPG) by oxidative phosphorylation
(Sirover, 1999; Watson and Banaszak, 1964). Studies of mammals have shown that the
expression of GAPDH can be affected by various metabolic conditions such as energy
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deficiency as a result of fasting (Corbin et aI., 2002; Rhoads et aI., 2003). [n addition,
there is evidence that GAPDH plays a role in apoptosis and proliferation in dividing rat
hepatocytes (C-9 rat cell line) in response to the elevated energy requirements associated
with cell division (Barbini et aI., 2007). Decrease in activity of PFK was observed in the
liver of rainbow trout in response to high protein diet (Cowey et aI., [98 [) and fasting
(Fideu et aI., [983). Recently, the activation of PFK was demonstrated to maintain
glycolysis in HIF-l deficient murine tumors (Golinska et aI., 2011). These authors have
all suggested that the increased PFK activity was a response to decrease glucose
availability. Interestingly, genes involved in carbohydrate metabolism were highly up-
regulated in liver of GH transgenic coho salmon relative to wild type salmon, and this
result was also found in domesticated strains that exhibited enhanced growth rate when
compared with wild type salmon (Devlin et aI., 2009). In light of these previous studies, it
is possible that the elevated expression of these transcripts involved in glycolysis
observed in fast-growing 3NGHTg Atlantic salmon may be linked to the elevated
carbohydrate metabolism.
4.2 Lipid metabolism
Lipid metabolism is another important aspect affecting somatic growth, and GH is
known to affect the expression of several transcripts encoding proteins involved in lipid
metabolism in salmonids (Gahr et aI., 2008; Rise et aI., 2006). In the current study, a total
of five transcripts involved in lipid metabolism (APOAI, APOAIV, ACBP, D5DP, and
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myelin basic protein) were identified by microarray as fast-growth associated transcripts
in both 3NGHTg Atlantic salmon families (Table 2).
Two Atlantic salmon microarray features encoding an APOAI-2-like protein were
found to be associated with enhanced growth in 3NGHTg salmon (Appendices 11 and IV).
Using BLASTn of these microarray-identified sequences against the NCBI's nucleotide
database, two APOAI-Iike paralogues, referred to as APOAI-I (GenBank 10: BT04977I )
and APOAI-2 (GenBank 10: BT048392) were identified (Table 4; Appendices 11 and IV).
Although no Atlantic salmon APOAI-I-representing microarray features were
differentially expressed in the current study, one microarray feature representing a
putative rainbow trout APOAI-l paralogue was among the informative growth-associated
transcripts of the current study (Appendix IV). In the current QPCR study, paralogue-
specific primers were designed for APOAI-I and APOAI-2; similar expression patterns
were detected for these APOAI paralogues, both having higher expression in fast-growing
families with the highest fold change found in the AS26 vs. AS25 comparison (Fig. 12).
In mammals, APOAI is a key protein component of the high-density lipoproteins (HDLs)
that play important roles in lipid metabolism and reverse transport of lipids (e.g. from
storage in adipose tissues to tissues that use it for energy production like skeletal muscle)
(Lewis and Rader, 2005). In study of teleost fish, APOAI was detected in hepatocytes of
cod liver in all larval stages and in several organs where apoptosis occurred suggesting an
important role of APOAI in the organogenesis and homeostasis in larval development
(Lange et aI., 2005). As a multi functional protein, APOAI also displayed potent
antimicrobial activities in common carp (Cyprinus cm'pia L.) and rainbow trout, showing
high expression in the primary defence barrier (e.g. epidermis, gills, and intestinal
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mucosa) and ability to inhibit growth of fish pathogens (Concha et aI., 2004; Villarroel et
aI., 2007). Like the APOAI paralogues, APOA-IV was found in the current microarray
and QPCR experiments to be more highly expressed in fast-growing 3NGHTg salmon
families AS It and AS26 in comparison to the slow-growing family (Table 2; Fig. II B).
In mammals, APOAIV is involved in the assembly of chylomicrons that deliver dietary
lipid from liver to peripheral tissues, and it is also known to play a vital role in the
regulation of food intake, particularly in intestinal lipid flux (Black, 2007). Interestingly,
an increase in transcript expression of APOAIV was observed in muscle of slow-growing
rainbow trout treated with exogenous GH (Gahr et aI., 2008). Given the above, the
association between high expression levels of apolipoprotein-encoding transcripts and
fast-growth may be linked to the high lipid demand of somatic cells for fast growth.
A transcript coding for acyl-CoA-binding protein (ACBP) was more highly
expressed in the fast-growing families relative to the slow-growing family in the
microarray studies (Table 2; Appendices II and IV), and the direction of its mRNA
expression response to fast growth was confirmed by QPCR (Fig. IIA). ACBP is a
10kDA protein that binds long chain acyl-CoA esters with very high affinity and
specificity, and its function is highly conserved in different species from yeast to humans
(Burton et aI., 2005). In the fruit fly (Drosophila melanogasler), ACBP was detected at
the mRNA level in most tissues that are associated with energy metabolism (Kolmer et
aI., 1994). ACBP has also been found in various tissues in rat at both protein and mRNA
levels with the highest concentration in liver (Bovolin et aI., 1990). Following ACBP
silencing, growth arrest and cell death were observed in human cell lines (i.e. HeLa,
HepG2, and Chang cells) (Faergeman and Knudsen, 2002). The depletion of ACBP in
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yeast Saccharomyces cerevisiae reduced synthesis of very long-chain fatty acids and
sphingolipids and caused alterations in membrane structure and organization (Gaigg et
aI., 200 I). Recent studies suggested that ACBP regulates transcription of genes involved
in phospholipid biosynthesis and fatty acid metabolism in yeast (Faergeman et aI., 2007)
and in human liver (Vock et aI., 2010). Therefore, the elevated transcript expression of
ACBP in fast-growing families of 3NGHTg salmon may indicate additional effects of
lipid biosynthesis occurring in these fish.
Delta-5-desaturase protein (D5DP) and delta-6-desaturase protein (D6DP)
catalyze the biosynthesis of eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), which are polyunsaturated omega-3 fatty acids that are essential for the health
and development of fish (Copeman et aI., 2002; Mazorra et aI., 2003). [n Atlantic salmon,
D5DP and D6DP transcripts are expressed at high levels in intestine, liver and brain
(Zheng et aI., 2005), and their mRNA expression levels were induced by a decrease in
dietary EPA and DHA (Monroig et aI., 2010). Moreover, the mRNA expression of D6DP
was induced in liver of GH transgenic coho salmon on a full ration compared to GH
transgenic coho salmon on a restricted ration or non-transgenic coho salmon on full ration
(Rise et aI., 2006). [n the current study, both D5DP- and D6DP-representing transcripts
were microarray-identified as differentially expressed in fast-growing and slow-growing
3NGHTg salmon liver samples in at least one comparison (Appendix [[ or [V), however,
only D5DP was expressed at higher levels in both fast-growing families of 3NGHTg
salmon (Table 2, Fig. II C). The higher expression of D5DP-encoding transcript observed
in fast-growing 3NGHTg salmon families might serve to compensate for the high demand
for EPA and DHA as a result of rapid growth. From an aquaculture perspective, not only
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is the expression level of D5DP important for growth performance, it could also help to
reduce the reliance on dietary EPA and DHA supplementation. The microinjection of the
masu salmon (Oncorhynchus masou) D5DP gene into zebrafish embryos was shown to
increase synthesis of EPA and DHA in the resulting adult zebrafish fed with poor live
food (i.e. Artemia nauplii that have less EPA and no DHA compared to commercial feed)
(Alimuddin et aI., 2007), which would help to reduce the requirement of fish meal/oil
content in feed formulation. Given the fact that D5DP-representing transcripts showed
high transcript levels in fast-growing 3NGHTg salmon families in this study, fast-
growing 3NGHTg Atlantic salmon strains with higher D5DP and D6DP transcript
expression could not only benefit aquaculture industry by growing faster but could also
potentially provide a superior nutritional product raised on a more sustainable feed
4.3 Amino acid metabolism
Previous studies of muscle, liver and intestine suggested that the fast growth
achieved by GH transgenic coho salmon is partly due to their ability to deposit a higher
percentage of dietary protein than their non-transgenic counterparts (Higgs et aI., 2009;
Raven et aI., 2008). Nitrogen retention appears to be an important step in efficiently
converting dietary protein to somatic growth as less ammonia excretion was observed in
GH-transgenic Arctic char (Salvelinus alpinus) and Nile tilapia (Oreochromis niloticus)
in comparison to their non-transgenic counterparts (Kobayashi et aI., 2007; Pitkanen et
aI., 1999). Glutamine synthetase (GS) is a key enzyme in this process as it retrieves
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nitrogen from ammonia, making it available to anabolic pathways in the form of
glutamine. An increase in GS activity was observed in liver oftransgenic coho salmon in
comparison to their non-transgenic counterparts (Leggatt et aI., 2009). Collectively, the
identification of GS as a liver transcript associated with fast growth in both microarray
comparisons in the current study (Appendices 1I and IV) may suggest a decrease in
ammonia excretion and thus an increase in dietary protein deposition in fast-growing
3NGHTg salmon. Since it was observed that GAPDH transcription in human hepatocytes
increased with the accumulation of glutamine (Claeyssens et aI., 2003), it is possible that
the higher transcript expression in GAPDH paralogues observed in fast-growing
3NGHTg salmon liver in the current study is linked to the increase in GS transcript
expression as a result of increase in glycolytic flux in anabolic processes. Interestingly,
our microarray studies also identified glutamate dehydrogenase (GDH) as a transcript
more highly expressed in fast-growing families relative to a slow-growing 3NGHTg
family (Table 2; Appendices 1I and IV). As part of the glutamate pathway, GDH is
mainly expressed in perivenous hepatocytes and can be involved in both utilization and
synthesis of glutamine (Reviewed in Watford, 2000). In the current study, the higher GS
transcript expression combined with elevated GDH transcript expression observed in
comparisons of fast-growing 3NGHTg salmon compared with slow-growing 3NGHTg
salmon may collectively suggest an elevated glutamine synthesis in these fish, which may
be the result of increased protein deposition required for rapid somatic growth.
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4.4 Iron homeostasis and oxygen transport
The liver of vertebrates is an important organ for iron storage and metabolism
(Reviewed in Graham et aI., 2007), and ferritin is essential for the storage of intracellular
iron. In hepatocytes, transferrin-bound iron that is circulated in plasma binds to transferrin
receptors on the cell membrane surface and is taken up into cells by endocytosis. The
non-transferrin-bound iron (NTBI) can be bound to serum proteins (e.g. albumin or citric
acid). Within endosomes, ferric iron (Fe3+) is converted to ferrous iron (Fe2+) by enzymes
of the six-transmembrane epithelial antigen of the prostate (STEAP) family and then
transported to the cytoplasm for essential physiological reactions. The unused Fe2+ is
stored in ferritin to prevent toxicity induced by iron overload (Kohgo et aI., 2008; Takami
and Sakaida, 2011). In the current microarray study, many transcripts encoding ferritin
heavy (FTH) and ferritin middle (FTM) subunits were identified as having higher
expression in fast-growing 3NGHTg Atlantic salmon liver (Table 2; Appendices II and
IV), and the QPCR study further confirmed the higher transcript expression of FTM in
fast-growing families of3NGHTg salmon when compared to a slow-growing family (Fig.
II D). Consistent with higher expression observed for ferritin-encoding transcripts, higher
expression for transcripts encoding transferrin and serum albumin in fast-growing
3NGHTg salmon families relative to a slow-growing family was also seen in the
microarray study (Appendices II and IV). These results may suggest an altered iron ion
homeostasis in these fish as transferrin and serum albumin both play important roles in
iron transport and storage (Silva and Hider, 2009). Iron homeostasis and oxygen
metabolism are closely linked processes as iron is involved in the redox reactions that
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allow hemoglobin to transport oxygen (Theil, 2003). Our microarray results showed that
the transcripts encoding several hemoglobin subunits were expressed at higher levels in
fast-growing families compared to a slow-growing family (Table 2). Elevated hepatic
transcript expression of hemoglobin subunits a and 13 were previously observed in GH
transgenic coho salmon, which had enhanced growth rate in comparison to their non-
transgenic counterparts (Rise et aI., 2006). Given the role of hemoglobin in oxygen
transport, it is reasonable to hypothesize that the elevated expression of hemoglobin-
encoding transcripts in fast-growing fish observed in this study is a response of enhanced
growth salmon to increased metabolic demands. However it is also possible that livers of
fast-growing fish are more highly vascularized than those of slow-growing fish, which
could lead to an increased number of circulating erythrocytes and consequently higher
levels ofhemoglobin transcripts (Rise et aI., 2006).
4.5 Other hepatic transcripts associated with fast-growing 3NGHTg Atlantic salmon
In the current study, several microarray-identified fast-growth associated
transcripts had immune- and stress-relevant functional annotations. Among those were:
two beta-2-microglobulin (82M) paralogues and major histocompatibility complex class I
(MHC-I) (Table 2; Appendices II and IV; Fig. 14). 82M plays an important role in
adaptive immune response to viral challenge in teleost. For example, 82M transcript
expression is increased in the liver and head-kidney of infectious salmon anaemia virus
(ISAV) injected Atlantic salmon (Jorgensen et aI., 2006; Le8lanc et aI., 20 I0) and in
spleen and intestine of rainbow trout during infectious hematopoietic necrosis virus
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(IHNV) infection (Hansen and La Patra, 2002). 82M is a light chain component of MHC
class I complexes that expose antigenic peptides to cytotoxic T-cells and subsequently
activate cellular immunity in the host for control of virus infections (York and Rock,
1996). Although it is known that MHC-I is involved in immune responses to viral
pathogens, and considered to be a robust hepatic stress indicator in rainbow trout
(Momoda et aI., 2007), the potential roles of these immune-relevant proteins in somatic
growth of salmonids remain to be studied. Nonetheless, the microarray results for the
82M paralogues were validated by the QPCR analysis, which indicates that these
transcripts may be involved in enhanced growth. Similar to the GAPDH paralogues, these
two B2M transcripts showed distinct expression profiles with B2M I having the highest
fold change in AS26 compared to AS25, while for 82M2 the highest fold change was
seen in AS 11. Differences in expression profiles between two paralogues might indicate
functional differentiation of transcripts corresponding to duplicated genes.
Although SEPPI and SEPP2 were identified as pseudogenes, they were observed
in the current microarray and QPCR studies to be highly expressed at the mRNA level in
one fast-growing family compared with the slow-growing family. In a previously
published microarray study, mRNA expression of SEPP was shown to be highly
repressed in Piscirickettsia salmonis-infected macrophages and head kidney in Atlantic
salmon (Rise et aI., 2004a). Further investigation is required to test whether SEPP I and
SEPP2 have molecular functions that are associated with growth performance, immune
response or other unknown biological processes.
Five nuclear protein I (NUPRI)-like features were greater than two-fold more
highly expressed in fast-growing 3NGHTg Atlantic salmon families compared with a
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slow-growing family in the microarray studies (Appendices 11 and IV), and one NUPRI-
like feature was consistently associated with fast-growth in both microarray comparisons
(Table 2). However, QPCR analysis of individual RNA samples failed to confirm the
microarray findings, showing no expression difference in one fast-versus-slow
comparison (AS 11 vs. AS25) but more than two-fold expression difference (p = 0.074) in
the other fast-versus-slow comparison (AS26 vs. AS25) (Fig. II E). Possible explanations
for disagreement between microarray and QPCR results (e.g. unknown paralogues
influencing microarray hybridization) have been presented previously. When a reference
Atlantic salmon genome sequence is available (Davidson et aI., 2010), it will be fairly
straightforward to identify and develop specific QPCR assays for all putative paralogues
for TOls in functional genomics studies. NUPRl was firstly identified as p8 in rat
pancreatic acinar cells during the acute phase of pancreatitis, and its mRNA expression
was detected in tissue cells in response to apoptosis and cell growth (Mallo et aI., 1997).
[n mouse liver, NUPRl depletion strongly altered the expression of genes involved in
vital cellular pathways and its up-regulation after exposure to various stress agents (e.g.
LPS and CCI4) suggested the importance of this protein in cellular defence system (Taieb
et aI., 2005; Vasseur et aI., 2003). A microarray study in rainbow trout liver reported
NUPRI transcript as a robust indicator of stress (Momoda et aI., 2007). On the other
hand, it was reported that expression of NUPR I transcript was indirectly suppressed by
somatic growth of OH transgenic coho salmon under different feeding strategies (Rise et
aI., 2006). Based on these findings, the induction of NUPRI mRNA level in the current
microarray study might suggest fast-growing 3NOHTg Atlantic salmon liver tissues
experience cellular stress and nutrient deficits.
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Two transcripts encoding histone subunits (H 1.0 and 3.3) were greater than two-
fold more highly expressed in fast-growing 3NGHTg Atlantic salmon compared with
slow-growing salmon liver (Appendices Il and IV). Human histone HI has several
variants that exhibited distinct functions in gene expression and cell growth (Sancho et
aI., 2008). In Atlantic salmon, H I was found to be an antimicrobial protein in liver
suggesting a role in innate immunity (Richards et aI., 200 I). Depressed regulation of
normally highly expressed genes was detected in H3.3-deficient Drosophila when
compared with Drosophila containing H3.3, suggesting that this protein is important for
proper transcription of genes (Sakai et aI., 2009). However, this result was not
consistently shown in some studies and whether this histone variant is essential in active
gene transcription is still under debate (Szenker et aI., 2011). Interestingly, H2A histone
family member Z and histone H5 transcripts were also shown by microarray to be more
highly expressed in GH transgenic coho salmon liver compared to control non-transgenic
coho salmon liver (Rise et aI., 2006). It was previously proposed that modulation of
histone-like transcript expression may be part of the mechanisms by which fast-growing
fish liver cells control overall transcription in a high-proliferative state (Rise et aI., 2006).
4.6 Conclusions
This study utilized DNA microarrays and QPCR to identify and validate hepatic
transcripts that were differentially expressed between fast-growing and slow-growing
3NGHTg Atlantic salmon families. Many of the transcripts that were identified as more
highly expressed in the fast-growing families compared with the slow-growing family are
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hypothesized to be associated with increased metabolic rate. This study improved our
understanding of the genes and molecular pathways involved in growth performance of
3NGHTg Atlantic salmon. The molecular biomarkers for fast-growing 3NGHTg Atlantic
salmon that were identified and validated in this study may guide the future development
of genetic markers for the selection of broodstock that can be used to generate rapidly
growing, reproductively sterile 3NGHTg Atlantic salmon.
4.7 Future research
In this study, functional genomics approaches were used to identify and validate
several growth-relevant transcripts in three 3NGHTg Atlantic salmon families. Further
research (e.g. outlined in the next two paragraphs) will be needed to build on these
results, with an ultimate goal of developing a set of molecular markers for selection of
GHTg Atlantic salmon that show enhanced growth performance after induction of
triploidy.
Among the six PIT-tagged experimental families in the current study, only one
slow-growing 3NGHTg Atlantic salmon family was eligible for functional genomics
analyses (see Materials and Methods for details). Future studies on growth-relevant
transcript expression using additional fast-growing and slow-growing 3NGHTg Atlantic
salmon families would improve the robustness and general applicability of the results.
In this study, many transcripts showed differences in level of expression in liver
between fast-growing and slow-growing 3NGHTg Atlantic salmon families. Several of
these transcripts, with functional annotations showing involvement in a number of
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metabolic pathways, were considered to be candidate genes contributing to growth
performance. Future structural (i.e. sequence) and transcript expression analyses of these
growth-relevant genes (e.g. through RNA-seq-based transcriptome profiling) would
identify SNPs that could be subjected to SNP genotyping with appropriate individuals to
test for association between SNP markers and the fast-growth phenotype. Such
association would suggest that there was a linked control of gene expression and SNPs
that influence growth performance of3NGHTg Atlantic salmon families.
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APPENDICES
APPENDIX I. Supplemental tables showing growth performance data of three triploid GH transgenic (3NGHTg) Atlantic salmon family (AS25,
ASII,and AS26) over a period of approximately 45 days.
Appendix I. A. The initial and final weight of 3NGHTg Atlantic salmon family (AS25, ASII, and AS26).
Sample name Mean initial SE initial Final weight (g)Initial weight (g) weight (g) weight (g)
Mean final
weight (g)
SE final
weight (g)
AS25_153J
AS25 154 F
AS25=155=F
AS25_156_M
AS25_157_M
AS25_159J
AS25 160 M
AS25~16(F
AS25 167 F
68.4
57.4
64.5
83.3
67.3
59.8
54.8
75.6
49.8
64.5 3.5 114.7
106.2
111.9
133.8
105.2
118.5
118.1
131.9
95.4
ASII 151 F 23.2 39.1 3.4 61.9
ASII-155-F 43.9 98.5
ASII-156-M 40.4 97.4
ASII-158-F 25.7 74.0
ASII-160-F 50.5 132.3
ASII-161-M 48.2 104.5
ASII-162-F 45.3 110.5
ASll-166-M 45.2 121.1
ASII-168-M 29.4 74.8
AS26 252 F 23.4 46.\ 3.2 77.9
AS26-253-F 43.9 87.2
AS26-254-F 44.7 118.7
AS26'=-256'=-M 51.3 115.1
122
AS26_257J
AS26_260_M
AS26_261J
AS26_263_M
AS26_264J
AS26 265 F
38.3
59.6
56.5
44.0
48.9
50.5
111.7
141.1
112.7
85.5
110.0
131.7
Appendix I. B. The initial and final length of 3NC;H!g Atlantic salmon family (AS25, ASI I, and AS26).
Sample name Initial length (cm) ~:;~hi~~~;1 leSn~::i:~~) Final length (cm) Mean finallength (cm) SE finallength (cm)
AS25_153J
AS25_154J
AS25_155J
AS25_156_M
AS25_157_M
AS25_159J
AS25_160_M
AS25_164J
AS25 167 F
ASII_15IJ
ASII_155J
ASIU56_M
ASII_158J
ASIU60J
ASII_161_M
ASIU62J
ASII_166_M
ASII 168 M
18.0
17.3
17.7
18.7
17.9
17.3
17.2
18.2
16.3
13.1
16.2
15.9
13.1
16.7
16.2
16.5
16.6
14.2
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21.4
20.9
21.9
22.3
20.3
21.6
21.5
22.1
20.4
17.7
20.2
20.7
18.0
22.4
21.0
21.3
21.8
19.2
AS26_253J
AS26 254 F
AS26j56'=-M
AS26 257 F
AS26'=-260'=-M
AS26_261J
AS26 263 M
AS2(26(F
AS26 265 F
15.6
15.9
16.6
15.2
17.3
16.2
15.6
16.6
16.4
19.5
2\.6
2 \.4
20.8
22.7
20.3
19.4
2\.5
22.8
Appendix I. C. The weight-specific growth rate (SGRw) of 3NGHTg Atlantic
salmon family (AS25, ASII, and AS26).
Sample name
AS25_153J
AS25_154J
AS25_155J
AS25_156_M
AS25_157_M
AS25_159J
AS25_160_M
AS25_164J
AS25 167 F
SGRw
1.20
\.46
1.28
\.10
\.06
\.59
\.83
1.29
\.51
Mean SGRw SE SGRw
ASll_151J 2.23
ASIU55J \.80
ASll 156 M \.96
ASII-::'15!CF 2.35
ASIU60J 2.19
ASll_161_M \.72
ASIU62J \.98
ASll 166 M 2.24
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2.08
AS26_252J 2.67 1.95 0.13
AS26_253J 1.53
AS26_254J 2.22
AS26_256_M 1.80
AS26_257J 2.43
AS26_260_M 1.96
AS26_261J 1.53
AS26_263_M 1.48
AS26_264J 1.80
AS26 265 F 2.13
Appendix I. D. The length-specific growth rate (SGRd of 3NGHTg Atlantic
salmon family (AS25, ASII, and AS26).
Sample name
AS25 153 F
AS25=154)
AS25_155J
AS25_156_M
AS25_157_M
AS25_159J
AS25_160_M
AS25 164 F
AS25-167-F
SGRL
0.40
0.45
0.50
0.41
0.30
0.52
0.53
0.45
0.52
MeanSGRL
0.45
SESGRL
ASII 151 F 0.68
ASII=155=F 0.49
ASII 156 M 0.59
ASII-::'158-::'F 0.71
ASII 160 F 0.67
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APPENDIX 11. Supplemental table containing 116 transcripts with greater than 2-fold higher expression in triploid growth hormone transgenic
(3NGHTg) Atlantic salmon family ASII (fast-growing) in comparison to 3NGHTg Atlantic salmon family AS25 (slow-growing) in any 3 out of 4
technical replicate microarrays including at least one dye-swap.
9E-87 6-phosphofructokinaseactivity;ATP
binding; Metal ion binding
(00:0003872;00:0005524;
00:0046872) [AIA4J1]
0.309
2.781 0.149
EST 1 Gene Name of Best BLASTX or
Length
BLASTN (N) Hit l (% ID)'
CA042535 40kDapeptidyl-prolylcis-trans 103
isomerase [AC007506; (100%)
Oncorhynchusmykiss]
40SribosomalproteinSII 105
[ACO 15454; Caligus clemensi] (100%)
40SribosomalproteinSI3 139(99%)
[AC008029; Oncorhynchus
mykiss]
40S ribosomal protein S27 87(98%)
[ABJ98653;Psellamaxima]
40S ribosomal protein S3 137
[ACI67079;Salmosalar] (100%)
6-phosphofructokinase, liver type 199(78%)
[AAI26579;Bosfaurus]
E
value' Function of Best BLAST Hie
Binding; Peptidyl-prolyl cis-trans
isomerase activity (GO:0005488;
GO:0003755) [CIBEQ3]
Structural constituent of ribosome
(GO:0003735) [CIC2FI]
Structural constituent of ribosome
(00:0003735) [CIB076]
Metal ion binding; Structural constituent
of ribosome (00:0046872; GO:0003735)
[AOEZY9]
RNA binding; Structural constituent of
ribosome (00:0003723; 00:0003735)
[B5X8A9]
X Fold
ChangeJ SEM
J
0.207
60SribosomalproteinLI3
[ACN 10300; Salmo salar]
27(100%) Structural constituent of ribosome
(00:0003735) [COH8DI]
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4.028
CB493696 Acyl-CoA-binding protein
[ACI68322;Salmosalar]
(ACBP,Fig.IIA)
42(95%) Fatty-acyl-CoAbinding(GO:0000062)
[B5XBV2]
0.587
Lipid binding (GO:0008289) [B5X8U6]
52(100%) 3E-20 Hydrogen ion transporting ATP synthase
activity,Rotationalmechanism;Proton-
transportingATPaseactivity,Rotational
mechanism (GO:0046933; GO:0046961)
[B5XCBO]
Apolipoprotein A-I precursor 44 (100%) 5E-16 Lipid binding (GO:0008289) [B5XBH3]
[ACI68193;Salmosalar]
(Salmo salar type 2) (APOAI-2,
Fig.12B)
Apolipoprotein A-I-2 54 (100%) 5E-14 Lipid binding (GO:0008289) [057524]
[AAB96973;Oncorhynchus
mykiss] (Oncorhynchlls mykiss
feature)
ApolipoproteinA-IVprecursor 121 (98%)
[ACI67266;Salmosalar]
(APOAIV, Fig. II B)
Apolipoprotein B [AC082023; 116 (40%)
Percajlavescens]
(Oncorhynchusmykissfeature)
Apolipoprotein B 100 (Mutant) 289 (34%)/ 1E-35/ Lipid transporter activity (GO:0005319)
[ADN03360; Homo 143 (97%) 8E-59 [EIA689]
sapiens]/[EZ905147;
Oncorhynchusmykiss] (B)(X)
(Salmosalarfeature)
ATP synthase subunit epsilon,
mitochondrial [ACI68480;
Salmosalar]
ATP synthase, H+ transporting, 192 (99%) I E-I 02 Hydrogen ion transmembrane transporter
mitochondrial FO complex, activity (GO:0015078) [B5DGH4]
subunitb,isoform I
[ACH70848;Salmosalar]
Beta-2 microglobulin [AFI80486; 799 (99%) 0 MHC class I protein complex
Salmosalar] (N)(Salmosalar
128
2.509
0.288
0.588
0.236
type1)(B2M1,Fig.14A) (GO:0042612) [Q9DG62] c
CB505897 Beta-2 microglobulin type 2 24(92%) 2E-12 MHC class I protein complex 3.400
[AAP51056;Oncorhynchlls (GO:0042612) [Q6XQIO] c
mykiss] (Salmosalartype2)
(B2M2,Fig.14B)
Beta-2-microglobulinprecursor 542(99%) 0 MHCclass I proteincompJex 3.004
[BT047559;Salmosalar](N) (GO:0042612) [Q9DD81]'
(Salmo salar type 2) (B2M2,
Fig. 14B)
Beta-2-microglobulinprecufsor 608(99%) 0 MHC class I protein complex 3.906
[BT047559;Salmosalar](N) (GO:0042612) [Q9DD81] c
(Salmo salar type 2) (B2M2,
Fig. 14B)
Beta-2-microglobulinprecursor 165(98%) 2E-74 MHC class I protein complex 3.971 1.052
[BT056667; Salmosalar] (N) (GO:0042612) [B9ELZ2] c
(Salmo salar type 2) (B2M2,
Fig.14B)
Beta-2-microglobulinprecursor 445 (91%) 2E-169 MHC class I protein complex
[BT057038;Salmosalar](N) (GO:0042612) [B5XE24] c
(Salmo salar type 3)
Beta-2-microglobulinprecursor 509(97%) 0 MHCclass I protein complex
[BT074080;Oncorhynchlls (GO:0042612) [CIBHKI] C
mykiss] (N)(Oncorhynchlls
mykissfeature)
Betaine-homocysteine 95(69%)1 4E- Betaine-homocysteineS-methyltransferase
methyltransferase[ACH70821; 486(92%) 27/0 activity; HomocysteineS-
Salmosalar]/[EZ763914; methyltransferase activity; Zinc ion
Oncorhynchllsmykiss] (0) binding (GO:0047150;
GO:0008898;GO:0008270) [B5DGE7]
Brain protein 44-like protein, 83(86%) 8E-36 Mitochondrial inner membrane
isoform CRA a [EDL02117; (GO:0005743)[D3Z5S0]'
MlIsmllsclllll;jrx)
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C-Cmotifchemokine20 76(91%) 2E-33 Chemokine activity (GO:0008009) 2.805 0.213
precursor [ACI66945; Salmo [B5X7X5]
salar]
Claudin-15[AD028272; 133(57%) 4E-35 Structural molecule activity (GO:0005198) 2.829 0.353
lctalurusfurcatus] [E3TD86]
CA050110 Cold-inducible RNA-binding 647(99%) 0 Nucleic acid binding; Nucleotide binding 2.535
protein [BT058753;Salmo (GO:0003676; GO:0000166) [COH8U7]
salar](N)
Complementcomponentl,q 141(36%) IE-13 Extracellular region (GO:0005576)
subcomponent-like4 [Q86Z23],
[AAIl0813; Homo sapiens] (X)
Delta5-desaturase-likeprotein 87(99%) 2E-45 Hemebinding;Oxidoreductaseactivity,
[ABU87822; Oncorhynchus acting on paired donors, with oxidation
masou](D5DP,Fig.llC) ofa pair of donors resulting in the
reduction of molecular oxygen to two
molecules of water (GO:0020037;
GO:OOI6717) [A7XUS7]
Digestive cysteine proteinase 2 185 4E-I08 Cysteine-type endopeptidase activity 2.378 0.571
precursor [ACI34170; Salmo (100%) (GO:0004197) [B5X4D9]
salar]
DNA-directed RNA polymerases 56(98%) 4E-24 DNA binding; DNA-directed RNA
I, Il,and III subunitRPABC2 polymerase activity (GO:0003677;
[ACOI3758;Esoxlucius] GO:0003899) [C I BXK5]
Elongation factor I-alpha I 38(100%) 2E-II GTP binding; GTPase activity; Translation 5.221 1.319
[ACNI1490;Salmosalar] elongation factor activity (GO:0005525;
(Salmosalarfeature) GO:0003924; GO:0003746) [COHBSI]
Elongation factor I-alpha 1 628 0 GTP binding; GTPase activity; Translation 2.697 0.628
[BT059777;Salmosalar] (NI (100%) elongation factor activity (GO:0005525;
(Salmosalarfeature) GO:0003924; GO:0003746) [COHBSI]
Extracellular matrix protein 1 640(83%) 7E-149 Cellular Component: Extracellular space
precursor [BT059193; Salmo (GO:0005615) [COHA37]
salar](N)
130
Ferritin-Hsubunit 65(95%) 8E-57 Ferric iron binding; Oxidoreductase
[AAK08117IAF338763; activity (GO:0008199; GO:0016491)
Oncorhynchusnerka] [Q98TTO]
Ferritin, middle subllnit 106 7E-56 Ferric iron binding; Oxidoreductase
[ACI33572;Sa/mosa/ar] (100%) activity (GO:0008199; GO:0016491)
(Sa/mosa/arfeature)(Fig.IID) [B5X2PI]
CB487639 Ferritin, middle subllnit 130(95%) IE-66 Ferric iron binding (GO:0008199)
[ACJ66713;Sa/mosa/ar] [B5X793]
(Oncorhynchus mykiss type I)
CB503780 Ferritin,middlesubunit 162 4E-89 Ferric iron binding (GO:0008199)
[ACI68639;Sa/mosa/ar] (100%) [B5XCR9]
(Sa/mosa/arfeature)
CB510731 Ferritin,middlesubunit 124 3E-66 Ferric iron binding; Oxidoreductase 2.182 0.369
[AC007744; Oncorhynchus (100%) activity (GO:0008199; GO:0016491)
mykiss] (Sa/mosa/arfeature) [CIBFEI]
(Fig. lID)
CA052094 Fructose-I,6-bisphosphatase 65(94%) 3E-17 Phosphoric ester hydrolase activity 3.024 0.546
f~U853449; Sa/mo marmorarus] (GO:0042578) [B5AJU4]
Fumarylacetoacetase 171(87%) IE-87 Fumarylacetoacetaseactivity
[AC009168; Osmerus mordax] (GO:0004334) [CIBJG5]
Gamma-aminobutyricacid 78(100%) 6E-37 Receptor activity (GO:0004872)
receptor-associatedprotein-like [B5X5M7]
2 [ACI66147;Sa/mosa/ar]
Glutamate dehydrogenase I, 515 0 Binding; Oxidoreductase activity, acting
mitochondrial precursor (100%) on the CH-NH2 group of donors, NAD
[BT044837;Sa/mosa/ar](NJ or NADP as acceptor (GO:0005488;
GO:OO 16639) [B5X I B8]
CB514092 Glutamine synthetase [ACI68482; 27(100%) 4E-8 ATP binding; Glutamate-ammonia ligase
Sa/mosa/ar] (Sa/mosa/ar activity (GO:0005524; GO:0004356)
feature) [B5XCB2j
Glutamine synthetase [ACI68482; 99(100%) 5E-52 ATP binding; Glutamate-ammonia ligase
131
Salmosalar] (Salmosalar activity (GO:0005524; GO:0004356)
feature) [B5XCB2]
GlutathioneS-transferase 159(97%) 3E-84 Glutathione transferase activity
[BAA76974; Oncorhynchus (GO:0004364) [Q9W647]
nerka]
CB492813 Glyceraldehyde-3-phosphate 113 5E-54 NADbinding;Glyceraldehyde-3- 3.564 0.76
dehydrogenase [AC133883; (100%) phosphate dehydrogenase
Salmosalar] (Oncorhynchus (phosphorylating) activity (GO:0051287;
mykisstype I) GO:0004365) [B5X3K2]
Glyceraldehyde-3-phosphate 146(99%) 5E-78 NAD binding; Glyceraldehyde-3-
dehydrogenase [ACI66269; phosphate dehydrogenase
Salmosalar] (Oncorhynchus (phosphorylating) activity (GO:0051287;
mykiss type 2) GO:0004365) [B5X5Z9]
Glyceraldehyde-3-phosphate 183 2E-100 NADbinding;Glyceraldehyde-3-
dehydrogenase [ACI66269; (100%) phosphate dehydrogenase
Salmosalar] (Salmo salar type (phosphorylating) activity (GO:0051287;
I) (GAPDH I, Fig. 13A) GO:0004365) [B5X5Z9]
Glyceraldehyde-3-phosphate 116 5E-60 NADbinding;Glyceraldehyde-3-
dehydrogenase [ACI69846; (100%) phosphate dehydrogenase
Salmosalar] (Salmo salar type (phosphorylating) activity (GO:0051287;
2) (GAPDH2, Fig. 13B) GO:0004365) [B5XG76]
Glyceraldehyde-3-phosphate 200 2E-110 NAD binding; Glyceraldehyde-3-
dehydrogenase [ACI69846; (100%) phosphate dehydrogenase
Salmosalar] (Salmosalartype (phosphorylating) activity (GO:0051287;
2) (GAPDH2, Fig. 13B) GO:0004365) [B5XG76]
Glyceraldehyde-3-phosphate 64(100%) IE-29 NAD binding; Glyceraldehyde-3- 5.119
dehydrogenase-2 [ACH70939; phosphate dehydrogenase
Salmosalar] (phosphorylating) activity (GO:0051287;
GO:0004365) [B5DGR5]
Heat shock 70kDaprotein 126(99%) 4E-66 ATP binding (GO:0005524) [B5X4Z3]
[AC134374;Salmosalar]
(Salmosalarfeature)
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Heat shock cognate 70 kDa 182 5E-99 ATP binding (GO:0005524) [P08108] 5.037 1.004
protein [AAB21658; (100%)
Oncorhynchusmykiss]
(Oncorhynchusmykissfeature)
CB501216 Hemoglobinsubunitalpha 143 5E-75 Heme binding; Oxygen binding; Oxygen
[ACI69100;Salmosalar] (100%) transporter activity (GO:0020037;
(Salmosalartype I) GO:0019825; GO:0005344) [B5XE30]
Hemoglobinsubunitalpha 143(99%) 9E-74 Hemebinding; Oxygen binding; Oxygen
[ACI69100;Salmosalar] transporter activity (GO:0020037;
(Salmosalartype I) GO:0019825; GO:0005344) [B5XE30]
Hemoglobinsubunitalpha 143 IE-75 Hemebinding;Oxygenbinding;Oxygen
[ACNI0007;Salmosalar] (100%) transporter activity (GO:0020037;
(Salmosalartype2) GO:0019825; GO:0005344) [COH718]
CA064277 Hemoglobinsubunitalpha 143(99%) IE-75 Heme binding; Oxygen binding; Oxygen
[ACNI0007; Salmo salar] transporter activity (GO:0020037;
(Salmosalartype2) GO:0019825; GO:0005344) [COH718]
C8498419 Hemoglobinsubunitalpha-I 143 8E-76 Heme binding; Oxygen binding; Oxygen
[AC007570; Oncorhynchus (100%) transporter activity (GO:0020037;
mykiss] GO:0019825; GO:0005344) [Q98974]
Hemoglobinsubunitalpha-4 142 5E-75 Hemebinding; Oxygen binding; Oxygen
[ACI66666;Salmosalar] (100%) transporter activity (GO:0020037;
(Salmosalartype I) (Salmo GO:0019825; GO:0005344) [B5X746]
salartypel)
Hemoglobinsubunitalpha-4 71(99%) 2E-54 Hemebinding; Oxygen binding; Oxygen
[ACN09908;Salmosalar] transporter activity (GO:0020037;
(Salmo salar type 2) (Salmo GO:0019825; GO:0005344) [COH789]
salartype2)
Hemoglobinsubunitbeta 94(90%) 4E-38 Hemebinding;Oxygenbinding;Oxygen
[ACI68762;Salmosalar] transporter activity (GO:0020037;
(Salmosalarfeature) GO:0019825; GO:0005344) [B5XD42]
Hemoglobinsubunitbeta 148 5E-80 Heme binding; Oxygen binding; Oxygen
[AC007479; Oncorhynchus (100%) transporter activity (GO:0020037;
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GO:OO 19825; GO:0005344) [C I BEM6]
e)
Hemoglobinsubunitbeta-I 131(69%) 2E-40 Heme binding; Oxygen binding; Oxygen
[ACN09863; Salmo salar] transporter activity (GO:0020037;
(Salmosalartype2) GO:0019825; GO:0005344) [COH744]
Hemoglobinsubunitbeta-I 143(98%) 3E-77 Hemebinding;Oxygenbinding;Oxygen
[ACNI0193;Salmosalar] transporter activity (GO:0020037;
(Salmo salar type I) GO:0019825; GO:0005344) [COH824]
Hemoglobinsubunitbeta-I 157(96%) 2E-82 Heme binding; Oxygen binding; Oxygen
[ACNIOI93; Salmo salar] transporter activity (GO:0020037;
(Salmosalartype I) GO:0019825; GO:0005344) [COH824]
Hemoglobinsubunitbeta-4 148 6E-80 Heme binding; Oxygen binding; Oxygen
[AC007576;Oncorhynchlls (100%) transporter activity (GO:0020037;
mykiss] GO:0019825; GO:0005344) [CIBEX3]
Heparin cofactor 11 304(80%)/ IE- Serine-type endopeptidase inhibitor
[AAN71003IAF515273; Danio 571(99%) 174/0 activity (GO:0004867) [Q8A YE2]
rerio]/[EZ764595;
Oncorhynchllsmykiss] (B) (X)
Histone H3.3 [BT057095; Salmo 684(93%) 0 DNA binding (GO:0003677) [B5DG7!]
salar](N)
Homeoboxprotein PRH 137(99%) 5E-66 Sequence-specific DNA binding; 2.177 0.221
[AC008286; Oncorhynchlls Sequence-specific DNA binding
mykiss] transcription factor activity;
Transcription regulator activity
(GO:0043565;GO:0003700;
GO:0030528) [C 1BGY3]
Kelch repeat and BTB (POZ) 76(96%)
domain containing 10
[ACH70794; Salmo salar]
Keratin 18, simple type I keratin 73(100%) 5E-24 Structural molecule activity (GO:0005198) 3.054 0.678
[CAA74664;Oncorhynchus [057607]
mykiss]
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67(73%) 2E-10 Binding (GO:0005488) [A8WE67]
85(45%) 3E-15 DNA binding; Zinc ion binding
(GO:0003677; GO:0008270) [Q99676]
46(52%) 5E-6 Protein binding (GO:00055 I5) [Q9HB66]
48(52%) IE-5 Methyltransferaseactivity(GO:0008168) 2.597
[B2RXM4]
566(99%) 0 MHCclasslproteincomplex
(GO:0042612) [A7KDZ8] c
446(97%) 0 Binding (GO:0005488) [COPUR7]
43(98%) IE-14 Integral to mitochondrial inner membrane
(GO:0031305) [B5XIN7] c
89(44%)/ IE-05/ Structural constituent of myelin sheath
44(100%) 4E-12 (GO:0019911) [Q512C7]
80(95%) IE-35 N-acetyltransferase activity (GO:0008080) 3.002
[B9ENY3j
Mitochondrial inner membrane
protein [ACI33218;Salmo
salar]
Myelin basic protein
[AAW52552;Danio
rerio]/[EZ764180;
Oncorhynchllsmykiss] (B)
N-terminalacetyltransferase
complexARDI subunit
homolog A [ACM09230; Salmo
salar]
Novel protein containing a 214(66%) 2E-71 Calcium ion binding (GO:0005509)
vitaminK-dependent [QILY06]
carboxylation/gamma-
carboxyglutamic (GLA) domain
[CAK04616; Danio rerio]
Kifl-bindingprotein
[ABW89743;Daniorerio]
Kruppel-relatedzincfinger
protein [AAC51180; Homo
sapiens]
McKusick-Kaufman syndrome,
isoform CRA_a [EAXI0343;
Homo sapiens]
Methyltransferaselike liB
[AAI57907;MlIsmllsclIllIs]
MHC Class I (Sasa-UBA)
[EF210363;Salmosalar]{N)
Mitochondrial fission I protein
[BT072691;Salmosalar]tN)
Nuclearautoantigenicsperm
protein (histone-binding)
226 (68%) 3E-68 Binding (GO:0005488) [Q7ZVH7] 2.982
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[AAH45857;Daniorerio]
Nuclear protein I [AAH02109; 57(56%) 4E-11 Nucleus (GO:0005634) [Q9WTKO] ,
MlIsmllsclI/lIs](X)(NUPRI,Fig.
lIE)
CA061586 Nuclear receptor coactivator 112(67%) IE-38 DNA binding (GO:0003677) [Q9P2WI] 2.393 0.136
GTI98 [AAL33609IAF440240;
Homo sapiens] (X)
Pancreatic secretory trypsin 67(100%) 2E-36 Serine-type endopeptidase inhibitor 2.729 0.561
inhibitor [ACM09634; Sa/mo activity (GO:0004867) [B9EQ37]
sa/ar]
Phosphatidylinositol-specific 71(45%) IE-9 Phospholipase C activity (GO:0004629)
phospholipaseC, X domain [Q9NUJ7]
containing I [CAI43217;Homo
sapiens]
1147 2E-115 Binding (GO:0005488) [Q68FHO] 2.269
(74%)
Pre-mRNA-splicingfactor 18 247 (55%)/ 3E-861 Spliceosomal complex (GO:0005681)
[AC009138; Osmerlls 513(88%) 3E-161 [CIBJD5],
mordax]/[EZ871571;
Oncorhynchlls mykiss] (B)
Prothymosin, alpha a 36(89%) 4E-8 Nucleus (GO:0005634) [Q6NV32]'
[AAH68334; Daniorerio] (X)
(Sa/mosa/artype I)
P~:~:~e~~]aJJi~:) ~1:'~~6s?t~:; 194(95%) 8E-78 Nucleus (GO:0005634) [Q6NV32]' 2.162 0.132
type 2)
RAS guanyl-releasing protein 2 65(89%) 3E-12 Guanyl-nucleotideexchangefactor 4.256 1.218
[BT044818;Sa/mosa/ar](N) activity; Calcium ion binding
(GO:0005085; GO:0005509) [B5X 199]
Retinol dehydrogenase 3 191(92%) 2E-98 Binding; Oxidoreductase activity 1.968
[ACI67927;Sa/mosa/ar] (GO:0005488; GO:0016491) [B5XAQ7]
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115(29%) IE-8 RNA binding; RNA-directed DNA
polymerase activity (GO:0003723;
GO:0003964) [Q64IX6]
Ribosomal protein L3-like 169 4E-96 Structural constituent of ribosome
[ACH70797;Salmosalar] (100%) (GO:0003735) [B5DGC3]
SelenoproteinP,plasma, la 169(58%)/ 2E- Selenium binding (GO:0008430)
[AAI55822;Danio 730(99%) 49/0 [A9JRW5]
rerio]/[BT072678;Salmosalar]
(B)(SEPPI, Fig.15A)
SelenoproteinP,plasma, la 169(58%)/ 2E- Selenium binding (GO:0008430)
[AAI55822;Danio 730(99%) 49/0 [A9JRW5]
rerio]/[BT072678;Salmosalar]
(B)(SEPPI,Fig.15A)
Serine/threonine-protein 623 0 Phosphoprotein phosphatase activity 2.262 0.268
phosphatasePPI-betacatalytic (100%) (GO:000472I) [COPUG4]
subunit putative mRNA
[BT072371; Salmosalar] (N)
EG910863 Serum albumin 2 [CAA43187; 232(78%) IE-96 Lipid binding; Metal ion binding
Salmosolar] (GO:0008289; GO:0046872) [Q03156]
SET and MYND domain- 153 6E-87 Zinc ion binding (GO:0008270) [B5X414] 2.376 0.457
containing protein 3 [ACI34045; (100%)
Solmosalar]
Short chain 298(74%)/ 4E- Binding; oxidoreductase activity
dehydrogenase/reductase family 582(89%) 129/0 (GO:0005488; GO:0016491) [Q7SZ49]
16C, member 5 [AAH54138;
Daniorerio]/[EZ765850;
Oncorhynchllsmykissj(Il)(X)
Signal transducer/activator of 754(68%) 2E-101 Calcium ion binding; protein binding; 2.117 0.116
transcriptionStatl [AAB60924; Sequence-specific DNA binding
Gallllsgalllls] (G) transcription factor activity; Signal
transducer activity (GO:0005509;
GO:0005515;GO:0003700;
137
166(87%)
50(84%)
GO:0004871) [013131]
Binding (GO:0005488) [B5X217]
181(43%)
Toxin-I [AAM21198IAF363273; 76 (89%)
Oncorhynchus mykiss] (Salmo
salarfeature)
Transposable element Tcbl 68 (78%) 8E-23 Unknown
transposase [ACNI1391; Salmo
salar] (Salmosalartype I)
Sigmafactoractivity;Sequence-specific
DNA binding transcription factor
activity; Transposase activity; DNA
binding (GO:0016987; GO:0003700;
GO:0004803; GO:0003677) [Q9PWOO]
142 (38%)/ 3E-15/ DNA binding; Sequence-specific DNA
448(79%) 3E-63 binding transcription factor activity;
Sigmafactoractivity;Transposase
activity (GO:0003677; GO:0003700;
GO:0016987; GO:0004803) [Q9PWOO]
238(83%)
Ubiquitin-conjugatingenzymeE2 133(98%)
T [ACM09373; Salmo salar]
Unknown (no significant BLAST
hits)
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Iron ion binding; Tryptophan 2,3-
dioxygenase activity (GO:0005506;
GO:0004833) [A7MBU6]
Small conjugating protein ligase activity
(GO:0019787) [B9EPC6]
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
0.456
3.815
4.596 0.772
IExpressed sequence tags (EST) were identified by gene name of best BLASTX or BLASTN hit (lowest E value < le-OS)
from nucleotide or protein database. The length of aligned region, percent identity over aligned region and associated E
value were presented. (N) For best BLASTN hits with informative gene name (NCBI); (8) For best BLASTX results of the
best BLASTN hit (NCBI) if best BLASTX or N hits were not applicable, presented in "gene name [BLASTX
results]/[BLASTN results]" format; (G) For BLAST results from cGRASP EST database (raw); (X) For best BLAST hits
from Homo sapiens, Mus musculus or Danio rerio in BLAST results (NCBI), listed only if functional annotation of best
BLASTX hit were not available. For features of same BLAST results, only Salmo salar features were processed with
bioinfomatics in MegAlign software and manually assigned as "Salmo salar type #" (if more than one type applicable) or
"Salmo salar feature" (only one type applicable) following their gene names.
2Function of the best BLASTX or BLASTN hit was interpreted as Gene Ontology (GO) in Swiss-Port protein
knowledgebase following priority of molecular function, cellular component C, and biological process b.
3Mean fold changes and standard errors of mean were calculated based on normalized data from GeneSpring software
(Agilent Technologies).
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APPENDIX Ill. Supplemental table containing 27 transcripts with greater than 2-fold higher expression in triploid growth hormone transgenic
(3NGHTg) Atlantic salmon family AS25 (slow-growing) in comparison to 3NGHTg Atlantic salmon family ASII (fast-growing) in any 3 out of 4
technical replicate microarrays including at least one dye-swap.
Gene Name of Best BLASTX or Length E Function of Best BLAST HitBLASTN (N) Hit (%ID) value
ADAMTS-I protein [BAEI6358; 148(72%) lE-58 Metalloendopeptidaseactivity;Zincion
Oryzias lalipes] (ADAMTS I, binding (GO:0004222; GO:0008270)
Fig.IIF) [Q4AED3]
Annexin A5 [ACNIOI84; Salmo 118(97%) 6E-57 Calcium ion binding; Calcium-dependent
salar](AA5,Fig.IIG) phospholipid binding (GO:0005509;
GO:0005544) [COH815]
ARM ET protein [AAH07282; 182(65%) 9E-57 Growth factor activity (GO:0008083)
Homo sapiens] (G)(X) [P55145]
Class I histocompatibility antigen 291(85%) 1E-71 MHCclass I protein complex
[BT059396; Salmosalar] (N) (GO:0042612) [COHAPO] C
Digestive cysteine proteinase 2 224(99%) 2E-128 Cysteine-type endopeptidase activity
precursor [ACI69888;Salmo (GO:0004197) [B5XGB8]
salar]
Gamma-glutamylhydrolase 149(83%) 2E-66 Omega peptidase activity (GO:0008242)
precursor [ACI66462; Sa/mo [B5X6J2]
sa/ar]
Golgin B I [BAG48317; Homo 144(48%) 2E-31 Golgi apparatus (GO:0005794) [B2ZZ91] C
sapiens] (X)
Hydroxyacidoxidase I 137 4E-70 FMNbinding;Oxidoreductaseactivity
[ACNI0394;Salmosalar] (100%) (GO:0010181; GO:0016491) [COH8M5]
Leucine rich repeat neuronal 3 279(71%) 9E-113 Protein binding (GO:0005515) [Q9H3 W5]
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X Fold
Change
2.490 0.512
2.847
[AAH35133; Homo sapiens]
Melanoma differentiation 207(98%)/ IE- ATP binding; ATP-dependenthelicase
associated gene 5 [CAZ27715; 369(85%) 103/ activity; nucleic acid binding
Oncorhynchus 5E-95 (GO:0005524;GO:0008026;
mykiss]/[EZ764472;Oncorhynch GO:0003676) [D7F7W8]
usmykiss] (B)
MHCclass lA core region 193(91%) 3E-63 MHCclasslproteincomplex
[HM210571;Oncorhynchus (GO:0042612) [Q9TNN8]'
mykiss](N)
MHCclass 11 antigen beta chain 234(90%) 4E-77 MHCclass 11 protein complex; Integral to
[EU008541; Salmosalar] (N) membrane (GO:00426 I3; GO:OO 16021)
[B2XBN8],
MTERF domain containing 1 185(66%) 2E-69 Promoter binding (GO:0010843) 2.369
[AAHI2995; Homo sapiens] (X) [Q96E29]
Myosinheavychain[BAGI6351; 129(91%) IE-68 ATP binding; Actin binding; Motor 2.709 0.742
COIyphaenoides yaquinae] activity (GO:0005524; GO:0003779;
GO:0003774) [B1Q382]
Neuromedin s [ACJ64069; Danio 98(51%) 4E-17 Unknown 2.354 0.268
rerio]
QILl [AAMI4633; Mus 119(35%) 5E-13 Mitochondrion (GO:0005739) [Q8R404] ,
musculus] (X)
Ras-relatedprotein Rab-27A 185(92%)/ 2E- GTP binding (GO:0005525) [C 1BK36]
[AC009389; Osmerus 166(92%) 104/
mordax]/[EZ770488; 3E-54
Oncorhynchusmykiss] (B)
EG924794 Retinoicacidreceptorgammab 328(84%) 2E-76 Sequence-specific DNA binding; 2.050
(Rargb) gene [EU025716;Salmo Transcription factor activity
salar](N) (GO:0043565; GO:0003700) [B3SU91]
RhamnosebindinglectinSTLI 55(87%) 4E-23 Sugar binding (GO:0005529) [Q9IB53] 2.318
[BAA92255;Oncorhynchus
mykiss]
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CA064204 391
(100%)
550(99%)
74(76%)
152(76%)
Calcium ion binding (GO:0005509)
[Q6DGT8]
Nucleic acid binding; Nucleotide binding;
Zinc ion binding (GO:0003676;
GO:0000166; GO:0008270) [B9EMR5]
Zinc ion binding (GO:0008270) [B5X428]
Zinc ion binding (GO:0008270) [B5X428]
Unknown (no significant BLAST
hits)
Please see Appendix II for footnotes.
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APPENDIX IV. Supplemental table containing 442 transcripts with greater than 2-fold higher expression in triploid growth hormone transgenic
(3NGHTg) Atlantic salmon family AS26 (fast-growing) in comparison to 3NGHTg Atlantic salmon family AS25 (slow-growing) in any 3 out of 4
Structural constituent of ribosome 10.159
(GO:0003735) [CIC2FI]
technical replicatemicroarrays including at least one dye-swap.
Gene Name of Best BLASTX or Length E
BLASTN (N) Hit (%ID) value
15-hydroxyprostaglandin 139(95%)
dehydrogenase [ACI69905;
Salmosalar]
2-peptidylprolylisomeraseA 93(100%)
[ACH70768; Salmo salar]
(Oncorhynchusmykissfeature)
CB493346 2-peptidylprolylisomeraseA 95(82%)
[ACH70768;Sall7losalar]
(Oncorhynchusl7lykissfeature)
3-ketoacyl-CoAthiolase 686(99%)
[BT045547;Salmosalar](N)
35kDaSRrepressorprotein 855(99%)
[BT059492;Salmosalar](N)
40kDapeptidyl-prolylcis-trans 103
isomerase [AC007506; (100%)
Oncorhynchusl7lykiss]
CB492405 40SribosomalproteinSll 105
[ACO 15454; Caligus c1el7lensi] (100%)
40SribosomalproteinSI2 132
[ACH70842; Salmo solar] (100%)
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Binding; Oxidoreductase activity
(GO:0005488; GO:0016491) [B5XGD5]
Peptidyl-prolyl cis-trans isomerase activity
(GO:0003755) [B5DG99]
Peptidyl-prolylcis-transisomeraseactivity
(GO:0003755) [B5DG99]
Ransferaseactivity,transferringacyl
groups other than amino-acyl groups
(GO:0016747) [B5X3C8]
Nucleic acid binding; Nucleotide binding
(GO:0003676; GO:0000166) [COHAY6]
Binding; Peptidyl-prolyl cis-trans
isomerase activity (GO:0005488;
GO:0003755) [CIBEQ3]
Structural constituent of ribosome
(GO:0003735) [B5DGG8]
X Fold
Change
3.054
2.483 0.339
139(99%)
[AC008029; Oncorhynchus
mykiss]
40Sribosomal protein SI4 143
[ACN09966;Salll7osalar] (100%)
40S ribosomal protein SI5 147(96%)
[ACN 10008; Salmo salar]
40sribosomal protein S16 146
[ACH70747; Salmo salar] (100%)
(Salmo salar feature)
40S ribosomal protein SI6 146
[ACNI0073;Salmosalar] (100%)
(Oncorhynchus mykiss feature)
40Sribosomal protein SI6 146
[ACNI0073;Salmosalar] (100%)
(Salmosalarfeature)
40SribosomalproteinS23 145
[ACNI0021; Salmosalar] (100%)
40S ribosomal protein S24 118(98%)
[BT044043;Salll7osalar] (N)
87(98%)
87(98%)
[ABJ98653; Pselta maxima]
(Oncorhynchusmykissfeature)
40SribosomalproteinS4 178
[ACNI0029; Salmo salar] (100%)
(Oncorhynchusmykiss feature)
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Structural constituent of ribosome
(GO:0003735) [CIBG76]
Structural constituent of ribosome
(GO:0003735) [COH7E7]
RNA binding; Structural constituent of
ribosome (GO:0003723; GO:0003735)
[COH7I9]
Structural constituent of ribosome
(GO:0003735) [B5DG73]
Structural constituent of ribosome
(GO:0003735) [COH7Q4]
Structural constituent of ribosome
(GO:0003735) [COH7Q4]
Structural constituent of ribosome
(GO:0003735) [COH7K2]
Nucieotidebinding; Structural constituent
of ribosome (GO:0000166; GO:0003735)
[B5RIB9]
Structural constituent of ribosome
(GO:0003735) [AOEZY9]
Structural constituent of ribosome
(GO:0003735) [AOEZY9]
Structural constituent of ribosome
(GO:0003735) [COH7LO]
40Sribosomal protein S4 177(99%) IE-95 Structural constituent of ribosome 33.052 24.103
[ACNI2376;Salmosalar] (GO:0003735) [COH7LO]
(Oncorhynchusmykiss feature)
CB496987 40Sribosomal protein S6 185 2E-100 Structural constituent of ribosome 2.472 0.284
[ACN09990; Salmo salar] (100%) (GO:0003735) [COH7HI]
CA042530 6-phosphofructokinase, liver type 199(78%) 9E-87 6-phosphofructokinaseactivity;ATP
[AAI26579;Boslaurus] binding; Metal ion binding
(GO:0003872;GO:0005524;
GO:0046872) [AIA4JI]
60SribosomalproteinLI0 210 4E-121 Structural constituent of ribosome 3.190
[ACNI0030; Salmo salar] (100%) (GO:0003735) [COH7LI]
CB494510 60SribosomalproteinLII 177 IE-97 Structural constituent of ribosome
[ACI69075;Salmosalar] (100%) (GO:0003735) [B5XE05]
(Oncorhynchusmykissfeature)
CB511063 60SribosomalproteinLII 171(99%) 6E-94 Structural constituent of ribosome
[ACI69075;Salmosalar] (Salmo (GO:0003735) [B5XE05]
salarfeature)
60SribosomalproteinLI3a 192 4E-94 Structural constituent of ribosome 2.279 0.476
[ACNI0380;Salmosalar] (100%) (GO:0003735) [COH8LI]
CB498637 60S ribosomal protein LI9 162(99%) 2E-52 Structural constituent of ribosome 3.760
[ACN09972; Salmo salar] (GO:0003735) [COH7F3]
CA044 I 18 60SribosomalproteinL21 160 3E-88 Structural constituent of ribosome
[ACH70979; Salmo salar] (100%) (GO:0003735) [B5DGV5]
CB509769 60SribosomalproteinL27a 147 2E-70 Structural constituent of ribosome
[ACI66567;Salmosalar] (100%) (GO:0003735) [B5X6U7]
60SribosomalproteinL28 105(99%) IE-64 Structural constituent of ribosome 2.995 0.700
[AC007782; Oncorhynchus (GO:0003735) [CIBFH9]
mykiss]
60S ribosomal protein L29 54(100%) 9E-25 Structural constituent of ribosome 4.519 0.981
[ACOI3335; Esox lucills] (GO:0003735) [CIBWD2]
60SribosomalproteinL3 205(99%) 8E-115 Structural constituent of ribosome 2.697 0.182
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[ACI66814;Sa/mosa/ar] (GO:0003735) [B5X7J4]
(Oncorhynchllslllykissfeature)
CA042790 60SribosomalproteinL3 123(99%) 3E-68 Structural constituent of ribosome
[ACI68315; Sa/lllo sa/ar] (Sa/lllo (GO:0003735) [B5XBU5]
sa/arfeature)
60SribosomalproteinL31 130(97%) 6E-57 Structural constituent of ribosome
[ACN09978;Sa/mosa/ar] (GO:0003735) [COH7F9]
CA047190 60SribosomalproteinL35 123 2E-49 Structural constituent of ribosome 5.350 2.256
[ACI66532; Sa/lllo sa/ar] (Sa/lllo (100%) (GO:0003735) [B5X6R2]
sa/arfeature)
60SribosomalproteinL35 123(99%) IE-46 Structural constituent of ribosome
[ACI67490;Sa/lllosa/ar] (GO:0003735) [B5X9HO]
(Oncorhynchllsmykisstype I)
60SribosomalproteinL35 407(94%) 8E-167 Structural constituent of ribosome
[BT047689;Sa/mosa/ar](Nl (GO:0003735) [B5X9HO]
(Oncorhynchus mykiss type 2)
CB494678 60SribosomalproteinL35a 110 3E-58 Structural constituent of ribosome 2.788
[ACN09951; Sa/mo sa/ar] (100%) (GO:0003735) [COH7D2]
CB501730 60SribosomalproteinL36 60(99%) 5E-30 Structural constituent of ribosome
[ACI67440; Sa/mo sa/ar] (Sa/mo (GO:0003735) [B5X9CO]
sa/artypel)
CA037622 60SribosomalproteinL36 108(99%) 3E-47 Structural constituent of ribosome 2.376 0.615
[ACI68713; Sa/mo sa/ar] (Sa/mo (GO:0003735) [B5XCZ3]
sa/artype2)
60SribosomalproteinL36 100(97%) 3E-48 Structural constituent of ribosome
[ACI68713;Sa/mosa/ar] (GO:0003735) [B5XCZ3]
(Oncorhynchllsmykissfeature)
CB497661 60SribosomalproteinL36 99(97%) 2E-47 Structural constituent of ribosome
[ACI68713;Sa/mosa/ar] (GO:0003735) [B5XCZ3]
(Oncorhynchllsmykissfeature)
CB507058 60SribosomalproteinL36a-1 106(96%) 4E-45 Structural constituent of ribosome
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[ACH70983; Salmo salar] (GO:0003735) [B5DGV9]
(Salmosalartype3)
60SribosomalproteinL37 93(89%) 6E-40 Structural constituent of ribosome
[ACN09993;Salmosalar] (GO:0003735) [COH7H4]
CB487825 60S ribosomal protein L38 48(94%) 4E-17 Structural constituent of ribosome
[ACN I0033; Salmo salar] (GO:0003735) [COH7L4]
CB497459 60SribosomalproteinL5 213 7E-I09 5SrRNA binding; Structural constituent of
[ACOO7720;Oncorhynchlls (100%) ribosome (GO:0008097; GO:0003735)
mykiss] [CIBFB7]
60SribosomalproteinL7 157(76%) 5E-56 Structural constituent of ribosome;
[AC007661; Oncorhynchlls Transcription regulator activity
mykiss] (GO:0003735; GO:0030528) [Cl BF58]
60S ribosomal protein L7a 164 IE-78 Ribosome (GO:0005840) [COH8FI] ,
[ACNI0320;Salmosalar] (100%)
60SribosomalproteinL8-1 205(86%) 5E-88 Structural constituent of ribosome
[ACH70990; Salmo salar] (GO:0003735) [B5DGW6]
CB492853 60SribosomaloroteinL9 139 3E-72 rRNAbinding; Structural constituent of
(100%) ribosome (GO:0019843; GO:0003735)
[B5DG02]
60SribosomalproteinL9 123 5E-62 rRNAbinding;Structuralconstituentof
[ACH70676; Salmo salar] (100%) ribosome (GO:0019843; GO:0003735)
(Oncorhynchllsmykissfeature) [B5DG02]
60S ribosomal protein L9 116(95%) 3E-52 rRNAbinding; Structural constituent of
[ACH70676;Salmosalar] ribosome (GO:0019843; GO:0003735)
(Oncorhynchusmykissfeature) [B5DG02]
72 kDatype IV collagenase 688 0 Metalloendopeptidase activity; Zinc ion
precursor [BT072163;Salmo (100%) binding (GO:0004222; GO:0008270)
salar](Nl [COPU91]
EG779795 Actin related orotein 2/3 comolex 149(37%) 5E-15 Cytoskeleton (GO:0005856) [EOVEQ7] ,
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corporis]
Actin-related protein 2/3 complex 429(99%)
subunit4[BT060120;Salmo
salar](N)
Actin-related protein 2/3 complex 681 (89%)
subunit5 [BTI25478;Salmo
salar](N)
292(91%)
Acyl-CoA synthetase [BT059131; 214 (91%)
Salmosalar](N)
Acyl-CoA-bindingprotein 42(95%)
[ACI68322;Salmosalar]
(ACBP,Fig.IIA)
Adeninenucleotidetranslocator 41 (88%)
s598 [BAD86711; Takifugu
rubripes]
Cytoskeleton (GO:0005856) [COH7WO] ,
Cytoskeleton (GO:0005856) [B5XCZ5] ,
Acyl carrier activity; Cofactor binding;
Phosphopantetheinebinding
(GO:0000036;GO:0048037;
GO:0031 177) [B5XB34]
Catalytic activity (GO:0003824) [B5X460]
Fatty-acyl-CoAbinding(GO:0000062)
[B5XBV2]
Binding; Transporter activity
(GO:0005488; GO:0005215) [Q5KSP2j
63 (99%) 7E-28 GTP binding (GO:0005525) [B5X3QI]
ADP-ribosylationfactor-like 716(99%)
protein 8B [BT046252; Salmo
salar](N)
ADP/ATP translocase 2 38 (95%)
[ACI67091;Salmosalar]
GTP binding (GO:0005525) [B5X5D3]
Binding; Transporter activity
(GO:0005488; GO:0005215) [B5X8C I]
CX035072 Alpha-2-macroglobulin-2
166
(78%)/
182(99%)
164(75%)
2E-74/ Metallocarboxypeptidase activity; Zinc ion
2E-87 binding (GO:0004181; GO:0008270)
[B8JM73]
Endopeptidase inhibitor activity
148
[BAA85039; Cyprinus carpio] (GO:0004866) [Q9PVU4]
Alpha-aspartyldipeptidase I11 3E-58 Serine-type peptidase activity 2.401
[ACI68014;Salmosalar] (100%) (GO:0008236) [B5XAZ4]
Alpha-globin I [BAAI3533; 143 IE-76 Heme binding; Oxygen binding; Oxygen
Oncorhynchusmykiss] (100%) transporter activity (GO:0020037;
GO:0019825; GO:0005344) [Q98973]
125(65%) IE-43 Aminopeptidase activity (GO:0004177)
[001357]
CB510708 Angiotensinogenprecursor 101(90%) 2E-24 Serine-type endopeptidase inhibitor
[BT045876;Salmosalar]{N) activity (GO:0004867) [B5X4A 7]
Antithrombin [CAB64714; Salmo 145(98%) 4E-I06 Serine-type endopeptidase inhibitor
salar] activity (GO:0004867) [Q9PTA8]
ApolipoproteinA-lprecursor 44(100%) 3E-16 Lipid binding (GO:0008289) [B5XBH3]
[ACI68193; Salmo salar] (Salmo
salartype 2) (APOAI-2, Fig.
12B)
CB506105 ApolipoproteinA-lprecursor 143 3E-62 Lipid binding (GO:0008289) [B5XBH3] 3.106
[ACI68193; Salmo salar] (Salmo (100%)
salartype2)(APOAI-2,Fig.
12B)
ApolipoproteinA-I-1 120(99%) 7E-48 Lipid binding (GO:0008289) [057523]
[AAB96972;Oncorhynchus
mykiss] (Oncorhynchus mykiss
type I)(APOAI-I,Fig.12A)
Apolipoprotein A-If [BAH58380; 143 IE-63 Unknown 3.019
Oncorhynchusmykiss] (100%)
ApolipoproteinA-IVprecursor 121(98%) 3E-57 Lipid binding (GO:0008289) [B5X8U6]
[ACI67266;Salmosalar]
(APOAIV, Fig. 11 B)
ApolipoproteinC-1 precursor 65(100%) 2E-32 ExtraceJlularregion(GO:0005576)
[ACI69086;Salmosalar] (Salmo [B5XEI6] ,
149
solar feature)
87(96%) 4E-39 Extracellular region (GO:0005576)
[B5XEI6]C
Aspartyl/asparaginylbeta- 185 4E-44/ Membrane (GO:0016020) [CIBYU8] C
hydroxylase [AC014201;Esox (64%)/ 3E-138
lucius]/[EZ77 1405; 397(91%)
Oncorhynchus mykiss] (B)
115 7E-57 ATPbinding; Hydrogen ion transporting
(100%) ATPsynthaseactivity,rotational
mechanism; Hydrogen-exporting ATPase
activity,phosphorylativemechanism;
Proton-transporting ATPase activity,
rotational mechanism (GO:0005524;
GO:0046933;GO:0008553;
GO:0046961) [B5RI36]
137(98%) 6E-54 Hydrogen ion transporting ATP synthase
activity, rotational mechanism
(GO:0046933) [COH702]
ATP synthase subunitO, 187 2E-90 Hydrogen ion transportingATPsynthase
mitochondrial precursor (100%) activity,rotationalmechanism
[ACI68940;Salmosa/ar] (GO:0046933) [B5XDMO]
108 8E-53 Hydrogen ion transmembrane transporter
(100%) activity (GO:0015078) [B5X611]
674(99%)
ATP-dependent RNA helicase 148(99%) 2E-76 ATPbinding;ATP-dependenthelicase
DDX39 [ACN58701; Sa/mo activity; Nucieic acid binding
solar] (GO:0005524;GO:0008026;
GO:0003676) [COPUM3]
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Autophagy-related protein 13 132(66%)
[DAA21766;Boslaurus]
Blymphocyteinducedmaturation 152(72%)
protein 1 [BAD02932; Takifugu
rubripes]
163
(100%)
97(100%)
Barrier-to-autointegration factorB 100(92%)
[BT048804;Salmosalar](N)
Basic transcription factor 3-1 149
[ACH70908; Salmo salar] (100%)
187
(100%)
116
(100%)
661(99%)
alar] (NJ(Salmosalar
(B2MI,Fig.14A)
Beta-2microglobulin[AFI80486; 799(99%)
Salmosalar]tNJ(Salmosalar
type 1)(B2Ml,Fig.14A)
Beta-2-glycoprotein I precursor 211(84%)
[ACNIOII0; Salmo salar]
(Salmo salar type 1)
132(96%)
151
Nucleic acid binding; Zinc ion binding
(GO:0003676; GO:0008270) [Q75UA3]
DNA binding (GO:0003677) [B5RI51]
DNA binding (GO:0003677) [B5XCN5]
Unknown
Integral to membrane; Mitochondrial
envelope (GO:0016021; GO:0005740)
[B5X7F5]C
MHCclass I protein complex
(GO:0042612)[Q9J966]C
MHCclass I protein complex
(GO:0042612) [Q9DG62] C
MHC class I protein complex
(GO:0042612) [Q9DG62] C
(Salmo salartype 2)
Beta-2-microglobulinprecursor 752
[BT046451; Salmosalar] (N) (100%)
(Salmo salar type 1)(B2MI,
Fig.14A)
Beta-2-microglobulinprecursor 542(99%)
[BT047559; Salmosalar] (N)
(Salmo salar type 2) (B2M2,
Fig.14B)
Beta-globin [CAA65945; Salmo 148
salar] (100%)
MHCclasslproteincomplex
(GO:0042612) [B5X5Y2]'
MHCclass I protein complex
(GO:0042612) [Q9DD81]'
Heme binding; Oxygen binding; Oxygen
transporter activity (GO:0020037;
GO:0019825; GO:0005344) [Q91473]
Bile salt export pump [ABJ55520; 99 (99%)
Oncorhynchusmykiss]
Beta-ureidopropionase
[ACM08325; Salmo salar]
81 (100%) 8E-40 Hydrolase activity,acting on carbon-
nitrogen (but not peptide) bonds
(GO:0016810) [B9ELC8]
ATP binding; ATPase activity,coupled to
transmembrane movement of substances
(GO:0005524; GO:0042626) [AOMH69]
4.465
0.300
Hydrolaseactivity,actingoncarbon-
nitrogen (but not peptide) bonds, in linear
amides (GO:0016811) [Q9DFF8]
114(97%) 5E-57 Hydrolaseactivity,actingoncarbon-
nitrogen (but not peptide) bonds, in linear
amides (GO:0016811) [Q9DFF8]
Biotinidasefragment I I11 (99%)
[AAG30007; Oncorhynchus
mykiss] (Oncorhynchus mykiss
feature)
Biotinidasefragment 1
[AAG30007;Oncorhynchus
mykiss] (Oncorhynchusmykiss
feature)
Brain protein 44-like protein 80(100%)
[ACI66404; Salmo salar] (Salmo
salartypel)
Brain protein 44-likeprotein 60(100%)
[ACI66612; Salmo salar] (Salfllo
salartype2)
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71(96%)
83(97%) 2E-28 Cytoplasm (GO:0005737) [COH8Z4]'
Ctype lectinreceptorC 186(94%) IE-76 Receptoractivity; Sugar binding
[AAT77222; Salmo salar] (GO:0004872; GO:0005529) [Q68S96]
92(91%)1 2E-461 Iron ion binding; Oxidoreductase activity
265(94%) 2E-I04 (GO:0005506; GO:0016491) [CIBLJ6]
27(100%) IE-8 Sugar binding (GO:0005529) [B5XAQ3]
'23;Salmo
C-type MBL-2 protein 145 IE-97 Sugar binding (GO:0005529) [Q4LAN6]
[CAJI4130;Oncorhynchus (100%)
mykiss]
37(90%)1 lE-Ill
261(95%) 4e-106
684(99%) 0 Calcium ion binding; Unfolded protein
binding (GO:0005509; GO:0051082)
[COPUU5]
128(88%) lE-54 Integral to membrane (GO:0016021)
[Q6P031] ,
CD166antigenhomolog 778
precursor [BT072099;Salmo (100%)
salar](N)
Coagulation factor IX precursor 73(81%) 2E-31 Caiciumionbinding;Serine-type 13.747 8.029
[AA033372IAF465277; endopeptidase activity (GO:0005509;
153
Coagulation factor IX precursor
[BT059341;Salmosalar](N)
(Salmosalartype I)
707
(100%)
GO:0004252) [Q804W8]
Calcium ion binding; Serine-type
endopeptidase activity (GO:0005509;
GO:0004252) [COHAI5]
CB494727 Cold-inducible RNA-binding 481 (96%)
protein [BT057316;Salmo
salar] (N)(Oncorhynchus mykiss
type 2)
Cold-inducible RNA-binding 514 (99%)
protein [BT058753;Salmo
salar] (N) (Salmo salar feature)
CB492859 Cold-inducible RNA-binding 594 (96%)
605(95%)
151(76%)
CB509933 Complement factor H precursor 137(76%)
CB493785 Complement factor HI protein 149(82%)
[ABY55261;Oncorhynchus
masouformosanus]
(Oncorhynchusmykissfeature)
CB497097 Complement factor HI protein 117(86%)
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Nucleic acid binding; Nucleotide binding
(GO:0003676; GO:0000166) [B5DGC5]
Nucleic acid binding; Nucleotide binding
(GO:0003676; GO:0000166) [COH8U7]
Nucleic acid binding; Nucleotide binding
(GO:0003676; GO:0000166) [EOR8ZI]
Nucleic acid binding; Nucleotide binding
(GO:0003676; GO:0000166) [EOR8Z1]
Serine-type endopeptidase activity
(GO:0004252) [Q9YGE7]
Cysteine-type endopeptidase inhibitor 2.488
activity (GO:0004869) [B5XDV8j
Protein dimerizationactivity; Sequence- 2.439 0.766
specific DNA binding; Sequence-specific
DNA binding transcription factor activity
(GO:0046983;GO:0043565;
GO:0003700) [COHBC6]
masollformosanlls]
(Oncorhynchllsmykissfeature)
Cyclic AMP-dependent 526(95%)
transcription factorATF-5
[BT059632;Salmosalar](Nl
Cystatin-B [ACI69028; Salmo 98(93%)
salar]
Cytochromeb-cl complexsubunit 110
7 [ACI66572;Salmosalar] (100%)
Cytochromecoxidase 102(99%)
polypeptide Via, mitochondrial
precursor [ACI66605;Salmo
salar] (Oncorhynchllsmykiss
feature)
Cytochrome c oxidase 102
polypeptide Via, mitochondrial (100%)
precursor [ACI69150;Salmo
salar] (Salmosalarfeature)
Cytochromecoxidase 79(99%)
polypeptideVllb,mitochondrial
precursor[ACI67848;Salmo
salar]
Cytochromec oxidase subunit4 177
isoform2,mitochondrial (100%)
precursor [ACI67065;Salmo
salar]
Cytochromecoxidasesubunit5B, 117(99%)
mitochondrial precursor
[AC007893; Oncorhynchlls
mykiss]
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Ubiquinol-cytochrome-c reductase activity
(GO:0008121) [B5X6V2]
Cytochrome-coxidaseactivity
(GO:0004129) [B5X6Y5]
Cytochrome-c oxidase activity
(GO:0004129) [B5XE80]
Cytochrome-coxidaseactivity
(GO:0004129) [B5XAH8]
Cytochrome-c oxidase activity
(GO:0004129) [B5X895]
Cytochrome-coxidaseactivity
(GO:0004129) [CIBFUO]
2.768 0.293
86(100%) Cytochrome-c oxidase activity
(GO:0004129) [B5XAX6]
Cytochrome oxidase subunit II 226(94%)
[AAD04736; Salmo salar]
204(76%) Electron carrier activity; Hemebinding;
Monooxygenaseactivity(GO:0009055;
GO:0020037; GO:0004497) [Q9DEW9]
Heme binding; Oxidoreductase activity,
acting on paired donors, with oxidation
ofa pair of donors resulting in the
reduction of molecular oxygen to two
molecules of water (GO:0020037;
GO:0016717) [Q6SESO]
Aromataseactivity;E1ectroncarrier
activity; Hemebinding(GO:0070330;
GO:0009055; GO:0020037) [093299]
Electron carrier activity; Hemebinding;
Oxidoreductase activity, acting on paired
donors, with incorporation or reduction
of molecular oxygen, reduced flavin or
flavoprotein as one donor, and
incorporation of one atom of oxygen
(GO:0009055;GO:0020037;
GO:0016712) [Q5TZ75]
327 1E-90/ Unknown
(57%)/ 0
507(99%)
51(100%)
Cytoplasmic tRNA 2-thiolation
protein 2 [DAA20129;Bos
fallrlls]/[BT072492;Salmo
salar](Bl
Delta-6 faltyacyldesaturase
D6fad_a [AAR21624; Salmo
salar]
CytochromeP450 218(94%)
monooxygenase[AAC26494;
Oncorhynchllsmykiss]
CytochromeP450, family 2, 133(76%)
subfamilyJ,polypeptide24
[AAI54482;Daniorerio]
Delta5-desaturase-likeprotein
[ABU87822; Oncorhynchlls
masoll](D5DP,Fig.11C)
87(99%) Heme binding; Oxidoreductase activity,
acting on paired donors, with oxidation
ofa pair of donors resulting in the
reduction of molecular oxygen to two
molecules of water (GO:0020037;
156
31(94%)
107(65%)
GO:0016717) [A7XUS7]
DiacylglycerolO-acyltransferaseactivity
(GO:0004144) [Q4V9FO]
2-AcylglyceroIO-acyltransferaseactivity
(GO:0003846) [Q3KPP4]
Diamineacetyltransferasel
[ACI67505;Sa/mosa/ar]
113
(100%)
88(96%)
N-acetyltransferase activity (GO:0008080)
[B5X915]
Differentially regulated trout 55(91%)
protein I
[AAG30030IAF281355;
Oncorhynchus mykiss] (Sa/mo
sa/arfeature)
DNA polymerase subunit delta-4 112
[ACM09657;Sa/mosa/ar] (100%)
56(98%)
Nucleus (GO:0005634) [B9EQ60] ,
DNA binding; DNA-directed RNA
polymerase activity (GO:0003677;
GO:0003899) [C I BXK5]
485 (91%) IE-I73 DNA binding; DNA-directed RNA
polymerase activity (GO:0003677;
GO:0003899) [B9ELF2]
DnaJ homolog subfamily A 437 (99%)
member 2 [BT057967; Sa/mo
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Heat shock protein binding; Unfolded
protein binding (GO:0031072;
salar](Nl GO:0051082) [B9EQP2]
Dual specificityprotein kinase 260(78%) 5E-25 ATP binding; Protein serine/threonine
~~K4 [BT045149; Salmo salar] kinase activity (GO:0005524;
GO:0004674) [B5X280]
Early meiotic induction protein 5, 163(94%) IE-83 Unknown 5.802
mitochondrial precursor
[AC008273; Oncorhynchlls
mykiss]
Elongation factor I-alpha 99(100%) 2E-49 GTP binding; GTPase activity; Translation
[ACN I0642; Salmo salar] elongation factor activity (GO:0005525;
(Salmosalarfeature) GO:0003924; GO:0003746) [COH9C3]
Elongation factor I-alpha 51(100%) 2E-20 GTP binding; GTPase activity; Translation 3.350
[ACN I0642; Salmo salar] elongation factor activity (GO:0005525;
(Oncorhynchusmykisstype I) GO:0003924; GO:0003746) [COH9C3]
Elongation factor I-alpha 145 2E-77 GTP binding; GTPase activity; Translation 36.190
[ACN I0642; Salmo salar] (100%) elongation factor activity (GO:0005525;
(Oncorhynchusmykisstype 2) GO:0003924; GO:0003746) [COH9C3]
Elongation factor I-alpha I 38(100%) IE-II GTP binding; GTPase activity; Translation 57.398 37.077
[ACNI1490;Salmosalar] elongation factor activity (GO:0005525;
(Salmosalarfeature) GO:0003924; GO:0003746) [COHBSI]
Elongation factor I-gamma 122 6E-69 Translation elongation factor activity 2.767 0.573
[ACI33692; Salmo salar] (Salmo (100%) (GO:0003746) [B5X311]
salarfeature)
Elongation factor I-gamma 73(92%) 2E-53 Translation elongation factor activity
[ACNIOI23;Salll1osalar] (GO:0003746) [COH7V4]
(Oncorhynchusll1ykissfeature)
Elongation factor 2 [ACNI0751; 211 (99%) 3E-I04 GTP binding; GTPase activity; Translation
Salll1osalar] elongation factor activity (GO:0005525;
GO:0003924; GO:0003746) [COH9N2]
Endoplasmic reticulum-Golgi 32(91%) 9E-12 ER-Golgi intermediate compartment 6.044 1.857
intermediate compartment membrane; Golgi apparatus;
protein 3 [AAIOOI26;Danio Endoplasmic reticulum membrane;
158
rerio] (Xl Integral to membrane (GO:0033 I 16;
GO:0005794;GO:0005789;
GO:00J6021) [Q80312] ,
Enolase 3-1 [ACH70930; Salmo 182(99%) 3E-101 Magnesium ion binding; Phosphopyruvate
salar] hydrataseactivity(GO:0000287;
GO:0004634) [B5DGQ6]
Enolase 3-2 [ACH7093 I; Salmo 167(99%) IE-91 Magnesium ion binding; Phosphopyruvate
salar] hydrataseactivity(GO:0000287;
GO:0004634) [B5DGQ7]
Erythrocyte membrane protein 96(89%)1 9E-26/ Unknown
band4.1-like3 [EAXOI645; 728(95%) 0
Homosapiens)/[EZ784403;
Oncorhynchus mykiss) (B)
Ester hydrolase Cl lorf54 156(99%) 3E-86 Hydrolase activity, acting on ester bonds;
homolog [ACOI1749; Caligus Zinc ion binding (GO:0016788;
rogercresseyi) (Salmosalar GO:0008270) [C I BRU6]
feature)
CB516671 EsterhydrolaseCllorf54 160 IE-90 Hydrolase activity,actingon ester bonds; 3.842 0.582
homolog [ACOI1749; Caligus (100%) Zinc ion binding (GO:0016788;
rogercresseyi) (Salmosalar GO:0008270) [Cl BRU6)
feature)
Extra spindle poles-like I 144(35%) IE-17 Peptidase activity (GO:0008233) 2.455 0.421
[AAI45845;MlIsmllscllllls) [A6H6EI)
ExtracelJularmatrixprotein I 97(97%) 3E-48 ExtracelJular space (GO:0005615)
precursor [ACN I0906; Salmo [COHA37),
salar) (Salmosalartype I)
ExtracelJularmatrixprotein I 587(84%) 3E-141 ExtracelJular space (GO:0005615)
precursor [BT059193; Salmo [COHA37),
salar)(N) (Salmo salar type 2)
ExtracelJularmatrixprotein I 568(99%) 0 ExtracelJular space (GO:0005615) 2.060 0.186
precursor[BT059193;Salmo [COHA37),
salar) (Nl (Salmosalar type 3)
159
CB498116 Fastmyotomalmuscietroponin- 72(100%) 2E-26 Unknown 3.997 0.619
T-I [ACH71024; Salmosalar]
106(86%) 6E-31 Endoplasmic reticulum membrane;
Integral to membrane (GO:0005789;
GO:OO 16021) [Q5CZNO] c
Fatty acid binding protein H- 133 IE-68 Lipid binding; Transporter activity 28.201
FABP [AAB53643; (100%) (GO:0008289; GO:0005215) [013008]
Oncorhynchllsmykiss]
(Oncorhynchllsmykissfeature)
Fatty acid binding protein H- 133 IE-68 Lipid binding; Transporter activity 7.126 2.484
FABP [AAB53643; (100%) (GO:0008289; GO:0005215) [013008]
Oncorhynchllsmykiss]
(Oncorhynchlls mykiss feature)
Ferritinheavysubunit 120(94%) 3E-65 Ferric iron binding; Ferroxidaseactivity
[AAB34575; Salmo salar] (GO:0008199;GO:0004322) [P49946]
(Oncorhynchllsmykisstype I)
Ferritinheavysubunit 139(99%) 2E-76 Ferric iron binding; Ferroxidaseactivity 4.218
[AAB34575; Salmo salar] (GO:0008199; GO:0004322) [P49946]
(Oncorhynchllsmykisstype I)
Ferritin-H subunit 65(95%) 8E-57 Ferric iron binding; Oxidoreductase
[AAK08117IAF338763; activity (GO:0008199; GO:0016491)
Oncorhynchllsnerka] [Q98TTO]
Ferritin, heavy polypeptide I-I 127(97%) 6E-69 Ferric iron binding; Oxidoreductase 3.783 0.654
[ACH70933;Salmosalar] activity (GO:0008199; GO:0016491)
[B5DGQ9]
Ferritin,heavysubunit 75(92%) 2E-75 Ferric iron binding; Oxidoreductase
[AC007472; Oncorhynchlls activity (GO:0008199; GO:0016491)
mykiss] (Oncorhynchllsmykiss [CIBEL9]
type 2)
Ferritin,heavysubunit 126 3E-86 Ferric iron binding; Oxidoreductase
[AC007472; Oncorhynchlls (100%) activity (GO:0008199; GO:0016491)
mykiss] (Oncorhynchlls mykiss [CIBEL9]
160
type 2)
Ferritin, heavy subunit 615(99%) 0 Ferric iron binding; Oxidoreductase
[BT059031;Salmosolar](N) activity (GO:0008199; GO:0016491)
(Salmo salar type I) [B5DGQ9]
Ferritin,heavysubunit 61(94%) 2E-14 Ferric iron binding; oxidoreductase
[BT059031;Salmosalar](N) activity (GO:0008199; GO:0016491)
(Salmosalartype2) [B5DGQ9]
CB487639 Ferritin,middlesubunit 130(95%) IE-66 Ferric iron binding; Oxidoreductase
[ACI66713;Salmosalar] activity (GO:0008199; GO:0016491)
(Oncorhynchllsmykisstype I) [B5X793]
CB503780 Ferritin,middlesubunit 162 4E-89 Ferric iron binding; Oxidoreductase
[ACI68639; Salmo salar] (Salmo (100%) activity (GO:0008199; GO:0016491)
salarfeature) [B5XCR9]
Ferritin,middlesubunit 70(100%) 6E-34 Ferric iron binding; Oxidoreductase
[ACI68920; Salmo salar] (Salmo activity (GO:0008199; GO:0016491)
salar feature) (FTM, Fig. lID) [B5XDKO]
Ferritin,middlesubunit 145(99%) 9E-79 Ferric iron binding; Oxidoreductase
[ACI69419; Salmo salar] (Salmo activity (GO:0008199; GO:0016491)
solar feature) (FTM, Fig. liD) [B5XEZ9]
Ferritin,middlesllbllnit 105(99%) IE-72 Ferricironbinding;Oxidoredllctase
[ACI69640; Salmo salar] (Salmo activity (GO:0008199; GO:0016491)
salarfeature)(FTM,Fig. liD) [B5XFMO]
Ferritin,middlesubunit 124 3E-66 Ferric iron binding; Oxidoreductase
[AC007744; Oncorhynchlls (100%) activity (GO:0008199; GO:0016491)
mykiss] (Salmosalarfeature) [CIBFEI]
(Fig. lID)
Ferritin, middle subunit 113 2E-59 Ferric iron binding; Oxidoreductase
[AC008179; Oncorhynchlls (100%) activity (GO:0008199; GO:0016491)
mykiss] (Oncorhynchlls mykiss [CIBGM6]
type 2)
Fibrinogenbetachainprecllrsor 491 010 Protein binding, bridging; Receptor
[ABJ98546;Larimichlhys (71%)1 binding (GO:0030674; GO:0005102)
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574(99%) [AOFJG5]
Forkhead box protein QI 192 (86%) 8E-95 Sequence-specific DNA binding;
[ACOI3697; Esox lucius] Sequence-specific DNA binding
transcription factor activity
(GO:0043565; GO:0003700) [C1BXE4]
Foxl2-like protein [HMI59472; 407 (83%) 2E-82 Sequence-specific DNA binding;
Salmo solar] (N) Sequence-specific DNA binding
transcription factor activity
(GO:0043565; GO:0003700) [E3UBG6]
Fructose-I,6-bisphosphatase 190(97%) 2E-119 Fructosel,6-bisphosphatel-phosphatase
[ACH70893; Salmo solar] activity (GO:0042132) [B5DGL9]
Fumarylacetoacetase [AC009168; 137 (88%) IE-69 Fumarylacetoacetase activity
Osmerus mordax] (Salmo solar (GO:0004334) [Cl BJG5]
type I)
Galactosamine (N-acetyl)-6- 72(75%) 5E-29 Sulfuricesterhydrolaseactivity
sulfate sulfatase [AAI29219; (GO:0008484) [AILIU7]
Daniorerio]
CA053189 Glutamate dehydrogenase I,
122
(100%)
71(100%)
43(87%)
694(99%)
162
Cation binding; Chitinbinding; Chitinase
activity (GO:0043169; GO:0008061;
GO:0004568) [B5AXN7]
DNA binding (GO:0003677) [B5X8E5]
Catalytic activity (GO:0003824)
[Q2MJT2]
Binding; Glutamate dehydrogenase
[NAD(P)+] activity (GO:0005488;
GO:0004353) [Q70PJ5]
Binding;Oxidoreductaseactivity,acting
mitochondrial precursor (100%) on the CH-NH2 group of donors, NAD or
[BT044837;Salmosalar] (NI NADP as acceptor (GO:0005488;
(Salmosalarfeature) GO:OO 16639) [B5X IB8]
Glutamine synthetase 78(100%) IE-38 ATP binding; Glutamate-ammonia ligase 33.222 10.108
[AAM73660IAF390022; activity (GO:0005524; GO:0004356)
Oncorhyncllllsmykiss] [Q8J133]
Glutathione peroxidase 3 492(99%)
precursor [BT072794; Salmo
salar](N)
Glutathione peroxidase type 2 71(85%) IE-28 Glutathione peroxidase activity
[AAV32968; Oncorhynchlls (GO:0004602) [Q5UTE7]
mykiss]
GlutathioneS-transferase 159(97%) 3E-84 Glutathione transferase activity
[BAA76974; Oncorhynchlls (GO:0004364) [Q9W647]
nerka]
Glutathione S-transferase A 48(98%) 5E-19 Transferase activity (GO:0016740)
[AC007597; Oncorhynchlls [CIBEZ4]
mykiss]
GlutathioneS-transferasetheta-1 155 6E-83 Transferase activity (GO:0016740) 20.463 16.928
[ACI33850;Salmosalar] (100%) [B5X3G9]
Glyceraldehyde-3-phosphate 113 5E-54 NAD binding; Glyceraldehyde-3- 17.508 6.500
dehydrogenase [ACI33883; (100%) phosphate dehydrogenase
Salmosalar] (Oncorhynchlls (phosphorylating) activity (GO:0051287;
mykisstype I) GO:0004365) [B5X3K2]
Glyceraldehyde-3-phosphate 123 3E-59 NAD binding; Glyceraldehyde-3- 3.727 0.789
dehydrogenase [ACI33883; (100%) phosphate dehydrogenase
Salmosalar] (Salmosalartype (phosphorylating) activity (GO:0051287;
3) GO:0004365) [B5X3K2]
CB498361 Glyceraldehyde-3-phosphate 146(99%) 5E-78 NAD binding; Glyceraldehyde-3- 4.953 1.826
dehydrogenase [ACI66269; phosphate dehydrogenase
Salmosalar] (Oncorhynchlls (phosphorylating) activity (GO:0051287;
mykiss type 2) GO:0004365) [B5X5Z9]
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Glyceraldehyde-3-phosphate 116 3E-60 NADbinding;Glyceraldehyde-3- 26.555
dehydrogenase [ACI69846; (100%) phosphate dehydrogenase
Salmosalar] (Salmo salar type (phosphorylating) activity (GO:0051287;
2) (GAPDH2, Fig. 13B) GO:0004365) [B5XG76]
CA041846 Glvcoprotein2fEAW50313; 72(44%)/ 7E-IO/
191(96%) 2E-80
558(95%) 0 Extracellular region (GO:0005576)
[B5X3N2],
340(86%) I.3E- Signal transducer activity (GO:0004871)
24 [P29387]
Heat shock 70kDa protein 8 94(91%) 5E-43 ATP binding (GO:0005524) [Q6TEQ5]
[AAQ97970;Daniorerio](X)
CB493960 Heatshock90kDaprotein 1 beta 59(100%) IE-26 ATPbinding; Unfolded protein binding
(GO:0005524; GO:0051 082) [Q5DW65]
EG860968 Heatshock90kDaprotein I beta 204(99%) 3E-98 ATPbinding; Unfolded protein binding
(GO:0005524; GO:0051082) [Q5DW65]
Heatshockcognate70kDa 109 4E-56 ATP binding (GO:0005524) [COHAK5]
protein [ACNI 1074; Salmo (100%)
salar]
CB498852 Heat shock cognate 71 kDa 207 4E-114 ATP binding (GO:0005524) [P08108]
(100%)
Heat shock protein 70isoform 3 I1I lE-56 ATP binding (GO:0005524) [B5DG30]
[ACH70704; Salmo salar] (100%)
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Heat shock protein 8 [AAH63228; 173(95%) 8E-89 ATP binding (GO:0005524) [Q6NYR4]
Daniarerio] (X)
Hemagglutinin/amebocyte 117(78%) 8E-56 Unknown 3.066 0.397
aggregation factor precursor
[ACI68653;Salmosalor]
Hemoglobin subunit alpha 143(99%) 4E-74 Heme binding; Oxygen binding; Oxygen 2.969 0.246
[ACI69100;Salmosalar] transporter activity (GO:0020037;
(Oncorhynchusmykiss feature) GO:0019825; GO:0005344) [B5XE30]
Hemoglobin subunit alpha 143(99%) 9E-74 Heme binding; Oxygen binding; Oxygen
[ACI69100; Salmo salar] (Salmo transporter activity (GO:0020037;
salarfeature) GO:0019825; GO:0005344) [B5XE30]
Hemoglobinsubunitalpha-I 143 8E-76 Heme binding; Oxygen binding; Oxygen 4.064 0.468
[AC007570; Oncorhynchus (100%) transporter activity (GO:0020037;
mykiss] (Oncorhynchus mykiss GO:0019825; GO:0005344) [Q98974]
feature)
Hemoglobinsubunitbeta-4 148 6E-80 Hemebinding; Oxygen binding; Oxygen
[AC007576;Oncorhynchus (100%) transporter activity (GO:0020037;
mykiss] (Oncorhynchus mykiss GO:OO 19825; GO:0005344) [C IBEX3]
feature)
Hemoglobinsubunitbeta-4 148(99%) 2E-78 Heme binding; Oxygen binding; Oxygen
[AC008020; Oncorhynchus transporter activity (GO:0020037;
mykiss] (Oncorhynchus mykiss GO:OO 19825; GO:0005344) [C IBG67]
feature)
Hemoglobinsubunitbeta-4 148 5E-80 Heme binding; Oxygen binding; Oxygen
[AC008020; Oncorhynchus (100%) transporter activity (GO:0020037;
mykiss] GO:OO 19825; GO:0005344) [C 1BG67]
Heparin cofactor 11 304 IE- Serine-type endopeptidase inhibitor
[AAN71003IAF515273; Danio (80%)/ 174/0 activity (GO:0004867) [Q8A YE2]
rerio]/[EZ764595; 571(99%)
Oncorhynchusmykiss] (B)(X)
Hepatocyte nuclear factor 4 alpha 463(94%) 2E-119 Sequence-specific DNA binding;
[AAH56550; Daniorerio] (G) Sequence-specific DNA binding
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transcription factor activity; Steroid
hormone receptoractivity; linc ion
binding (GO:0043565; GO:0003700;
GO:0003707; GO:0008270) [Q6PHH5]
High affinity copper uptake 114(84%) 4E-47 Copper ion transmembrane transporter 2.748 0.325
protein 1 [ACNII071;Salmo activity (GO:0005375) [COHAK2]
salar]
High-mobilitygroup20B 117(86%) IE-48 DNA binding (GO:0003677) [Q503ll]
[AAH95120;Daniorerio]
Histone deacetylase 2 [BT045315; 619(99%) 0 Histone deacetylase activity
Salmosalar](Nl (GO:0004407) [B5X2P6]
Histone HI.O [ACNI0192; Salmo 82(100%) 3E-42 DNA binding (GO:0003677) [COH823]
salar]
Homogentisate 1,2-dioxygenase 78(84%) 4E-34 Homogentisate 1,2-dioxygenaseactivity 2.063 0.173
[AAI52650;Daniorerio](X) (GO:00044 I I) [Q6P2V4]
Inhibitor of DNA 126 IE-65 Transcription regulator activity 6.110 3.946
binding/differentiation ID (100%) (GO:0030528) [Q4VKK4]
[AAX46287; Oncorhynchlls
mykiss]
Inositoll,4,5-trisphosphate3- 197(77%) 4E-17 Inositol trisphosphate 3-kinaseactivity 2.606 0.634
kinase A [BCI23676;Bos (GO:0008440) [A4FV33]
tallrlls](N)
Inositol-trisphosphate3-kinaseA 112(60%) 2E-29 Unknown 2.616 0.204
[DAA25447;Bostallrus]
Intelectin2 [ACC62157;Danio 168(71%) 2E-70 Receptorbinding(GO:0005102) 8.082
rerio] [CIIHVO]
Intraflagellartransport52 131(94%) lE-55 Flagellum (GO:OO 19861 )[C I BJV5] c
homolog [AC009308; Osmerlls
mordax]
Kelch repeat and BTB (POl) 76(96%) 5E-35 Unknown 4.020 1.000
domain containing 10
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[ACH70794;Salmosalar]
Keratin 18, simple type I keratin 73(100%) 5E-24 Structural molecule activity (GO:0005198) 7.347 2.658
[CAA 74664; Oncorhynchus [057607]
mykiss]
Kifl-bindingprotein 67(73%) 2E-IO Binding (GO:0005488) [A8WE67] 6.078 0.706
[ABW89743;Daniorerio]
(Oncorhynchusmykissfeature)
Kifl-bindingprotein 74(79%)/ 8E-26/ Binding (GO:0005488) [A8WE67] 2.048 0.262
[ABW89743;Danio 489(94%) 0
rerio]/[EZ853027;
Oncorhynchus mykiss] (B) (Salmo
salarfeature)
154(57%) IE-35 Cysteine-type endopeptidase inhibitor
activity (GO:0004869) [C 1BX66]
Oncorhynchusmykissfeature)
Kininogen-I precursor 184(60%) 2E-49 Cysteine-type endopeptidase inhibitor 4.787
[ACOI3619;Esoxlucills] activity (GO:0004869) [C 1BX66]
(Oncorhynchusmykissfeature)
Leukocytecell-derived 55(84%) IE-20 Response to bacterium (GO:0009617) 3.630
chemotaxin2[ABDI6188; [QOHOR9]b
Daniorerio] (X)
Leukocyteelastaseinhibitor 136(88%) 7E-57 Serine-type endopeptidase inhibitor
[ACI34221;Salmosalar] activity (GO:0004867) [B5X4JO]
Lipocalinprecursor[ACI68588; 136 IE-74 Binding; Transporter activity 2.989 0.537
Salmosalar] (Salmosalartype (100%) (GO:0005488; GO:00052I 5) [B5XCL8]
2)
Lipocalinprecursor[ACI69895; 84(100%) IE-41 Binding; Transporter activity
Salmosalar] (Salmosalartype (GO:0005488; GO:000521 5) [B5XGC5]
I)
Lipocalinprecursor[ACI69895; 151(93%) IE-74 Binding; Transporter activity
Salmosalar] (Salmosalartype (GO:0005488; GO:000521 5) [B5XGC5]
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Lipocalinprecursor[ACI69895; 137 3E-74 Binding; Transporter activity
Salmosalar] (Salmosalartype (100%) (00:0005488; 00:0005215) [B5XOC5]
I)
147(99%) 5E-81 Binding; Transporter activity
(00:0005488; 00:0005215) [B5XOT3]
71(48%)/ lE-18/ Binding;Transporteractivity
179(98%) 7E-79 (00:0005488; 00:0005215) [C3KJQO]
216(89%) 7E-64 Binding; Transporter activity
(00:0005488; 00:0005215) [B5XCL8]
Liver-basic fatty acid binding 126(84%) 4E-55 Lipid binding; Transporter activity
protein b [ACA64701; Cyprinu5 (00:0008289; 00:0005215) [B3FQT5]
carpio]
90(99%) 7E-47 Defense response to bacterium
(00:0042742) [Q64JE5] b
54(62%)
36(87%)
LysozymeC 11 precursor 95(99%) lE-51 Lysozyme activity (00:0003796)
[ACI67735;Salmosalar] [B5XA65]
633(99%) 0 Membrane (00:0016020) [COH9AO] ,
Malate dehydrogenase 2-1, NAD 102(99%) 9E-86 L-malate dehydrogenase activity; binding
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(mitochondrial) [ACH70948;
Sa/mosa/ar] (Oncorhynchus
mykissfeature)
130
(100%)
406(91%)
(GO:0030060; GO:0005488) [B5DGS4]
L-malatedehydrogenase activity; binding
(GO:0030060; GO:0005488) [B5X514]
Malate dehydrogenase, 185(91%) 5E-60 Unknown
cytoplasmic (MDH) gene
[HQ287747; Coregonus
elupeajormis] (Nl(Sa/mosa/ar
type I)
Malate dehydrogenase, 140(90%) IE-41 Unknown
cytoplasmic (MDH) gene
[HQ287747;Coregonus
elupeajormis] (N) (Sa/mo sa/ar
type 2)
107 5E-61 L-malate dehydrogenase activity; binding
(100%) (GO:0030060; GO:0005488) [COH8P8]
202(94%) 7E-110 Serine-type endopeptidase activity
(GO:0004252) [QILWH3]
75(90%) 2E-15 Serine-type endopeptidase activity
(GO:0004252) [QILWH3]
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(Salmosalartype2)
Membrane-spanning4-domains 139(41%) IE-14 Integral to membrane (GO:0016021)
subfamily A member 4A [B5XDT3] c
[ACI69003;Salmosalar]
lIothionein B[AY267818; 536(85%) 8E-134 Metal ion binding (GO:0046872) [P68502]
'elinus alpil7l1s] (N)
Metallothionein-A[AF098071; 369(98%) 7E-174 Metal ion binding (GO:0046872) [P68505]
Salvelil7l1salpil7l1s](N)
MHC Class I (Sasa-UBA) 566(99%) 0 MHC class I protein complex
[EF210363;Salmosalar](Nl (GO:0042612) [A7KDZ8] c
MHC class I a region [ABI62342; 207 (94%) 7E-79 MHCclasslproteincomplex
OncorhYl7chlls mykiss] (N) (GO:0042612) [Q5FBUO] c
Mu-crystallinhomolog 149 5E-79 Binding; Catalytic activity (GO:0005488;
[ACM08876; Salmo salar] (100%) GO:0003824) [B9EMX9]
Myelin basic protein 89 (44%)! IE-05! Structural constituent of myelin sheath 16.938 11.593
[AAW52552;Danio 44(100%) 4E-12 (GO:001991 I) [Q512C7]
rerio]![EZ764 180;
Oncorhynchllsmykiss](Il)
Myelin protein zero-like protein 2 46(68%) 3E-JI Membrane (GO:OO 16020) [B5XAW9] c
precursor [ACI67989; Sallllo
salar] (Salmo salar type I)
Myelin protein zero-like protein 2 54(67%) 7E-12 Membrane (GO:OO 16020) [B5XAW9] c
precursor [ACI67989; Sallllo
salar] (Sallllo salar type 2)
Myristoylatedalanine-richC- 630 0 Calmodulin binding; kinase activity 2.303
kinasesubstrate [BT045958; (100%) (GO:0005516; GO:0016301) [B5X419]
Salmosalar](N)
N2,N2-dimethylguanosine tRNA 126(98%) 3E-69 RNA binding; tRNA (guanine-N2-)- 3.904
methyltransferase [ACNI 1277; methyltransferase activity; Zinc ion
Salmosalar] binding (GO:0003723; GO:0004809;
GO:0008270) [COHB58]
170
81 (100%) 6E-42 Unknown
Cytoplasm; Nucleus (GO:0005737;
GO:0005634)[Q8JIU7]'
CA044305 NADH dehydrogenase I alpha
subcomplexsubunit4
[ACM08519; Salmo salar]
(Salmosalarfeature)
NADH dehydrogenase I alpha 42 (96%) 7E-20 Unknown
subcomplexsubunit4
[AC008391;Oncorhynchus
mykiss] (Oncorhynchus mykiss
feature)
NADH dehydrogenase I alpha 81 (100%) 2E-41 Unknown
subcomplexsubunit4
[AC008391; Oncorhynchus
mykiss] (Oncorhynchus mykiss
feature)
NADH dehydrogenase iron-suI fur 107 (99%)
protein 5 [AC168144;Salmo
salar]
Nascent polypeptide-associated 109(99%)
complex alpha polypeptide
[AAM21714;Daniorerio] (X)
(Oncorhynchusmykisstype I)
CK991355 Nascent polypeptide-associated 109 (99%) 8E-38 Cytoplasm; Nucleus (GO:0005737;
complex alpha polypeptide GO:0005634) [Q8JIU7] ,
[AAM21714; Danio rerio] (X)
(Oncorhynchus mykisstype 2)
CA366949 Nascent polypeptide-associated 107
complexsubunitalpha (100%)
[BT074369; Oncorhynchus
mykiss] (N)(Oncorhynchus
mykisstype3)
Non-muscle actin [EFW40167; 42(100%) 5E-17 Unknown
CapsasporaolVczarzaki]
171
4.443 1.821
0.812
9.862
0.355
Nonhistone chromosomal protein 542
H6 [BT074292; Oncorhynchus (100%)
mykiss](N)
DNA binding (GO:0003677) [C 1BFL7] 16.408
113(61%) 4E-36 Nucleic acid binding; Zinc ion binding
(GO:0003676; GO:0008270) [A2BG91]
171 (77%) 3E-62 Ion channel activity (GO:0005216)
[B8JHY6]
49(74%)/ 3E-12/ Zinc ion binding (GO:0008270)
747 (99%) 0 [BOUXR5]
Novelproteinsimilartovertebrate 75(55%)
solute carrier (sodium-coupled
nucleoside transporter) family 28
[CAKI0822; Daniorerio] (X)
Nucleoside binding; Nucleoside:sodium
symporter activity (GO:0001882;
GO:0005415) [QILX55]
EG898351
57 (56%) 4E-II Nucleus (GO:0005634) [Q9WTKO] c
59 (56%) 1E-8 Nucleus (GO:0005634) [Q9WTKO] c
552(90%)
697(90%)
172
type 2)
CA044682 Nuclear protein 1 [BT056591; 219 2E-J09 Unknown 3.209 0.478
Salmosalar] (Nl(Salmosalar (100%)
type 3)
Nuclear receptor subfamily 5. 77(88%) 5E-32 Sequence-specific DNA binding; 4.103
group A, member 5 [AAI63909; Sequence-specific DNA binding
Daniorerio] transcription factor activity; Steroid
hormone receptoractivity; Zinc ion
binding (GO:0043565; GO:0003700;
GO:0003707; GO:0008270) [B3DKN2]
Nucleoside diphosphate kinase 165(98%) 2E-90 ATP binding; Nucleoside diphosphate
[ACM80355; Oncorhynchus kinase activity (GO:0005524;
mykiss] GO:0004550) [COKIP7]
Nucleoside diphosphate kinase A 139 2E-76 ATP binding; Nucleoside diphosphate 3.339 0.324
[ACI68568;Salmosalar] (100%) kinase activity (GO:0005524;
GO:0004550) [B5XCJ8]
OCIA domain-containing protein 145(81%) 5E-47 Unknown 4.064 0.350
2 [ACI69700;Salmosalar)
Olfactomedin 4 [AAH47740; 137(53%) 6E-36 Extracellular space (GO:0005615)
Homo sapiens) [Q6UX06)C
CB493774 Omithinedecarboxylaseantizyme 43(96%) IE-23 Ornithine decarboxylase inhibitor activity
small isoforrn [AAP82032; (GO:0008073) [Q6X3F2]
Paralichlhysolivaceus]
OrphannuclearreceptorSHP 193(61%) 2E-57 DNA binding; Sequence-specific DNA
[AANI7673; Oreochromis binding transcription factor activity;
nilolicus] Steroidhormonereceptoractivity
(GO:OO03677;GO:OOO3700;
GO:0003707) [Q8AUM4]
Pancreatic progenitor cell 73(72%)
differentiation and proliferation
factorb [AD028364; IClalurlls
jurcalus] (Oncorhynchllsmykiss
173
feature)
115(63%) 8E-26 Unknown
157 3E-87 Calcium ion binding; Protein-arginine
(100%) deiminaseactivity(GO:0005509;
GO:0004668) [B9WPX5]
Phosphoglycerate mutase 1
[BT044637;Salmosalar](N)
Phytanoyl-CoAdioxygenase,
peroxisomal precursor
[ACI33694;Salmosalar]
732(99%)
112(87%)
160(93%)
227(85%)
672(99%)
301
(83%)/
717(98%)
157(97%)
174
2,3-Bisphosphoglycerate-dependent
phosphoglycerate mutase activity
(GO:0046538) [B5XOR8]
Oxidoreductase activity,acting on single
donors with incorporation of molecular
oxygen, incorporation of two atoms of
oxygen (GO:0016702) [B5X313]
Serine-type endopeptidase activity
(GO:0004252) [Q5DVP8]
Serine-type endopeptidase activity
(GO:0004252) [Q5DVP8]
DNA binding; RNA binding; RNA-
directed DNA polymerase activity;
Aspartic-type endopeptidase activity;
Ribonuclease H activity; Zinc ion
binding (GO:0003677; GO:0003723;
GO:0003964;GO:0004190;
GO:0004523; GO:0008270) [Q2VF30]
Sequence-specific DNA binding;
Sequence-specific DNA binding
[ACNI0506;Salmosalar] transcription factor activity;
Transcription regulator activity
(GO:0043565;GO:0003700;
GO:0030528) [COH8Y7]
247 3E-86/ Spliceosomal complex (GO:0005681)
(55%)/ 3E-161 [CIBJD5] ,
513(88%)
186(86%)
,AF04305IAFI92969;
ncorhynchusmykiss]
Prefoldinsubunit3 [BT072072; 102(90%) 6E-25 Unfolded protein binding (GO:0051082)
Salmosalar](N) [COPU61]
634(97%) 0 Cysteine-type endopeptidase activity
(GO:0004197) [Q64HYO]
Proteasomesubunitalphatype2 106 3E-55 Threonine-type endopeptidase activity
[AC008660; Oncorhynchus (100%) (GO:0004298) [CIBI07]
mykiss]
163(34%) IE-13 Calcium ion binding (GO:0005509)
[E2BWV3]
36(89%) 4E-8 Nucleus (GO:0005634) [Q6NV32j ,
102 2E-52 4-Alpha-hydroxytetrahydrobiopterin
(100%) dehydratase activity (GO:0008124)
[B9ELA9]
71(65%)/ 3E- Acyltransferase activity (GO:0008415)
545(99%) 15/0 [Q8BKZ9]
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Ras-relatedprotein Rab-IA 352 (99%) 2E-173 GTP binding (GO:0005525) [COHAK6] 2.821 0.493
[BT059362; Salmosalar] (N)
Receptorforactivatedprotein 174 (96%) 4E-I10 Angiogenesis (GO:0001525) [042248] b 3.206
kinase C [AAB81617; Danio
rerio] (Xl (Salmosalar feature)
Receptorforactivatedprotein 174 (96%) 4E-I10 Angiogenesis (GO:OOO 1525) [042248] b
kinase C [AAB81617; Danio
rerio] (X) (Oncorhynchus mykiss
type I)
Receptor for activated protein 174 (96%) 4E-I10 Angiogenesis (GO:0001525) [042248] b 7.095
kinase C [AAB81617; Danio
rerio] (X)(Oncorhynchllsmykiss
type 2)
Reproduction regulator 2 110(40%) IE-13 Unknown
[AAN02165; Epinephelus
coioides]
RERI retention in endoplasmic 160(80%) 8E-18 Integral to membrane (GO:0016021)
reticulum I [BT045447;Salmo [B5X328],
salar](Nl
Reticulon4[BK004986; 637(99%) 0 Endoplasmic reticulum (GO:0005783) 3.779 0.886
Oncorhynchusmykiss](N) [Q4FZ68]
Retinoicacidreceptorgammab 391(86%) 5E-100 Retinoic acid receptoractivity; Sequence- 2.841 1.010
[EU025716;Salmosalar](Nl specific DNA binding; Sequence-specific
DNA binding transcription factor
activity; Steroid hormone receptor
activity; Zinc ion binding (GO:0003708;
GO:0043565;GO:0003700;
GO:0003707; GO:0008270) [B3TDG8]
CA050645 Retinoicacidreceptorresponder 27(100%) 7E-7 Receptoractivity(GO:0004872)
protein 3 [ACI69191;Salmo [B5XECI]
salar]
Retinol-binding protein 139 3E-80 Retinoid binding; Transporter activity 3.629 0.883
176
(100%)
135(71%)
115(29%)
(GO:0005501; GO:0005215) [Q90Y51]
Lipid binding; Transporter activity
(GO:0008289; GO:0005215) [E3TGB7]
RNA binding; RNA-directed DNA
polymerase activity (GO:0003723;
GO:0003964) [Q64IX6]
160 5E-57/ RNA binding; RNA-directed DNA
(69%)/52 IE-05 polymerase activity (GO:0003723;
(89%) GO:0003964) [Q7T271]
RhoGTPase activating protein 116(48%) 3E-18 GTPase activator activity (GO:0005096)
IIA [AAH63444; Homo [Q6P4F7]
sapiens] (X)
RibosomalproteinLI2 165 2E-88 Structural constituent of ribosome
[ACH70859; Salmo salar] (100%) (GO:0003735) [B5DGI5]
RibosomalproteinLI9 148 6E-70 Structural constituent of ribosome
[BT043693;Salmosalar](N) (100%) (GO:0003735) [B5DGD4]
51(100%) IE-22 Unknown
44(100%) 3E-12 Structural constituent of ribosome
(GO:0003735) [A9ZTC2]
85(93%) 4E-25 Structuralconstituentofribosome
(GO:0003735) [A9ZTC2]
RibosomalproteinS30 133 2E-58 Structural constituent of ribosome
[ACA05173; Oncorhynchus (100%)
177
masouformosanus] (GO:0003735) [BIA311]
141 (71%) 3E-51 Nucleic acid binding; Pancreatic
ribonuclease activity (GO:0003676;
GO:0004522) [BOFFJ3]
141(71%) 3E-51 Nucleic acid binding; Pancreatic
ribonuclease activity (GO:0003676;
GO:0004522) [BOFFJ3]
RWD domain-containing protein 117
1 [AC007902; Oncorhynchus (100%)
mykiss]
SIOOcalciumbindingprotein
[CAJ90906;Salmosalar]
Secreted phosphoprotein 24
[CAD21625; Salmo salar]
141(88%)
142(31%)
79(100%)
Calcium ion binding (GO:0005509)
[QOKFS2]
Extracellular region (GO:0005576)
[Q710Al]'
SelenoproteinPaprecursor 583(99%)
[BT072221; Salmosalar] (N)
(Salmo salar type 2) (SEPP2,
Fig.15B)
SelenoproteinS[ACNI0331;
696(99%)
706
(100%)
60(100%)
178
Selenium binding (GO:0008430)
Salmosalar]
32(88%)
Serineincorooratorl [BT045730; 670(99%)
Serum albumin [ABF57673; 165 (99%)
Oncorhynchusmykiss]
Serum albumin 2 [CAA43187; 130 (99%)
Salmosalar] (Salmo salar type
I)
Serum albumin 2 [CAA43187; 232 (78%)
Salmosalar] (Salmo salar type
2)
Serum amyloid P component 108(47%)
precursor[AAA40093;Mus
musculus] (X)
Similartonon-LTR 125(47%)
retrotransposablef
[COH8G2]
Serine-type endopeptidase inhibitor
activity (GO:0004867) [BOY3R7]
Membrane (GO:0016020) [B5X3WI] ,
Extracellular space (GO:0005615)
[A5HOJ9],
Lipid binding; Metal ion binding
(GO:0008289; GO:0046872) [Q03156]
Lipid binding; Metal ion binding
(GO:0008289; GO:0046872) [Q03156]
Metal ion binding; Sugar binding
(GO:0046872;GO:0005529) [PI2246]
RNA binding; RNA-directed DNA
polymerase activity (GO:0003723;
GO:0003964) [Q86EK6]
CA049970
Small EDRK-rich factor 2
[ACM08444; Salmo salar]
61(100%)
656
(100%)
Nucleic acid binding (GO:0003676)
[B5XGC3]
45 (85%) 8E-17 Growth factor activity (GO:0008083)
[AOA7YO]
SPARC precursor [AC134168;
Salmosalar] (Oncorhynchus
55(84%)
179
Calcium ion binding (GO:0005509)
[B5X4D7]
Unknown
Membrane (GO:0016020) [Q4VBS7] c
Actin binding (GO:0003779) [B5XB79]
Endoplasmic reticulum membrane;
Integral to membrane (GO:0005789;
GO:OO 16021) [Q6TAW2] c
DNA binding; Transposase activity
(GO:0003677; GO:0004803) [AOP9K9]
Cellredoxhomeostasis(GO:0045454)
[B9EPZ9]b
Nucleic acid binding; Nucleotide binding
(GO:0003676; GO:0000166) [B5X3DO]
Nucleic acid binding; Nucleotide binding
(GO:0003676; GO:0000166) [COH9Z3]
Calcium ion binding (GO:0005509)
[B5X4D7]
5E-52/ Sterol binding; Transferase activity,
o transferring acyl groups other than
amino-acyl groups (GO:0032934;
GO:0016747) [Q6P4V5]
mykissfeature)
SPARC precursor [BT045906; 499(99%)
Salmosalar] (N)(Salmosalar
feature)
530(95%)
650(99%)
755(97%)
149
(72%)/
498(91%)
<iss](")
Stress-associated endoplasmic 53(85%)
reticulum protein family member
2 [AAI00484;MlIsmllscllllls](X)
Tcl-liketransporase[BAF37936; 214(96%)
Oncorhynchllsmykiss]
Thioredoxin [ACM09596; Salmo 110(81%)
salar]
242(92%)
85(43%)
[AAH77569; Xenopus laevis]
Thymosinbeta-II [BT057462; 672(99%)
Salmosalar] (N)(Salmosalar
feature)
180
676(94%)
43(94%)
lar] (Oncorhynchus
ature)
Thymosinbeta-12 [ACI67890; 43(100%)
Salmosalar] (Salmosalar
feature)
Thymosinbeta-12 [ACI67890; 43(100%)
Salmosalar] (Salmosalar
feature)
76(90%)
76(90%)
~corhynchusmykiss] (Salmo
lar type 2)
Trafficking protein particle 711(99%)
complex subunit 3 [BT060107;
Salmosalar](N)
89(100%)
657(98%)
701
(100%)
17;Salmosalar](NJ
Transmembrane protein 179B 44(100%)
[ACM08784; Salmo salar]
Transposable element Tcl 147(80%)
181
Actin binding (GO:0003779) [B5XB79]
Actin binding (GO:0003779) [B5XAMO]
Actin binding (GO:0003779) [B5XAMO]
Actin binding (GO:0003779) [B5XAMO]
Unknown
Guanylate cyclase activity; Hemebinding
(GO:0004383; GO:0020037) [COH7U8]
Ferric iron binding (GO:0008199)
[Q9PTI3]
Catalytic activity (GO:0003824) [COPUI7]
Endoplasmic reticulum; Integral to
membrane (GO:0005783; GO:0016021)
[B9EQJ2],
Integral to membrane (GO:0016021)
[B9EMN7],
DNA binding; Transposaseactivity
Transposable element Tcbl 120(93%)
transposase[BT072386;Salmo
salor] (N) (Salmo salar type 2)
Transposable element Tcb2 52(89%)
transposase [ACN 10944; Salmo
salar]
Transposase [BAA8346l; Oryzias 44(66%)
lafipes] (Salmo salar type 3)
Transposase-like mRNA 339(80%)
[BT043992; Salmosalar] (N)
623(99%)
640(99%)
715(99%)
l4;Salmosalar](N)
'feature)
Tripartite motif-containing protein 685(97%)
16 [BT045784;Salmosalar] (N)
(Salmosalarfeature)
CX245969 Trvotophan2,3-dioxygenase 238(83%)
miorerio]
[AAH71532; 101(74%)
?rio]
Type 1collagen alpha 2 chain
182
(GO:0003677; GO:0004803) [B5XDR8]
Unknown
Nucleic acid binding (GO:0003676)
[Q9PTVO]
DNA binding; Transposaseactivity
(GO:0003677; GO:0004803) [B5R/68]
Zinc ion binding (GO:0008270) [B5X415]
Zinc ion binding (GO:0008270) [B5X415]
Zinc ion binding (GO:0008270) [B5X415]
Zinc ion binding (GO:0008270) [B5X415]
Iron ion binding; Tryptophan 2,3-
dioxygenase activity (GO:0005506;
GO:0004833) [A 7MBU6]
GTPbinding; GTPaseactivity; Structural
molecule activity (GO:0005525;
GO:0003924; GO:0005198) [Q6lQ78]
Extracellular matrix structural constituent
[BAB79230; Oncorhynchus
keta]
Ubiquitin [ACNI014l; Salmo
salar]
(100%)
156
(100%)
242
(100%)
520(91%)
(GO:0005201) [Q8UUJ3]
Small conjugating protein ligase activity
(GO:0019787) [B5XIW6]
Binding; Oxidoreductase activity,acting
on the CH-OH group of donors, NAD or
NADP as acceptor; Small conjugating
protein ligase activity (GO:0005488;
GO:0016616; GO:0019787) [B5X314]
Ubiquitin/ribosomalfusion 126
protein homologue [CAJ90900; (100%)
Salmosalar]
UDPglucuronosyltransferase I 231 (74%)
familypolypeptidea3 isoform I
[ADC9192l; Danio rerio]
Unknown (no significant BLAST
183
Structural constituent of ribosome
(GO:0003735) [QOKFS8]
Transferase activity, transferringhexosyl
groups (GO:0016758) [D3XD50]
hits)
CA053884 Unknown (no significant BLAST
hits)
Unknown (no significant BLAST NA NA Unknown 2.239 0.287
hits)
CA059408 Unknown (no significant BLAST
hits)
Unknown (no significant BLAST NA NA Unknown 9.479 3.686
hits)
Unknown (no significant BLAST NA NA Unknown 3.359 1.230
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST NA NA Unknown 3.723 0.784
hits)
CB492559 Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
CB498122 Unknown (no significant BLAST
hits)
Unknown (no significant BLAST NA NA Unknown 2.811 0.428
hits)
CB509762 Unknown (no significant BLAST NA NA Unknown
hits)
CB510700 Unknown (no significant BLAST NA NA Unknown 30.090 15.646
hits)
CK990274 Unknown (no significant BLAST NA NA Unknown
hits)
184
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Uroporphyrinogendecarboxylase 55(99%)
[ACI33757;Salmosalar]
V-Fos transformation effector 236
(ribosomal protein S3A) (100%)
[ACH70890; Salmo salar]
Vitamin D receptora [AAI62213; 216(90%)
Daniorerio]
185
Unknown
Unknown
0.168
0.361
Uroporphyrinogendecarboxylaseactivity
(GO:0004853) [B5X376]
Structural constituent of ribosome 2.339 0.357
(GO:0003735) [B5DGL6]
Sequence-specific DNA binding; 2.857 0.060
Sequence-specific DNA binding
transcription factor activity; Steroid
horrnone receptoractivity; Transcription
regulator activity; Vitamin Dbinding;
Zinc ion binding (GO:0043565;
GO:0003700;GO:0003707;
GO:0030528;GO:0005499;
GO:0008270) [Q9PTN2]
209(42%) 2E-24 Zineionbinding(GO:0008270)
[D3ZQQ2]
71 (100%) 2E-2\ DNA binding (GO:0003677) [B8Y7S9]
Y-box binding protein
[BT043918;Salmosalar](N)
340(98%)
202(69%)
DNA binding (GO:0003677) [B5DH09]
Proteinbinding;Zine ion binding
(GO:0005515; GO:0008270) [A8Y5G5]
Lme transporter LII'I [BT057412; 620
'" (100%)
Zonadhesin-likegene 448(85%)
[AY785950;Salmosalar](N)
Please see Appendix 11 for footnotes.
186
MetaJiontransmembranetransporter
aetivity(GO:0046873) [B9EP37]
Membrane (GO:0016020) [Q5S3NJ]'
APPENDIX V. Supplemental table containing 102 transcripts with greater than 2-fold higher expression in triploid growth hormone transgenic
(3NGHTg) Atlantic salmon family AS25 (slow-growing) in comparison to 3NGHTg Atlantic salmon family AS26 (fast-growing) in any 3 out of 4
technical replicate microarraysincludingatleastonedye-swap.
Gene Name of Best BLASTX or
BLASTN (N) Hit
Length
(%ID)
E
value
X Fold
Change
6-Phosphofructo-2- 116
kinase/fructose-2,6- (100%)
biphosphatase4[ACI34300;
Salmosalar]
Acyl-CoAdehydrogenasefamily 628
member 10 [BT045545; Salmo (100%)
salar](N)
ADAMTS-I protein [BAEI6358; 148 (72%)
Oryzias latipes] (ADAMTSI,
Fig.IIF)
Adaptor related protein complex 1203
(AP)-3deltasubunit (72%)
[BAA36591;Bostaurus] (G)
240(99%)
594(99%)
125(99%)
187
6-Phosphofructo-2-kinaseactivity;ATP
binding (GO:0003873; GO:0005524)
[B5X4R9]
Hydrolase activity (GO:0016787)
[B5X3C6]
Metalloendopeptidaseactivity;Zincion
binding (GO:0004222; GO:0008270)
[Q4AED3]
Binding; Protein transporter activity
(GO:0005488; GO:0008565) [Q865SI]
GTPbinding; GTPaseactivity; Structural
molecule activity
(GO:0005525;GO:0003924;
GO:0005198) [PI8288]
Purinergicnucleotidereceptoractivity,G-
protein coupled (GO:0045028)
[COH8T9]
[ACI33076;Sa/mosa/ar] mechanism;Prolon-lransportingATPase
aClivity,rolalionalmechanism
(00:0005524;00:0046933;
00:0046961) [B5X195)
ATPsynlhase,H+lransporling, 139 5E-57 Hydrogen ionlransportingATPsynlhase 6.908 2.607
milochondrialFOcomplex, (100%) aClivity,rolalionalmechanism
subunit c-3 [ACH70907; Sa/mo (00:0046933) [B5DON3]
sa/ar]
C~~I~~;6n7u5c6~~a~~:~~~:,~]n(~) 672(99%) 0 Nucleic acid binding; Zinc ion binding(00:0003676; 00:0008270) [B9EM75]
Chemokine receptortype 3 117(84%) 3E-18 C-Cchemokinereceploractivity
[BT059440; Sa/mosa/ar] tN) (00:0016493) [COHAT4)
Cisplalinresislance-associaled 582(99%)
overexpressedprotein
[BT059502;Sa/mosa/ar](N)
Claudin28b[ACK86563; 175(99%) 4E-68 Structural molecule activity (00:0005198)
Oncorhynchusmykiss] [C7S8F2]
Claudin-3 [BT044690; Sa/mo 782(99%) 0 Strucluralmoleculeaclivity(00:0005198)
sa/ar]tN) [B5XOXI]
Complement factor Dprecursor 193(99%) IE-109 Serine-type endopeplidase aClivily
[ACI69539;Sa/mosa/ar] (00:0004252) [B5XFB9]
Dealh-inducerobliterator I 273(53%) 9E-55 Unknown 3.939 0.967
[CBN81033;Dicen/rarchus
/abrax]
DOM-3 homolog Z [EDL83433; 62(65%)/ 4E-J9/
Rallusnorvegicus]/[v; 210(93%) 3e-78
Oncorhynchus nerka] (B)
Dynaclinsubunit5 [ACM08710; 169(99%) 6E-84 Transferase activity (00:0016740) 2.698 0.468
Salmosalar] [B9EMG3)
Ectonucleolide 477(85%) 7E-124 Hydrolaseaclivity;Melalionbinding;
pyrophosphalase/phosphodiesler Nucleic acid binding (00:0016787;
188
Elongation factor, RNA
polymerase 11,2 [BT049474;
Salmosalar](N)
180(78%)
70(85%)
106(99%)
GO:0046872; GO:0003676) [COPU84]
Serine-type endopeptidase activity
(GO:0004252) [Q4QY81]
RNA polymerase 11 transcription
elongation factor activity; Translation
elongation factor activity (GO:0016944;
GO:0003746) [B5XEK5]
Translation initiation factor activity
(GO:0003743) [CIBGV9]
Ezrin-radixin-moesin-binding 802 (98%) 0 Unknown
phosphoprotein 50 [BT045262;
Salmosalar](N)
237(99%)/
386(96%)
Growth hormone 2 [EU621899; 86(85%) IE-II Hormone activity (GO:0005179)
Salmosalar](N) [B22922]
44(71%) 0.0000 Signal transducer activity (GO:000487 I)
00004 [Q6PBR4]
141 2E-75 Binding (GO:0005488) [B5X4Q2]
(100%)
49(94%) 5E-1O GTPbinding; Hydrolase activity, acting on
acid anhydrides (GO:0005525;
GO:0016817) [A8WCJ8]
EG887324 Leukocyteelastaseinhibitor 70(95%) 3E-19 Serine-type endopeptidase inhibitor
189
[BT044977;Salmosalar](N) activity (GO:0004867) [B5XIQ8]
Membrane-spanning transport 209(73%) 3E-86 Developmental pigmentation; 10.255 4.528
protein I [AAK58462;MlIs Transmembrane transport (GO:0048066;
mllscllllls] (X) GO:0055085) [Q54IS3]b
329(95%) 3E-142 MHCclass I protein complex 2.762
(GO:0042612) [Q5FBT8] c
,]tN )
MHCclass 11 antigen beta chain 69(92%) 2E-15 MHCclass 11 protein complex; integral to 3.817
[EU008541;Salmosalar](N) membrane (GO:0042613; GO:0016021)
[B2XBN8]C
Microtubule associated 169(73%) 2E-49 ATPbinding; Protein serine/threonine
serine/threoninekinase-like kinase activity (GO:0005524;
[AAH78324;Daniorerio] (X) GO:0004674) [Q6DBX4]
CX025770 Myotilin [AAD44754IAFI44477; 151(51%) IE-40 Actin binding; Structural constituent of 6.699
HOll1osapiens] (X) muscle (GO:0003779; GO:0008307)
[Q9UBF9]
N-acetylated alpha-linked acidic 62(68%) IE-14 Peptidase activity (GO:0008233) 1.895 0.271
dipeptidase-like I [AAI71342; [A2BGQ8]
Daniorerio]
CA057355 N-acylneuraminate 297(97%) IE-136 Nucleotidyltransferaseactivity 5.467 2.978
cytidylyltransferase[BT044895; (GO:0016779) [B5XIH6]
Salll1osalar](N)
NEDD8-activatingenzymeEI 105 5E-51 ATPbinding; Acid-amino acid ligase
catalyticsubunit[ACI33010; (100%) activity; Small protein activating enzyme
Salll1osalar] activity (GO:0005524; GO:0016881;
GO:0008641) [B5XI29]
NOD-likereceptorC 152(45%)/ 6E-221 Receptoractivity(GO:0004872)
[ABU89560;Danio 172(92%) lE-56 [A8DYI7]
rerio]/[EZ780618;Oncorhynchlls
lI1ykiss] (B)
Non-histone chromosomal protein 549(99%) 0 DNA binding (GO:0003677) [B9ELY5]
190
H6 [BT057525; Salma salar] (N)
Novelmajorfacilitator 108(36%) 4E-12 Transmembrane transport (GO:0055085)
superfamilyprotein[CAL49372; [Q07GOO]b
Xenopus (Silurana)/ropicalis]
Novel protein similar to 124 (83%)/ 9E-48/ Nucleolus (GO:0005730) [B8A4H5]
vertebrate exosome component I 701(99%) 0
[CAXI3911;Danio
rerio]/[EZ777662;Oncorhynchus
mykiss] (B)
CA061927 Novel protein similar to 156(41%) 3E-22 Nucleic acid binding; Zinc ion binding
vertebrate pogo transposable (GO:0003676; GO:0008270) [A8E7N7]
element with ZNF domain
(POGZ) [CAP09536; Danio
rerio]
Nuclear VCP-like [AAH44464; 78(66%) IE-15 ATPbinding;Nucleoside-triphosphatase
Daniorerio] activity(GO:0005524;GO:0017111)
[Q803I9]
109(89%) 5E-44 SPOTS complex; Integral to membrane
(GO:0035339; GO:0016021) [Q9CPZ6] c
CA061377 Ornithine decarboxylase I 721(99%) 0 Ornithine decarboxylase activity
[BT045263; Salmosalar] (N) (GO:0004586) [B5X2J4]
Ortholog of mouse zinc finger 627(43%) 4.6E- DNA binding; Zinc ion binding
proteinZFP64 [CAB90277; 37 (GO:0003677; GO:0008270) [Q9NPA5]
Homo sapiens] (G)
Peptidyl-prolylcis-trans 164(99%) 8E-85 Peptidyl-prolylcis-transisomeraseactivity 2.382
isomerase A [ACM09531 ; Salmo (GO:0003755) [B9EPT4]
salar]
Polyunsaturated fatty acid 101(94%) 4E-32 Integral to membrane (GO:0016021) 6.872 3.138
elongasegene[GU238431;Salmo [Q8AWE7]C
salar](N)
Probabledimethyladenosine 150 IE-80 rRNA (adenine-N6,N6-)- 4.011
transferase [ACI69951;Salmo (100%) dimethyltransferaseactivity
191
salar]
rotein-glutaminegamma- 65(100%)
glutamyltransferaseK
[BT045232;Salmosalar](N)
Pyruvate kinase [BT04385 I; 642(99%)
Salmosalar](N)
185
(100%)
570(99%)
107(87%)
715(99%)
193(94%)
205
(100%)
Structural maintenance of 40(75%)
chromosomes I B [CAQ08672;
Homo sapiens]
ssoroflKK-epsilon 82(92%)
15625;Salmosalar](N)
TATA box binding protein 450(52%)
192
(GO:OOOO 179) [B5XGI I]
Protein-glutamine gamma-
glutamyltransferaseactivity
(GO:0003810) [B5X2G3]
Magnesium ion binding; Potassium ion
binding; Pyruvate kinase activity
(GO:0000287;GO:0030955;
GO:0004743) [B5DGUI]
ATPbinding; Protein serine/threonine
kinase activity (GO:0005524;
GO:0004674) [B5X2V6]
Phosphoprotein phosphatase activity
(GO:0004721) [COPU36]
Cation transmembrane transporter activity
(GO:0008324) [E3TBWO]
Binding (GO:0005488) [B5DGG3]
Response to stress (GO:0006950)
[CIKGR5]b
ATP binding (GO:0005524) [Q8NDV3]
Unknown
DNA binding; RNA polymerase I
Tetratricopeptiderepeatprotein 38(100%)
32 [ACI67454;Salmosalar]
BX080010 TNFreceptor-associatedfactor6 255(68%)
[BAI68387;Plecoglossus
allivelisallivelis]
CA056951 Transmembraneprotein50A 728(99%)
[BTI25442;Salmosalar](N)
381(94%)
88(56%)
CA063300 Trioartitemotif-containing 119(40%)
EG815176 TSRI protein [AAI61761; 174(74%)
Xenopus (Silurana) Iropicalis]
CA050457 TSRI, 20S rRNA accumulation, 174(71%)
homolog(yeast) [CAI24249;
Musmusculus]
known (nosignifi
its)
CA055445 Unknown (no significant BLAST
hits)
lOwn (no significant BLAST NA NA
)
193
transcription factor activity; General
RNA polymerase 11 transcription factor
activity (GO:0003677; GO:0003701;
GO:0016251) [Q15573]
Binding (GO:0005488) [B5X9D4]
Receptoractivity; Ubiquitin-proteinligase
activity; Zinc ion binding (GO:0004872;
GO:0004842; GO:0008270) [D2Z0 1I]
Integral to membrane (GO:0016021)
[B5XE68]C
ATP binding; ATPase activity,coupled to
transmembrane movement of substances
(GO:0005524; GO:0042626) [P79909]
DNA binding; Transposaseactivity
(GO:0003677; GO:0004803) [COHBQ6]
Zinc ion binding (GO:0008270)
[CIBKKO]
Nucleus (GO:0005634) [B 1WBH9] b
Nucleus (GO:0005634) [Q5SWD9] b
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
194
Unknown
Unknown
3.387 0.763
3.066
2.968
0.381
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
Unknown (no significant BLAST
hits)
V-set and transmembrane 681
domain-containingprotein2-like (100%)
protein precursor [BT072624;
Salmosalar](N)
WDrepeatdomaincontaining82 68(92%)
[AAH31502; Mus musCIIlus] (X)
CA062063 WD repeat-containing protein 68 195 (79%)
[BT045482; Salmosalar] (N)
195
Unknown
Unknown
Unknown
PTW/PPI phosphatase complex;
Chromatin (GO:0072357; GO:0000785)
[Q8BFQ4],
2.480
2.385
5.649
0.586
0.218
0.214
0.195
0.328
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APPENDIX VI. Supplemental tables showing QPCR relative quantity (RQ) data for informative transcripts normalized to PABPI mRNA
expression.
Appendix VI. A. QPCR relative quantity (RQ) data for ACBP normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASll_3N_155J
ASII 3N 156 M
ASII-='3N-='16o-=.F
ASII_3N_161_M
ASII 3N 162 F
ASlljN~166-=-M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_164J
AS25 3N 167 F
RQ
4.10
9.52
3.57
5.27
6.11
5.14
9.64
7.89
6.03
3.00
3.06
2.46
5.37
3.33
4.52
Average SE Fold change ASI I1AS25 Fold change AS26/AS25
6.19 0.93 1.39 1.67
4.46
AS26_3N_253J 2.24
AS26_3N_254J 21.83
AS26 3N 256 M 5.97
AS26-='3N-='257-='F 12.15
AS26 3N 260 M 6.69
AS26-3N-261-F 6.61
AS26 -3N -263 -M 1.00
AS26-3N-265-F 3.05
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Appendix VI. B. QPCR relative quantity (RQ) data for APOAIV normalized to PARPI mRNA expression
Sample name
ASll_3N_15IJ
ASII 3N 155 F
ASlljN'::-156'::-M
ASII_3N_160J
ASIl_3N_161_M
ASII_3N_162J
ASll_3N_166_M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_I64J
AS25_3N_167J
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26_3N_257J
AS26_3N_260_M
AS26_3N_26IJ
AS26_3N_263_M
AS26 3N 265 F
RQ
6.92
84.03
29.07
6.84
49.87
41.22
8.76
5.28
23.49
6.47
1.00
4.70
3.81
7.01
18.06
36.70
92.00
54.17
31.42
16.25
89.27
14.72
20.37
Average SE Fold change ASII/AS25 Fold change AS26/AS25
32.39 10.83 3.71 5.08
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Appendix VI. C. QPCR relative quantity (RQ) data for APOAJ-I normalized to PARPJ mRNA expression
Sample name
ASII 3N 151 F
ASII)N=I55)
ASII_3N_156_M
ASII_3N_160J
ASII_3N_161_M
ASII_3N_162J
ASII_3N_166_M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS253N 157 M
AS25~3N~159~F
AS25_3N_160_M
AS25_3N_164J
AS25_3N_167J
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26_3N_257J
AS26_3N_260_M
AS26_3N_26IJ
AS26 3N 263 M
AS26-3N-265-F
RQ
1.40
1.85
1.65
1.16
2.75
2.07
1.43
1.48
1.32
1.09
2.11
1.17
1.13
1.00
1.50
4.21
2.93
2.80
2.39
2.55
2.68
2.18
1.59
Average SE Fold change ASJJlAS25 Fold change AS26/AS25
1.76 0.20 1.30 1.97
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Appendix VI. O. QPCR relative quantity (RQ) data for APOAI-2 normalized to PABPl mRNA expression
Sample name
ASII_3N_15IJ
ASIl 3N 155 F
ASlljN':'-156':'-M
ASII_3N_160J
ASII_3N_161_M
ASII_3N_162J
AS1I_3N_166_M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_164J
AS25 3N 167 F
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26_3N_257J
AS26_3N_260_M
AS26_3N_26IJ
AS26_3N_263_M
AS26 3N 265 F
RQ
1.00
4.29
3.59
1.44
4.77
3.50
2.62
2.65
3.02
1.57
5.33
1.32
1.24
1.55
1.86
7.92
4.99
4.57
4.58
4.33
5.79
2.75
2.74
Average SE Fold change ASIl/AS25 Fold change AS26/AS25
3.03 0.53 1.31 2.03
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Appendix VI. E. QPCR relative quantity (RQ) data for B2M normalized to PABPl mRNA expression
Sample name
ASll_3N_15IJ
ASll_3N_155J
ASII_3N_156_M
ASII_3N_160J
ASII 3N 161 M
ASll-=-3~162-=-F
ASIl_3N_166_M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_164J
AS25 3N 167 F
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26_3N_257J
AS26_3N_260_M
AS26_3N_26IJ
AS26_3N_263_M
AS26 3N 265 F
RQ
1.82
3.45
3.35
1.68
6.17
6.01
1.92
1.97
2.04
1.26
1.83
1.24
1.95
1.38
1.00
5.46
4.75
4.88
4.09
7.52
18.56
3.53
2.35
Average SE Fold change ASII/AS25 Fold change AS26/AS25
3.49 0.73 2.20 4.03
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Appendix VI. F. QPCR relative quantity (RQ) data for B2M2 normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASII 3N 155 F
ASlljN::-J56'=-M
ASII_3N_160J
ASII 3N 161 M
ASII-='3N-='162-='F
ASII_3N_166_M
AS25 3N 154 F
AS25)N=155)
AS25_3N_156_M
AS25_3N_157_M
AS25 3N 159 F
AS25jN'=-160'=-M
AS25_3N_164J
AS25_3N_167J
AS26_3N_253J
AS26 3N 254 F
AS26jNj56'=-M
AS26_3N_257J
AS26_3N_260_M
AS26_3N_26JJ
AS26 3N 263 M
AS26-3N-265-F
RQ
5.02
17.69
19.55
6.54
39.23
\7.69
10.93
1.00
1.91
2.45
1.71
1.36
1.60
1.27
1.40
13.9\
7.67
10.62
13.67
14.57
34.30
8.42
5.17
Average SE Fold change ASI1/AS25 Fold change AS26/AS25
16.66 4.34 10.50 8.53
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Appendix VI. G. QPCR relative quantity (RQ) data for D5DP normalized to PABPI mRNA expression
Sample name
ASII 3N 151 F
ASII)N=I55)
ASII_3N_156_M
ASII_3N_160J
ASII_3N_161_M
ASII_3N_162J
ASII_3N_166_M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25 3N 159 F
AS25jN'=-160'=-M
AS25_3N_164J
AS25 3N 167 F
AS26_3N_253J
AS26 3N 254 F
AS26jN)56'=-M
AS26_3N_257J
AS26 3N 260 M
AS2(3N-='261-='F
AS26_3N_263_M
AS26 3N 265 F
RQ
1.59
8.13
9.39
2.11
14.45
8.37
2.98
2.36
4.4\
1.00
5.38
1.14
1.90
1.36
2.70
11.50
12.56
15.76
13.38
25.08
30.80
5.81
5.22
Average SE Fold change ASIIIAS25 Fold change AS26/AS25
6.72 1.78 2.65 5.93
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Appendix VI. H. QPCR relative quantity (RQ) data for FTM normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASII_3N_155J
ASII_3N_156_M
ASll_3N_160J
ASII_3N_161_M
ASII_3N_162J
ASII_3N_166_M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_164J
AS25_3N_167J
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26_3Nj57J
AS26_3N_260_M
AS26_3N_26IJ
AS26_3N_263_M
AS26 3N 265 F
RQ
2.51
3.88
4.00
1.80
5.91
3.28
2.36
1.64
1.90
1.78
1.00
1.44
2.48
1.45
1.36
4.77
3.78
3.45
4.33
9.24
11.39
2.31
1.91
Average SE Fold change ASllfAS25 Fold change AS26/AS25
3.39 0.52 2.08 3.16
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Appendix VI. I. QPCR relative quantity (RQ) data for GAPDHl normalized to PARP] mRNA expression
Sample name
ASII_3N_15IJ
AS11_3N_155J
AS11_3N_156_M
ASll_3N_160J
AS11_3N_161_M
AS11_3N_162J
ASll 3N 166 M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_I64J
AS25 3N 167 F
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26 3N 257 F
AS26jNj60'=-M
AS26_3N_26IJ
AS26_3N_263_M
AS26 3N 265 F
RQ
2.90
6.40
6.28
1.02
11.09
5.97
3.25
1.38
2.77
1.00
2.36
1.30
1.46
1.02
1.75
8.64
12.31
11.58
11.76
15.29
19.30
5.04
3.92
Average SE Fold change ASII/AS25 Fold change AS26/AS25
5.27 1.24 3.23 6.73
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Appendix VI. J. QPCR relative quantity (RQ) data for GAPDH2 normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASII_3N_155J
ASII_3N_156_M
ASII_3N_160J
ASII_3N_161_M
ASII_3N_162J
ASII 3N 166 M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_J57_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_164J
AS25 3N 167 F
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26 3N 257 F
AS26jN)60'::-M
AS26_3N_26IJ
AS26 3N 263 M
AS26-3N-265-F
RQ
4.72
25.53
17.53
1.83
16.60
9.48
4.23
2.04
4.34
1.64
1.93
1.00
1.40
1.30
4.50
4.98
11.06
4.00
12.60
5.80
9.75
10.72
3.84
Average SE Fold change ASIIIAS25 Fold change AS26/AS25
11.42 3.29 5.03 3.46
0.48
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Appendix VI. K. QPCR relative quantity (RQ) data for SEPPl normalized to PARPl mRNA expression
Sample name
ASII_3N_15IJ
ASII_3N_155J
ASII 3N 156 M
ASII-='3N-='160-='F
ASII 3N 161 M
ASII-='3N-='162-='F
ASII 3N 166 M
AS25_3N_154J
AS25 3N 155 F
AS25)N=-156-=-M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_164J
AS25_3N_167J
AS26 3N 253 F
AS26)N)5(F
AS26 3N 256 M
AS2(3N-='257-='F
AS26_3N_260_M
AS26 3N 261 F
AS26jNj63-=-M
AS26 3N 265 F
RQ
1.48
3.90
2.42
1.42
5.74
3.57
1.97
1.58
1.83
1.00
1.56
1.48
1.68
2.42
2.24
3.79
4.44
4.05
4.92
6.07
10.89
2.15
2.68
Average SE Fold change ASlllAS25 Fold change AS26/AS25
2.93 0.59 1.70 2.83
4.87
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Appendix VI. L. QPCR relative quantity (RQ) data for SEPP2 normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASII_3N_155J
ASII_3N_156_M
ASII 3N 160 F
ASlljN'=-161'=-M
ASII_3N_162J
ASII 3N 166 M
AS25_3N_154J
AS25_3N_155J
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25_3N_164J
AS25 3N 167 F
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26 3N 257 F
AS26jNj60'=-M
AS26 3N 261 F
AS26jNj63'=-M
AS26 3N 265 F
RQ
2.15
6.65
6.49
2.44
9.09
6.49
2.94
1.82
3.76
1.05
1.78
1.30
1.52
1.00
1.97
11.59
9.27
9.09
7.22
13.57
14.68
3.99
3.10
Average SE Fold change ASIllAS25 Fold change AS26/AS25
5.18 1.01 2.92 5.11
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Appendix VI. M. QPCR relative quantity (RQ) data for NUPRI normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASII_3N_155J
ASII_3N_156_M
ASII_3N_160J
ASII_3N_161_M
ASII_3N_162J
ASII 3N 166 M
AS253N 154 F
AS25-3N-155-F
AS25jN'::-156'::-M
AS25 3N 157 M
AS253N-159-F
AS25jN'::-160'::-M
AS25 3N 164 F
AS25)N=167)
AS26_3N_253J
AS26_3N_254J
AS26_3N_256_M
AS26_3N_257J
AS26_3N_260_M
AS26_3N_26IJ
AS26_3N_263_M
AS26 3N 265 F
RQ
1.31
1.63
1.83
1.19
3.02
1.72
2.57
2.14
2.30
1.29
2.55
1.58
2.33
1.68
1.61
2.46
2.54
3.28
4.94
7.88
10.37
1.00
2.33
Average SE Fold change ASI1IAS25 Fold change AS26/AS25
1.89 0.25 0.98 2.25
0.16
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Appendix VI. N. QPCR relative quantity (RQ) data for ADAMTS-I normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASII 3N 155 F
ASlljN'=-156":-M
ASII_3N_160J
ASII_3N_161_M
ASII_3N_162J
ASII 3N 166 M
AS25_3N_154J
AS25 3N 155 F
AS25jN":-156":-M
AS25_3N_157_M
AS25 3N 159 F
AS25jN":-160":-M
AS25_3N_164J
AS25_3N_167J
AS26 3N 253 F
AS2(3N)54=F
AS26_3N_256_M
AS26 3N 257 F
AS26jNj60":-M
AS26 3N 261 F
AS26-3N-263-M
AS26-3N-265-F
RQ
11.70
1.55
1.03
2.72
2.45
1.71
2.15
2.29
1.17
1.63
1.63
1.49
2.75
2.35
1.56
3.72
6.40
5.72
2.71
4.89
4.94
1.00
5.80
Average SE Fold change ASII/AS25 Fold change AS26/AS25
3.33 1.41 1.79 2.37
210
Appendix VI. O. QPCR relative quantity (RQ) data for AA5 normalized to PABPI mRNA expression
Sample name
ASII_3N_15IJ
ASII_3N_155J
ASII_3N_156_M
ASII_3N_160J
ASII_3N_161_M
ASII 3N 162 F
ASlljN'=-166'=-M
AS25 3N 154 F
AS25)N=155)
AS25_3N_156_M
AS25_3N_157_M
AS25_3N_159J
AS25_3N_160_M
AS25 3N 164 F
AS25-3N-167-F
AS26 3N 253 F
AS26-3N-254-F
AS26jN'=-256'=-M
AS26_3N_257J
AS26_3N_260_M
AS26 3N 261 F
AS26jN'=-263'=-M
AS26 3N 265 F
RQ
1.37
1.12
1.10
1.04
2.38
1.79
1.00
1.20
2.41
1.28
1.39
1.36
1.68
1.20
1.70
1.86
1.55
1.4\
2.52
2.08
2.70
1.14
1.03
Average SE Fold change ASII/AS25 Fold change AS26/AS25
1.40 0.19 0.92 1.\7
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APPENDIX VU. Transcripts (46) with greater than 2-fold expression in diploid growth hormone transgenic Atlantic salmon family AS11 in
comparison to its triploid counterparts in any30utof4technical replicated arrays.
Gene Name of Best BLASTX or
BLASTN (N) Hit
Length(%
ID)
XFold
Change
0.8693.098
6.948
6.149Unknown [COH9X4]
Unknown [Q4RCI6]
83(49%)
109(91%)
237(53%)
503(90%)
847(93%)
516(97%)
152(88%)
523(96%)
560(93%)
496(84%)
491(89%)
96(100%)
Pyridoxal phosphate binding;
Succinyldiaminopimelate
transammaseactlvlty
(GO:0030170;GO:0009016)
[QORCS6]
Unnamed protein product rCAG04255; 149 (81%) 3e-65 ATP binding; DNA photolyase
Onmycontig mRNA sequence
[EZ775803; Oncorhynchlls mykiss] (N)
Onmycontig mRNA sequence
[EZ854926;Oncorhynchllsmykiss](N)
Unnamed protein product [CAG 13897;
Telraodonnigroviridis]
Onmycontig mRNA sequence
[EZ806257; Oncorhynchlls mykiss] (N)
No significant BLASTX or BLASTN
hit
Bardet-Biedl syndrome 7 protein
[ACNI0843; Salmo salar]
Onmycontig mRNA sequence
[EZ825292;ncorhynchllsnerka](N)
Onmycontig mRNA sequence
[EZ853893; Oncorhynchlls mykiss](N)
Onmycontig mRNA sequence
[EZ769629; Oncorhynchlls mykiss](N)
Onmycontig mRNA sequence
[EZ775375;Oncorhynchllsmykiss](N)
Onmycontig mRNA sequence
[EZ781375; Oncorhynchlls mykiss](N)
Onmycontig mRNA sequence
[EZ860178;Oncorhynchllsmykiss](N)
N-succinyl-L,L-diaminopimelate
aminotransferase [CAJ64748; Frankia
alniACNl4a]
212
Telraodonnigroviridis]
Zgc: 65774 [AAH56511; Danio rerio] 105 (63%)
activity; Protein
serine/threonine kinase activity
(00:0005524;00:0003913;
00:0004674) [Q4S527]
Unknown [Q6PHL2]
Oenomic sequence [OQ505858; Salmo 387 (87%)
salar](N)
Engulfment and cell motility protein 1 744(99%)
putative mRNA [BT045058; Salmo
salar](N)
Mixed_tissue cDNA [Salmo salar] (N) 711 (98.5%)
RNA binding; Structural
constituent of ribosome
(00:0003723;00:0003735)
[A7KIL2]
Binding (00:0005488)
[B5XIY9]
2.566 0.461
0.621
0.759
2.880
Transporter activity
(00:0005215) [A4IOIO]
Cellular component: integral to
membrane (00:0016021)
[Q6IQ88]
Unknown
OTPaseactivatoractivity
(00:0005096) [COSU62]
Unknown [B5XITI]
Sequence-specific DNA binding;
Transcription factor activity
(00:0043565;00:0003700)
[Q4SBW8]
Unknown
68(63%)
50(80%)
146(76%)
702(85%)
635(98%)
217(75%)
229(62%)
725(91%)
Onmycontig mRNA sequence
[EZ774413; Oncorhynchus mykiss] (N)
Tuberin-1ikeprotein I splicingvariant2
[BAH47606; Danio rerio]
Bcl2 antagonist of cell death putative
mRNA [BT060 150; Salmo salar] (N)
MC053020, isoform CRA a
[EDLI8762;Musmuscuhls]
Unnamed protein product rCA009754; 94 (84%) le-41 Unknown [Q4RPC81
Nmycontig mRNA sequence
[EZ775280; Oncorhynchus mykiss] (N)
Unnamed protein product [CAOOI864;
Telraodonnigroviridis]
No significant BLASTX or BLASTN
hit
LOC560459 protein [AAI34875; Danio
rerio]
Transmembrane protein 19 [AAH71522;
Daniorerio]
213
102(49%)
Onmycontig mRNA sequence 246 (92%)
[EZ914509; Oncorhynchus mykiss] (N)
40kDapeptidyl-prolylcis-trans 105(100%)
isomerase [AC007506; Oncorhynchus
mykiss]
543(93%)
461(91%)
180(82%)
365(94%)
563(100%)
224(92%)
640(98%)
Onmycontig mRNA sequence 311 (88%)
[EZ806707; Oncorhynchus mykiss] (N)
Dexamethasone-induced Ras-related 45(88%)
protein 1 precursor [ACI66407;Salmo
solar]
PhospholipaseA-2-activatingprotein 41 (100%)
[ACN 11 01 0; Salmo solar]
No significant BLASTX or BLASTN hit
214
Binding; Peptidyl-prolyl cis-trans
isomerase actIvIty
(GO:0005488;GO:0003755)
[CIBEQ3]
Isomerase activity (GO:0016853)
[COHAW6]
Unknown
Unknown [Q4SGG3]
Unknown [COH9L8]
Binding; Proton-transporting
ATPaseactivity,rotational
mechanism (GO:0005488
GO:0046961) [B5XIYI]
Unknown
GTPbinding;GTPaseactivity
(GO:0005525;GO:0003924)
[B5X6D7]
Unknown [COHAE I]
~
0
N
0;
.~
~ !~
APPENDIX VIII. Transcripts (133) with greater than 2-fold expression in triploid growth hormone transgenic Atlantic salmon family ASH in
comparison to its diploid counterparts in any30utof4technical replicatedarrays.
Hypothetical protein [BAF94331; 176(91%)
Fundulusheteroclitus]
Onmycontig mRNA sequence 603 (99%)
[EZ905614;Oncorhynchusmykiss](N)
SelenoproteinP,plasma,la[AAI59241; 32(71%)
Daniorerio]
Disulfide-isomerase A4 precursor 245(97%)
putative mRNA [BT072419; Salmo
salar](N)
Onmycontig mRNA sequence 497 (92%)
Gene Name of Best BLASTX or
BLASTN (N) Hit
HSC71 [AAB21658; Oncorhynchus
mykiss]
Onmycontig mRNA sequence
[EZ769635; Oncorhynchus mykiss](N)
Delta5-desaturase-likeprotein
[ABU87822; Oncorhynchus masou]
Heatshock90kDaprotein 1 beta
isoform b [BAD90024; Oncorhynchus
Length(%
ID)
182(100%)
196(92%)
87(98%)
204(98%)
45(97%)
ATPbinding(GO:0005524)
[P08108]
Unknown
Heme binding; Oxidoreductase
activity, acting on paired
donors, with oxidation ofapair
of donors resulting in the
reduction of molecular oxygen
to two molecules of water
(GO:0020037;GO:0016717)
[A7XUS7]
ATPbinding;Unfoldedprotein
binding (GO:0005524;
GO:0051 082) [Q5DW65]
ATPbinding; Protein
serine/threonine kinase activity
(GO:0005524;GO:0004674)
[Q28EK6]
Unknown [A9CQJ8]
Selenium binding (GO:0008430)
[A9JRW5]
Unknown
XFold
Chan2e
216
[EZ77 I031; Oncorhynchus mykiss) (Nf
CA055690 Vitellogenin I [AATII177; Solvelinus 210(90%) 4e-I08 Lipid transporter activity 5.762 1.258
alpinus) (00:0005319) [Q6J526]
Onmycontig mRNA sequence 604(85%) ge-158 Unknown
[EZ764240;Oncorhynchusmykiss](N)
Delta5-desaturase-likeprotein 81(98%) 2e-42 Heme binding; Oxidoreductase
[ABU87822; Oncorhynchus masou) activity,actingonpaired
donors,withoxidationofapair
of donors resulting in the
reduction of molecular oxygen
to two molecules of water
(00:0020037;00:0016717)
[A7XUS7)
HC040021 [EAW75736; Homo 83(46%) 2e-16 Unknown
sapiens)
Onmycontig mRNA sequence 582(99%)
[EZ764823; Oncorhynchus mykiss) (N)
Zgc: 113828 [AAH96945; Danio rerio) 119(52%) ge-25 Serine-type endopeptidase
inhibitor activity (00:0004867)
[Q4V9D6)
Alpha actin [AAF75784IAF267496; 112(99%) 7e-59 ATPbinding; Protein binding
Salmotrulla) (00:0005524;00:0005515)
[Q918KI)
Calreticulinprecursor[ACI33338; 112(98%) 5e-62 Calcium ion binding; Unfolded
Salmosalar) protein binding (00:0005509;
00:0051082) [B5X207)
CD80-like protein [CA025516; 106(69%) 4e-39 Unknown [A IIMH7) 4.611
Oncorhynchusmykiss]
RNA-binding protein 24-B [ACI33185; 163(98%) le-57 Nucleic acid binding; Nucleotide
Salmosalar) binding (00:0003676;
00:0000166) [B5XIK4)
CB510761 FBPL4 [ABB29988; Oncorhynchlls 151(93%) 5e-83 Biological Process: Cell adhesion 4.548 0.639
mykiss) (00:0007155) [Q2LK91)
Tripartite motif-containing protein 25 26(96%) le-07 Protein binding; Zinc ion binding 4.528 1.306
[ACI68199;Salmosalar) (00:0005515;00:0008270)
[B5XBH9)
Onmycontig mRNA sequence 395(91%) 3e-147 Unknown
217
[EZ854526; Oncorhynchlls mykiss] (N)
Apolipoprotein A-I precursor 44(100%) 7e-16 Lipid binding (GO:0008289)
[ACI68193;SalmosalarJ [B5XBH3]
Onmycontig mRNA sequence 423(90%) 4e-145 Unknown 3.905
[EZ832962; Oncorhynchllsnerka](N)
Unknown [ACN31742; Zea mays] 79(70%) 5e-26 Unknown [COPC47]
Hydroxysteroiddehydrogenase-like 103(100%) 7e-40 Oxidoreductase activity; Sterol
protein 2 [ACNI0404IACNI2769; binding (GO:0016491;
Salmosalar] GO:0032934) [COH8N5]
Profilin-2 [ACI343I 31ACM08604; 139(100%) ge-77 Actin binding (GO:0003779)
Salmosalar] [B5X4T2]
Apolipoprotein A-I-2 [AAB96973; 54(100%) 5e-14 Lipid binding (GO:0008289)
Oncorhynchllsmykiss] [057524]
Glyceraldehyde-3-phosphate 64(100%) 4e-30 NAD or NADH binding; 3.698 0.526
dehydrogenase-2 [ACH70939; Salmo Glyceraldehyde-3-phosphate
salar] dehydrogenase
(phosphorylating) activity
(GO:0051287;GO:0004365)
[B5DGR5]
Nmycontig mRNA sequence 326(83%) le-75 Unknown 3.619
[EZ887914; Oncorhynchlls mykiss](N)
Vitellogenin 1 [AATIII77; Salvelinlls 211(90%) le-I09 Lipid transporter activity
alpinlls] (GO:0005319) [Q6J526]
SelenoproteinPaprecursorputative 730(99%) 0 Unknown 3.569
mRNA [BT072678; Salmo salar] (N)
Glutamine synthetase 99(100%) 8e-52 Glutamate-ammonia ligase
[AC1684821ACN I03261ACN 105171A activity (GO:0004356)
CN12686;Salmosalar] [B5XCB2]
Heat shock 70 kDa protein 126(99%) 3e-66 ATPbinding(GO:0005524) 3.420 0.516
[ACI34374IACNI 1053; Salmo salar] [B5X4Z3]
Onmycontig mRNA sequence 573(91%) 0 Unknown
[EZ784933,Oncorhynchllsll7ykiss](N)
Hypothetical protein EHI_IOI930 41(85%) le-14 Unknown [BIN5S6]
[EDS88682;Emall7oebahislOlyrica
HM-I:IMSS]
Onmycontig mRNA sequence 652~ 0 Unknown 3.348 1.129
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[EZ777580;OncorhynchllslllykiSs](N)
FBP32 precursor [ABB29989; Morone 62 (74%)
saxalilis]
Complement factor H precursor 137 (75%)
[CAF25505; Oncorhynchlls mykiss]
Inducedmyeloidleukemiacell 617(100%)
differentiationproteinMcI-lhomolog
putative mRNA [BT072485; Sallllo
salar](N)
Adenylylcyclase-associatedprotein I 610(99%)
putative mRNA [BT045210; Sallllo
salar](N)
CHKI checkpoint-like protein 47(91%)
[ABK29471; Helicoverpa armigera]
Sec61 alpha form B 176(98%)
[AAK29082IAF346601;
Oncorhynchllsmykiss]
KIAA I1 09 [ACN58652; Sallllo salar] 243 (100%)
Biological Process: cell adhesion
(GO:0007155) [Q2LK90]
N/A[Q2L4Q6]
Actin binding (GO:0003779)
[B5X2EI]
Unknown [B6A8G9]
P-P-bond-hydrolysis-driven
protein transmembrane
transporter activity
(GO:0015450) [Q98SN8]
Unknown [COPUB8]
1.060
0.826
3.050 0.515
3.081 0.437
Unknown [B5X326]
Unknown [C3Z0S3]
Calcium ion binding
(GO:0005509) [B9EMB8]
Unknown
63(38%)
411(92%)
684(99%)
411 (90%)
97(100%)
655(93%)
Onmycontig mRNA sequence
[EZ91 0586; Oncorhynchlls mykiss] (N)
Plasminogen activator inhibitor 1 RNA- 113 (100%)
binding protein [ACI33707;Salmo
salar]
SelenoproteinPaprecursorputative
mRNA [BT072678; Salmo salar] (N)
Onmycontig mRNA sequence
[EZ906468; Oncorhynchlls mykiss] (N)
Chromosome 20 open reading frame 149 121 (100%) 2e-58 Biological Process:Cell
Hypothetical protein
BRAFLDRAFT_102843 [EEN53827;
Branchioslolllajloridae]
Onmycontig mRNA sequence
[EZ841842;Oncorhynchllsmykiss](N)
Sorcin [ACM08665;Sallllosalar]
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[ACH70875; Salmo solar]
No significant BLASTX or BLASTN hit
differentiation; Multicellular
organismaldevelopment
(GO:0030154;GO:0007275)
[B5DGKI]
Unknown 3.026 0.884
Fumarylacetoacetae [AC009168; 227 (86%) le-112 Fumarylacetoacetase activity
Osmerus mordax] (GO:0004334) [Cl BJG5]
TyrosinephosphatasetypelVA2 44(100%) 7e-17 Proteintyrosine/serine/threonine
[ACM08235; Salmo solar] phosphatase activity
(GO:0008138) [B9EL38]
Delta-5fattyacyldesaturase(D5fad) 606('100%) 0 Oxidoreductase activity
Gene [GU294485; Salmo solar] (N) (GO:OO 16491) [D2Y360]
Enolase 3-2 [ACH70931; Salmo solar] 192 (100%) 4e-98 Magnesium ion binding;
Phosphopyruvatehydratase
activity (GO:0000287;
GO:0004634) [B5DGQ7]
Heat shock protein hsp90 [AAB49983; 138 (89%) 2e-61 ATP binding; Unfolded protein
Oncorhynchus IshalVylscha] binding (GO:0005524;
GO:005J082) [P87397]
Eggshell protein [CAA04221;Salmo 203 (100%) ge-117 Unknown [042465]
solar]
Elongation factor I-alpha I 38 (100%) 2e-11 GTP binding; GTPase activity;
[ACNI1490; Salmo solar] Translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COHBSI]
CB496785 Carboxylic ester hydrolase [AAA67523; 165 (86%) 2e-84 Carboxylesterase activity
Salmo solar] (GO:0004091) [Q92149]
Extracellular matrix protein I precursor 569 (94%) 0 Cellular Component:
putative mRNA [BT059193; Salmo Extracellular space
solar] (N) (GO:0005615) [COHA37]
CB494095 Superoxide dismutase putative mRNA 534 (97%) 0 Metal ion binding; Superoxide
[BT073392; Oncorhynchus mykiss] (N) dismutase activity
(GO:0046872;GO:0004784)
[CIBFL3]
Glutamine synthetase [ACI68482; 80 (100%) 5e-40 Glutamate-ammonia ligase
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2.987
2.950
2.934
2.897
0.594
Salmosalar]
CB504246 FBP32II precursor [ABB29992; Morone 153 (67%)
chrysops]
EG910863 Serum albumin 2 [CAA43187; Salmo 232 (78%)
salar]
Novel protein (im: 7136654) 71 (92%)
[CAPI9604;Daniorerio]
Onmycontig mRNA sequence 634 (99%)
[EZ763734; Oncorhynchus mykiss] (N)
PLAC8-like protein I putative mRNA 469 (81%)
[BT072227;Salmosalar](N)
Nuclear protein I [ACI68567; Salmo 74 (90%)
salar]
Onmycontig mRNA sequence 362 (93%)
[EZ7761 15; Oncorhynchus mykiss] (N)
Transposase [AAP49009; Rana pipiens] 78 (50%)
706(98%)
66(100%)
243(100%)
176(40%)
172(93%)
activity (GO:0004356)
[B5XCB2]
Biological Process: cell adhesion
(GO:0007155) [Q2LK87]
Lipid binding; Metal ion binding
(GO:0008289;GO:0046872)
[Q03156]
Protein binding (GO:0005515)
[A8Y5S9]
Unknown
Unknown [B5XCJ7]
DNA binding; Transposase
activity (GO:0003677;
GO:0004803) [Q6XIZ4]
Unknown
Unknown [B5XCX9]
Heat shock protein binding
(GO:0031072) [B5X4V9]
Growth factor activity
(GO:0008083) [Q4SKE3]
Lipoic acid binding
(GO:0031405) [COH8GI]
107(99%) 3e-58 Binding;Glucose-6-phosphate
dehydrogenase activity
(GO:0005488;GO:0004345)
[A5JNMO]
Transmembrane protein 106B 190 (100%) 3e-81 Integral to membrane
221
[ACI69652; Salmo salar) (GO:OO 16021) [B5XFN2)
Novel protein similar to human and 112 (54%) le-24 GTP binding (GO:0005525)
mouse ADP-ribosylation factor-like [B8JLB2)
14 (ARLI4) [CAXI3605; Danio
rerio)
5-aminolevulinatesynthase, erythroid- 30(100%) 3e-IO 5-aminolevulinatesynthase 2.603
specific, mitochondrial precursor activity; Pyridoxal phosphate
[ACNI0630; Salmo salar] binding; Transferase activity,
transferring nitrogenous groups
(GO:0003870;GO:0030170;
GO:0016769) [COH9BI)
CA038129 Onmycontig mRNA sequence 285 (88%) 3e-93 Unknown 2.595 0.478
[EZ847363; Oncorhynchlls mykiss)(N)
Onmycontig mRNA sequence 668 (83%)
[EZ817404; Oncorhynchllsnerka)(N)
Zinc finger protein 180, isoform CRA_a 88 (70%)
[EDM08120;Rallllsnorvegiclls)
Onmycontig mRNA sequence 702 (92%) 0 Unknown 2.572 0.415
[EZ766617; Oncorhynchus mykiss) (N)
CA053571 Flavin reductase [ACI67715; Salmo 82 (100%) le-41 Unknown [B5XA45)
salar)
Complement Clq-like protein 4 101 (45%) 2e-18 Unknown [B9EPU5)
precursor [ACM09542; Salmo salar)
Onmycontig mRNA sequence 620 (99%)
[EZ905653; Oncorhynclllls mykiss) (N)
IgH locus B genomic sequence 701 (98%)
[GUI29140;Salmosalar)(N)
Glutathione peroxidase type 2 71 (84%) 3e-28 Glutathione peroxidase activity
[AAV32968; Oncorhynchlls mykiss) (GO:0004602) [Q5UTE7)
Notchless protein homolog I 67 (100%) le-32 Unknown [COPUL3) 2.487
[ACN58698; Salmo salar)
Catechol-O-methyltransferase domain- 85 (92%) 2e-60 O-methyltransferase activity 2.454 0.090
containing protein I [ACI69067; (GO:0008171) [B5XDZ7)
Salmosalar)
Onmycontig mRNA sequence 534 (92%)
[EZ852424; Oncorhynchlls mykiss) (N)
Sodium/potassium-transporting ATPase 647 (100%) 0 Sodium:potassium-exchanging
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subunitbeta-233putativemRNA ATPase activity (GO:0005391)
[BT059333;Salmosalar](N) [COHAH7]
Spartin[ACNI0853;Salmosalar] 217(94%) 8e-107 Unknown [COH9Y4] 2.410
Glycine cleavage system Hprotein, 79(100%) 6e-38 Lipoic acid binding 2.407 0.385
mitochondrial precursor [ACNI0330; (GO:0031405) [COH8GI]
Salmosalar]
Crystallin gamma M2b [ACL98 I I0; 70(80%) le-26 Unknown [B9V3T5]
Epinepheluscoioides]
Onmycontig mRNA sequence 513(93%)
[EZ81 1233; Oncorhynchusmykiss](N)
Unnamed protein product [CAG08548; 188(85%) le-92 ATP binding; Zinc ion binding
Te/raodonnigroviridis] (GO:0005524 GO:0008270)
[Q4RST4]
Onmycontig mRNA sequence 674(74%) 2e-128 Unknown 2.371 0.282
[EZ829065;Oncarhynchusnerka](N)
CA040315 Onmycontig mRNA sequence 529(95%) 0 Unknown 2.350
[EZ764761;Oncorhynchusmykiss](N)
Transforminggrowthfactor-beta- 46(84%)
inducedproteinig-h3precursor
[ACI34040;Salmosalar]
Putative H3 histone family3Bvariant I 79(89%) le-33 DNA binding (GO:0003677)
[ACH46259; Taeniopygia gUlla/a] [B5G4P8]
Hypothetical protein CHGG_10452 112(34%) 5e-08 Transcription factor activity; Zinc
[EAQ84048; Chae/omium globosum ion binding (GO:0003700;
CBS 148.51] GO:0008270) [Q2GNK2]
Onmycontig mRNA sequence 569(93%) 0 Unknown
[EZ914073;Oncorhynchusmykiss](N)
Proteasome maturation protein 142(99%) 2e-73 CellularComponent:Proteasome
[AC008214; Oncorhynchus mykiss] complex (GO:0000502)
[CIBGRI]
No significant BLASTX or BLASTN hit N/A N/A Unknown
Onmycontig mRNA sequence 465(98%) 0 Unknown 2.245 0.340
[EZ782390; Oncorhynchus mykiss] (N)
Programmed cell death protein 10 52(100%) 3e-21 Unknown [B9EN83]
[ACM08980;Salmosalar]
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Sequence-specific DNA binding;
Transcription factor activity
(GO:0043565;GO:0003700)
[B5X8V6]
Unknown
Protein binding (GO:0005515)
[B2ZRS8]
Cellular Component: Integral to
membrane (GO:0016021)
[B5XDT3]
Unknown
Receptoractivity(GO:0004872)
[B9EQFO]
Protein binding (GO:0005515)
[A3QJZ8]
Cellular Component: MHC class I
protein complex (GO:0042612)
[CIC2P2]
Glutathione transferase activity
(GO:0004364) [Q9W647]
Unknown
660(99%)
739(99%)
578(97%)
658(98%)
703(94%)
200(78%)
159(96%)
147(70%)
129(100%)Transcription factorPU.1 [ACI67276;
Onmycontig mRNA sequence
[EZ763908; Oncorhynchus mykiss] (N)
U3 small nucleolarribonucleoprotein 205(99%) 6e-113 Nucleic acid binding
protein IMP4 rACI66547; Salma (GO:0003676) [B5X6S7]
Onmycontig mRNA sequence 351 (82%)
[EZ796597; Oncorhynchus mykiss](N)
Receptor expression-enhancing protein 5 189(98%)
[ACM09747; Salmo salar]
Novel protein similar to vertebrate 114(77%)
leucine-rich repeats andcalponin
homology (CH) domain containing
family [CAM56750; Danio reria]
Beta-2-microglobulinprecursor 93(100%)
[ACOI5545; Caligus clemensi]
224
salar]
Onmycontig mRNA sequence 534 (92%)
[EZ824458; Oncorhynchlls mykiss] (N)
mRNA for simple type 11 keratin K8a 665 (97%)
[AJ272373; Oncorhynchlls mykiss](N)
Onmycontig mRNA sequence 718 (87%)
[EZ825789;Oncorhynchllsnerka](N)
Novel cds [BT072567; Salmo salar] (N) 846 (100%)
Fastmyotomalmuscleactin 138(100%)
[AAG25672IAF304406; Salmo salar]
High affinity copper uptake protein 1 714(99%)
putative mRNA [BT059358; Salmo
salar](N)
Onmycontig mRNA sequence 318 (77%)
[EZ888359; Oncorhynchlls mykiss] (N)
TSC22 domain family protein 3 40 (95%)
[ACI34064;Salmosalar]
Carbonic anhydrase putative mRNA 600 (99%)
[BT058764;Salmosalar](N)
See Appendix 11 for footnotes.
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Structural molecule activity
(GO:0005198) [Q90YH3]
Unknown
ATPbinding; protein binding
(GO:0005524;GO:0005515)
[Q78BU2]
Copper ion transmembrane
transporleractivity
(GO:0005375) [COHAK2]
Unknown
Transcription factor activity
(GO:0003700) [B5X433]
Carbonate dehydratase activity;
zinc ion binding (GO:0004089;
GO:0008270)rB5X3181
APPENDIX IX. Transcripts (17) with greater than 2-fold expression in diploid growth hormone transgenic Atlantic salmon family AS25 in
comparison to its triploid counterparts in any30utof4technicaI replicated arrays.
Gene Name of Best BLASTX or Length(%
BLASTN (N) Hit ID)
Glycerol-3-phosphatedehydrogenase 36(97%)
[AAK07737; Salmo salar]
HypotheticalproteinMGCl46992 155(41%)
[AAI21550; Xenopus (Silurana)
tropicalis]
Onmycontig mRNA sequence 485(91%)
[EZ763914; Oncorhynchusnerka] (N)
34(94%)
alar]
Unknown large open reading frame 99(100%)
mRNA [BT072179; Salmo salar] (N)
Leukocytecell-derived chemotaxin 2 55(100%)
precursor [ACI68507;Salmosalar]
Unnamed protein product [CAF98477; 246(29%)
Tetraodonnigroviridis]
Stannin [ACN10806; Salmo salar] 87(100%)
40SribosomalproteinS3 [ACI67079; 137(100%)
Salmosalar]
Hepcidin-1 precursor [ACI67048; Salmo 31(93%)
salar]
Onmycontig mRNA sequence 587(91%)
[EZ764712; Oncorhynchus mykiss]
CB499145 B-cel! receptor-associatedprotein 31 203(100%)
putative mRNA [BT045436; Salmo
salar]
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XFold
Change
NAD or NADH binding
(GO:0051287) [Q98SJ9]
Nucleic acid binding
(GO:0003676) [QOV910]
Cellular Component:
Extracellular region
(GO:0005576) [B5X878]
Unknown
Unknown [B5XCD7]
Unknown [Q4SLK5]
Unknown [COH9T7]
RNA binding (GO:0003723)
[B5X8A9]
Cellular Component:
Extracellular region
(GO:0005576) [B5X878]
Unknown
Receptoractivity(GO:0004872)
[B5X317]
Glyceraldehyde-3-phosphate 157 (100%) 8e-85 NAD orNADH binding 2.428 0.413
dehydrogenase [ACI69846; Salmo (GO:0051287) [B5XG76]
salar]
Onmycontig mRNA sequence 464 (85%) le-l27 Unknown 2.287 0.257
[EZ769153; Oncorhynchus mykiss] (N)
Acyl-CoA-binding protein putative 405 (90%) le-146 Acyl-CoA binding (GO:0000062)
mRNA [BT049229; Salmo salar] (N) [B5XDWO]
Histone H2A.x [ACN09953; Salmo 121 (100%) le-47 DNA binding (GO:0003677)
salar] [B5X5B2]
Apolipoprotein A-IV precursor 97 (96%) 2e-44 Lipid binding (GO:0008289)
[ACI67068; Salmo salar] [B5X898]
See Appendix II for footnotes.
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APPENDIX X. Transcripts (18) with greater than 2-fold expression in triploid growth hormone transgenic Atlantic salmon family AS25 in
comparisontoitsdiploidcounterpartsinany30utof4technicaI replicated arrays.
Gene Name of Best BLASTX or
BLASTN (N) Hit
Length(%
ID)
X Fold
Change
RNA binding
(GO:0003723) [COHAI9]
Protein binding; ubiquitin-protein
ligase activity; zinc ion binding
(GO:0005515;GO:0004842;
GO:0008270) [042498]
Unknown [B8JHY9]
Lipid transporter activity
(GO:0005319) [Q6J526]
Lipid transporter activity
(GO:0005319) [Q6J526]
Unknown
Protein binding (GO:0005515)
[B5XIH3]
Unknown [Q4S5U3]
Antioxidant activity;
Oxidoreductase activity
(GO:0016209;
GO:0016491) [B5XFD8]
Unknown [Q6POB5]
85(49%)
50(46%)
90(98%)
46(73%)
108(99%)
147(71%)
107(59%)
153(96%)
578(97%)
211 (90%)
700(97%)
556(91%)
FKIAA0680 [AAC60292; Takifugu
rubripes]
Novel protein [CAXI4664; Dania
reria]
Alpha-actinin [AAN77132; Dan/a 139 (82%) 2e-59 Actin binding; calcium ion
rer/a] binding (GO:0003779;
Thioredoxin-dependentperoxide
reductase, mitochondrial precursor
[ACI69558;Salmasalar]
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Protein domain specific binding
(GO:OO 19904) [COHA31]
Iron ion binding; iron-suI fur
cluster binding; protein binding
(GO:0005506;GO:0051536;
GO:0005515) [B5XFT9]
Unknown
GO:0005509) [Q8AX99]
Unknown507(89%)
722(99%)
351(89%)
601(99%)
Onmycontig mRNA sequence
[EZ799290; Oncorhynchus mykiss] (N)
Protein gamma-I putative mRNA
[BT059187;Salmosalar](N)
CA055196 Iron-suI fur cluster assembly enzyme
ISCU, mitochondrial precursor
putative mRNA [BT049908; Salmo
salar](N)
CB517029 ATP-citrate synthase putative mRNA
[BT072721;Salmosalar](N)
Glutathione S-transferase alpha 3 161 (97%) 8e-84 Glutathione transferase activity
rAC166699; Salmo salar] (GO:0004364) [B5X779]
See Appendix II for footnotes.
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APPENDIX XI. Transcripts (124) with greater than 2-fold expression in diploid growth hormone transgenic Atlantic salmon family AS29 in
comparison to its triploid counterparts in any3 outof4technicaIreplicatedarrays.
Gene Name of Best BLASTX or
BLASTN (N) Hit
Onmycontig mRNA sequence
[EZ807050; Oncorhynchus mykiss](N)
Unknown
Onmycontig mRNA sequence
[EZ834937;Oncorhynchusnerka](N)
BCL-WAY [ADB55705; Danio rerio]
Unnamed protein product [CAF90322;
Tetraodonnigroviridis]
Tripartite motif-containing protein 16
[ACI34059;Salmosolor]
Onmycontig mRNA sequence
[EZ902546; Oncorhynchlls mykiss](N)
Predicted protein [ED045690;
Nematostellavectensis]
LAGllongevityassurancehomolog2
[AC009885; Osmerlls mordax]
Structural maintenance of chromosomes
1B [CAQ08672; Homo sapiensl
Length(%
ID)
305(93%)
569(92%)
136(68%)
93(90%)
152(77%)
80(94%)
159(34%)
112(59%)
40(75%)
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Unknown
Biological Process: regulation of
apoptosis(GO:0042981)
[D2Y5Q2]
Sequence-specific DNA binding
transcription factor activity;
zinc ion binding (GO:0003700;
GO:0008270) [Q4T9WO]
Protein binding; zinc ion binding
(GO:0005515;GO:0008270)
[B5X428]
Unknown
Unknown [A7RS65]
Sequence-specific DNA binding;
sequence-specific DNA binding
transcription factor activity
(GO:0043565;GO:0003700)
[CIBLl2]
ATPbinding; protein binding
(GO:0005524;GO:0005515)
X Fold
Change
3.480
0.819
[Q8NDV3]
Tripartite motif-containing protein 16 74(76%) le-26 Protein binding; zinc ion binding
[ACI34059;Salmosalar] (GO:0005515;GO:0008270)
[B5X428]
Unnamed protein product [CAG06263; 89(79%) 6e-23 Protein binding (GO:0005515)
Tetraodonnigroviridis] [Q4RZB9]
Onmycontig mRNA sequence 476(98%) 0 Unknown 3.326 0.555
[EZ831450;Oncorhynchllsnerka](N)
Cytochromecoxidasesubunitlll 133(91%) 2e-55 Cytochrome-c oxidase activity
[BAG69265;/sohawaiiensis] (GO:0004129) [B5BQ78]
ADAMTS-I protein [BAEI6358; 148(72%) 4e-59 Metalloendopeptidaseactivity;
Oryziaslatipes] zinc ion binding (GO:0004222;
GO:0008270) [Q4AED3]
Onmycontig mRNA sequence 747(85%) 0 Unknown
[EZ792797; Oncorhynchlls mykiss](N)
Novel protein similar to vertebrate L1M 229(93%) le-113 Sequence-specific DNA binding;
homeobox 9 [CAK04966; Danio sequence-specific DNA binding
rerio] transcription factor activity;
zinc ion binding (GO:0043565;
GO:0003700;GO:0008270)
[QILWV4]
LOC560459 protein [AAI34875; Danio 162(67%) 3e-60 Transporter activity
rerio] (GO:0005215) [A4IGIO]
Unnamed protein product [CAG05465; 230(61%) 8e-76 Biological Process: signal 3.081
Tetraodonnigroviridis] transduction (GO:0007165)
[Q4SIL7]
Onmycontig mRNA sequence 540(86%) 2e-135 Unknown
[EZ777208; Oncorhynchlls mykiss](N)
Musculoaponeuroticfibrosarcoma 615(100%) 0 Sequence-specific DNA binding;
oncogene-like mRNA [BT043547; sequence-specific DNA binding
Salmo salar] (N) transcription factor activity
(GO:0043565;GO:0003700)
[B5DFY8]
Unknown
Onmycontig mRNA sequence 167(92%) 6e-55 Unknown 2.956 0.335
rEZ851328;Oncorhynchllsmykiss](N)
231
Novel protein similar to H.sapiens 200(93%)
LYST,lysosomaltraffickingregulator
[CAXI3573;Daniorerio]
Onmycontig mRNA sequence 687 (91%)
[EZ806691; Oncorhynchlls mykiss] (N)
Leukocyte cell-derived chemotaxin 2 55(100%)
precursor [ACI68507;Salmosalar]
Onmycontig mRNA sequence 701 (99%)
[EZ7745 17; Oncorhynchlls mykiss] (N)
Unknown
Onmycontig mRNA sequence 348 (99%)
[EZ901676;Oncorhynchllsmykiss](N)
Onmycontig mRNA sequence 162 (88%)
[EZ909514; Oncorhynchlls mykiss](N)
BAC clone RP23-27C10 from 403 (97%)
chromosome 1 [ACI25377; MlIs
mllscll/lls](N)
Onmycontig mRNA sequence 407 (81%)
[EZ865755; Oncorhynchlls mykiss] (N)
BAC SOl88122 [DQI56150; Salmo 513 (90%)
salar](N)
Tetraspanin-8 [ACI68451; Salmo salar] 94 (96%)
KIAA0415 [ACNI 1261;Salmosalar] 178 (100%)
Unknown [B7ZCY9]
Unknown [B5XCD7]
Metal ion binding (GO:0046872)
[QOH917]
Cellular Component: integral to
membrane (GO:0016021)
[B5XC81]
Unknown [COHB42]
77(67%)
469(98%)
89(98%)
Unknown [A4FUL9]
Unknown
Unknown [B5X398]
232
246(93%)
175(99%)
301(93%)
423(99%)
60(65%)
383(92%)
244(90%)
117(74%)
Onmycontig mRNA sequence 312 (92%)
[EZ823781;Oncorhynchusnerka](N)
Onmycontig mRNA sequence 480 (93%)
[EZ770909; Oncorhynchus mykiss] (N)
Cathepsin S precursor [ACNI2762; 128 (100%)
Salmosalar]
Gamma-aminobutyric-acid receptor rho- 30 (90%)
lA subunit precursor [AADI7894;
Moroneamericana]
269(92%)
500(84%)
Structural molecule activity
(GO:0005198) [C7S8F2]
Unknown
Protein binding (GO:0005515)
[Q4SNX7]
Unknown
Unknown [BOUYH7]
Cysteine-type endopeptidase
activity (GO:0004197)
[COHDJ6]
Extracellularligand-gated ion
channel activity; receptor
activity (GO:0005230;
GO:0004872) [Q9YGQ4]
Unknown
Onmycontig mRNA sequence 73(94%)
233
0.286
482(89%)
86(76%)
Onmycontig mRNA sequence 616 (96%)
[EZ820222;Oncorhynchusnerka](N)
Xaa-Pro aminopeptidase 3 [ACI33098; 86 (100%)
Salmosalar]
Unknown large open reading frame 269(99%)
mRNA [BT072506; Salmo salar] (N)
Cytosolic sulfotransferase 2 [ACI66365; 184(100%)
Salmosalar]
Olutamate-rich WO repeat containing I 170 (89%)
[AAH78350;Daniorerio]
Interferon-inducibleOTPase band 225(99%)
interferon-inducibleOTPa~ea genes
[EU221179; Salmo salar] (N)-
459(95%)
114(97%)
375(91%)
52(81%)
Onmycontig mRNA sequence 651 (94%)
[EZ907053; Oncorhynchus mykiss] (N)
Ubiquitin-likeproteinFUBlputative 109(98%)
234
ATPbinding;kinaseactivity
(00:0005524;00:0016301)
[Q7ZUN7]
Unknown
Aminopeptidase activity;
manganese ion binding
(00:0004177;00:0030145)
[B5XIB7]
Unknown
Sulfotransferaseactivity
(00:0008146) [B5X695]
Unknown [Q60BV2]
OTP binding; hydrolase activity,
acting on acid anhydrides
(00:0005525;00:0016817)
[A8WCJ8]
Unknown
Cysteine-type endopeptidase
activity (00:0004197)
[Q6IQM5]
Unknown
Insulin-like growth factor
binding; serine-type
endopeptidase activity
(00:0005520;00:0004252)
[Q60MIO]
Unknown
Structural constituent of ribosome
34(80%)
311(85%)
150(99%)
Onmycontig mRNA sequence 492 (89%)
[EZ802768; Oncorhynchlls mykiss] (N)
BAC CH214-397C7 [AC203456; Salmo 401 (89%)
salar](N)
Beta-ureidopropionase putative mRNA 257 (99%)
[BT056453;Salmosalar](N)
Creatine kinase, mitochondrial 2 372(99%)
(ckmt2) mRNA [BT043498; Salmo
salar](N)
Retrotransposableelement 724(100%)
Tf2155kDaproteintype3putative
mRNA [BT071928; Salmo salar] (N)
Onmycontig mRNA sequence 224 (92%)
[EZ906305; Oncorhynchlls mykiss](N)
Novel protein similar to vertebrate 43(80%)
structural maintenance of
chromosomes 6 [CAN88051; Danio
reriol
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(GO:0003735) [B5DGJ7]
Unknown [Q4TDT8]
Threonine-type endopeptidase
activity (GO:0004298)
[A7KE01]
Phosphoinositidebinding;protein
binding (GO:0035091;
GO:0005515) [COHAU8]
Unknown
Hydrolase activity, acting on
carbon-nitrogen (but not
peptide) bonds (GO:0016810)
[B9ELC8]
ATPbinding;kinaseactivity
(GO:0005524;GO:0016301)
[B5DFT9]
DNA binding (GO:0003677)
[COPUI4]
Unknown
ATPbinding(GO:0005524)
[A5PN27]
Onmycontig mRNA sequence 543(85%) le-131 Unknown 2.296
[EZ835434;Oncorhynchusnerka](N)
Arylhydrocarbonreceptor2alphagene; 218(92%) 2e-78 Cellular Component: MHC class I 2.285 0.399
aryl hydrocarbon receptor I beta-like protein complex (GO:0042612)
protein gene, MHCclass I antigen [DOQYP6]
gene, Sasa-UHAI*OIOI allele, MHC
class I antigen gene,Sasa-
UHA2*0101 allele, and 1-
acylglycerol-3-phosphateO-
acyltransferase3gene,andpyroxidal
kinasegene,partialcds[FJ969489;
Salmosalar](N)
Potential DNA-binding protein 459(99%) 0 DNA binding (GO:0003677)
C 17orf49 homolog putative mRNA [B5X3Q7]
[BT045676;Salmosalar](N)
Onmycontig mRNA sequence 129(94%)
[EZ861227;Oncorhynchusmykiss](N)
Onmycontig mRNA sequence 129(95%)
[EZ860285; Oncorhynchus mykiss] (N)
Onmycontig mRNA sequence 480(95%)
[EZ912532; Oncorhynchus mykiss] (N)
Ubiquitin-proteinligase 192(94%) 2e-73 Ligase activity; protein binding;
RNF8 putative mRNA [BT059506; zinc ion binding (GO:0016874;
Salmosalar](N) GO:0005515;GO:0008270)
[COHBOO]
Onmycontig mRNA sequence 447(85%) le-I05 Unknown
[EZ863492;Oncorhynchusmykiss](N)
Onmycontig mRNA sequence 464(86%)
[EZ769153;Oncorhynchusmykiss](N)
Unnamed protein product [CAG02378; 67(48%) 2e-IO Serine-type endopeptidase
Telraodonnigroviridis] activity (GO:0004252)
[Q4SAF4]
Onmycontig mRNA sequence 664(88%) 0 Unknown
[EZ792040;Oncorhynchusmykiss](N)
CA062686 Onmycontig mRNA sequence 117(94%) 3e-38 Unknown
[EZ804766;Oncorhynchusmykiss](N)
Tprprotein [AAI34978;Daniorerio] 142(58%) le-36 Unknown [A4QN67] 2.214 0.406
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Cytokine receptor common gamma 733(90%) 0 Receptoractivity(GO:0004872) 2.213 0.192
chain [AJ276623;Oncorhynchus [Q9DEQI]
mykiss](N)
Interferon-inducibleGTPase band 214(98%) ge-98 GTP binding; hydrolase activity,
interferon-inducibleGTPa~e a genes acting on acid anhydrides
[EU221179;Salmosalar](N)- (GO:0005525;GO:0016817)
[A8WCJ8]
ProbabJeE3ubiquitin-proteinligase 642(99%) 0 Unknown 2.190
TRIPI2 putative mRNA [BT072452;
Salmo salar] (N)
Immunoglobulin heavy chain gene locus Unknown [QIWCB6] 2.189
[DQ400445;!ctalurllspunctatus](N)
PhosphatidylinositoI4-kinase,catalytic, 274(91%) ge-145 l-phosphatidylinositoI4-kinase
beta (predicted) [ACC64591; activity; ATP binding
Rhinolophus ferrllmequinum] (GO:0004430;GO:0005524)
[B2KI64]
Unknown 2.176 0.273
Onmycontig mRNA sequence 370(94%)
[EZ842642; Oncorhynchlls mykiss](N)
Monocyte to macrophage differentiation 427(95%) 0 Cellular Component: integral to
protein putative mRNA [BT045655; membrane (GO:0016021)
Salmosalar](N) [B5X3N6]
RAB 14, member RAS oncogene family, 62(99%) 5e-28 Unknown
isoform CRA_a [EDL08644; Mus
musculus]
Clone BAC CHOR1214-68019 genomic 126(95%) 2e-44 Receptorbinding(GO:0005102)
sequence [GQ505860;Salmosalar](N) [DOUGD8]
Onmycontig mRNA sequence 520(90%) 0 Unknown 2.159
[EZ905198; Oncorhynchus mykiss] (N)
Clone BAC CHORI214-92I04 238(93%) 8e-84 Threonine-type endopeptidase
[EF427384;Salmosalar](N) activity (GO:0004298)
[A7KEOI]
CB499556 GTP-bindingproteinerahomolog 114(100%) 4e-59 GTP binding; RNA binding 2.144 0.169
[ACI33449;Salmosalar] (GO:0005525;GO:0003723)
[B5X2B8]
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Onmycontig mRNA sequence 322(91%) 2e-115 Unknown 2.124 0.130
[EZ858346; Oncorhynchus mykiss] (N)
Tetratricopeptiderepeatprotein 32 38(100%) ge-14 Unknown [B5X9D4]
[ACI67454;Salmosalar]
Mitochondrial import inner membrane 649(99%) 0 Protein transporter activity 2.101 0.102
translocasesubunitTim22 putative (GO:0008565) [B5X7C3]
mRNA [BT046942; Salfllo solar] (N)
Tetraspanin-3 putative mRNA 501(100%) 0 Unknown
[BT071955;Salmosalar](N)
Clone BAC CHOR1214-129P21 143(93%) 3e-48 RNA binding; structural
genomic sequence [GQ505858;Salfllo constituent of ribosome
salar](N) (GO:0003723;GO:0003735)
[A7KIL2]
Onmycontig mRNA sequence 176(95%) 8e-69 Unknown
[EZ851708; Oncorhynchusmykiss](N)
CB511319 Onmycontig mRNA sequence 497(92%) 0 Unknown 2.076 0.353
[EZ912330;Oncorhynchllsmykiss](N)
Unnamed protein product [CAF89010; 80(37%) 8e-07 Transferase activity, transferring
Telraodonnigroviridis] glycosylgroups(GO:0016757)
[Q4TDM2]
C-Cmotifchemokine21 precursor 699(99%) 0 Chemokineactivity 2.063 0.258
putative mRNA [BT048856; Salmo (GO:0008009) [B5XCT7]
salar](N)
Junctionplakoglobin [ACI33223;Salmo 201(81%) 2e-82 Binding (GO:0005488) [B5X 1P2] 2.062
solar]
Unnamed protein product [BAG52002; 234(70%) 2e-76 RabGTPaseactivatoractivity;
Homo sapiens] calcium ion binding
(GO:0005097;GO:0005509)
[B3KQEO]
CA050767 Onmycontig mRNA sequence 802(90%) 0 Unknown 2.047 0.295
[EZ911859;Oncorhynchusmykiss](N)
Diamineacetyltransferase 1 79(98%) 2e-35 N-acetyltransferaseactivity
[ACN 10066; Salmo solar] (GO:0008080) [COH7P7]
Onmycontig mRNA sequence 411 (98%) 0 Unknown
[EZ789840;Oncorhynchusmykiss](N)
Churchill protein [ACI70031;Salmo 112(100%) ge-64 Transcription activator activity; 1.999 0.121
solar] zinc ion binding (GO:0016563;
238

APPENDIX XII. Transcripts (444) with greater than 2-fold expression in triploid growth hormone transgenic Atlantic salmon family AS29 in
comparison to its diploid counterparts in any3 outof4technicaI replicated arrays.
Gene Name of Best BLASTX or
BLASTN (N) Hit
Heat shock 70 kDa protein [ACI34374;
Salmosalar]
Zgc: 113828 [AAH96945; Danio rerio]
Alpha-enolase putative mRNA
[BT072686;Salmosalar](N)
Annexin A4 [ACI69256; Salmo salar]
Length(%
ID)
126(99%)
119(53%)
29(100%)
150(99%)
106(98%)
286(91%)
182(100%)
54(100%)
44(100%)
115(29%)
110(74%)
240
ATPbinding(GO:0005524)
[B5X4Z3]
Serine-type endopeptidase
inhibitor activity (GO:0004867)
[Q4V9D6]
Peptidyl-prolylcis-trans
isomerase activity
(GO:0003755) [C IBH42]
Unknown
Calcium ion binding; calcium-
dependent phospholipid binding
(GO:0005509;GO:0005544)
[B5XEI6]
Unknown
ATPbinding(GO:0005524)
[P08108]
Lipid binding (GO:0008289)
[057524]
Lipid binding (GO:0008289)
[B5XBH3]
RNA binding; RNA-directed
DNA polymerase activity
(GO:0003723;GO:0003964)
[Q64IX6]
Electroncarrieractivity;heme
binding;monooxygenase
XFold
Change
CA056648
Elongation factor EFl alpha
[ACP56687;Oncorhynchus
Ishawylscha]
651(100%)
112(99%)
45(100%)
36(56%)
36(98%)
26(100%)
636(99%)
326(84%)
76(90%)
129(94%)
60(97%)
241
activity (GO:0009055;
GO:0020037;GO:0004497)
[CIK735]
GTPbinding;GTPaseactivity
(GO:0005525;GO:0003924)
[COH966]
ATP binding; protein binding
(GO:0005524;GO:0005515)
[Q9I8KI]
GTPbinding; GTPase activity;
translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[C3VPX4]
Unknown [D6PVT6]
NAD or NADH binding;
glycerol-3-phosphate
dehydrogenase [NAD+]
actlvlty;protetn
homodimerizationactivity
(GO:0051287;GO:0004367;
GO:0042803) [Q98SJ9]
Iron ion binding; iron-sulfur
cluster binding; protein binding
(GO:0005506;GO:0051536;
GO:0005515) [B5XFF3]
Unknown
Unknown [Q8JJ66]
Unknown
Cellular component: glycine
mitochondrial precursor [ACNI0330; cleavage complex;
Salmosalar] mitochondrion (GO:0005960;
GO:0005739) [COH8GI]
Glyceraldehyde-3-phosphate 113(100%) 7e-54 NAD or NADH binding;
dehydrogenase [ACI33883;Salmo glyceraldehyde-3-phosphate
salar] dehydrogenase
(phosphorylating) activity
(GO:0051287;GO:0004365)
[B5X3K2]
Elongation factor I-alpha 1 38(100%) 2e-11 GTP binding; GTPase activity; 9.211 1.348
[ACNI1490; Salmosalar] translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COHBSI]
Delta5-desaturase-likeprotein 87(99%) 2e-45 heme binding; oxidoreductase
[ABU87822; Oncorhynchlls masoll] activity,actingonpaired
donors,withoxidationofapair
of donors resulting in the
reduction of molecular oxygen
to two molecules of water
(GO:0020037;GO:0016717)
[A7XUS7]
RNA-binding protein PNOI 106(99%) 4e-51 RNA binding (GO:0003723)
[ACOI3732;Esoxlllcills] [CIBXH9]
Onmycontig mRNA sequence 585(99%) 0 Unknown
[EZ908260; Oncorhynchlls mykiss] (N)
Onmycontig mRNA sequence 353(94%)
[EZ908637; Oncorhynchlls mykiss] (N)
CB488137 Highmobilitygroup-Tprotein 156(99%) le-86 DNAbinding;transposase
[ACN 11467; Salmo salar] activity (GO:0003677;
GO:0004803) [COHBP8]
Si: dkey-14d8.7 protein [AAI35062; 174(59%) 6e-62 Unknown [MQN85]
Daniorerio]
CB499596 Hydroxysteroiddehydrogenase-like 103(100%) 7e-40 Oxidoreductase activity; sterol
protein 2 [ACNI0404; Salmo salar] binding (GO:0016491;
GO:0032934) [COH8N5]
HCG40021 [EA W75736; Homo 83(47%) 6e-17 Unknown 8.416 1.809
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sapiens]
Apolipoprotein B [CAA57449; Salmo 60(74%) 2e-08 Unknown [Q91480] 8.051
salar]
Glutamine synthetase [ACI68482; 27(100%) 4e-08 Glutamate-ammonia ligase 7.449 2.855
Salmosalar] activity (GO:0004356)
[B5XCB2]
Elongation factor I-alpha [ACNI0642; 145(100%) le-77 GTP binding; GTPase activity;
Salmosalar] translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COH9C3]
Glutamine synthetase [ACI68482; 99(100%) 6e-52 Glutamate-ammonia ligase 7.174 2.305
Salmosalar] activity (GO:0004356)
[B5XCB2]
Cytochrome P450 [AAD54014; 110(70%) 3e-61 Electroncarrieractivity;heme
Fundulusheleroclilus] binding;monooxygenase
activity (GO:0009055;
GO:0020037;GO:0004497)
[Q9PVII]
40S ribosomal protein S3 [ACI67079; 137(100%) 2e-70 RNA binding; structural 6.978
Salmosalar] constituent of ribosome
(GO:0003723;GO:0003735)
[B5X8A9]
Serum albumin 2 [CAA43187; Salmo 232(79%) le-96 Lipid binding; metal ion binding
salar] (GO:0008289;GO:0046872)
[Q03156]
CA055480 Unknown 6.842 2.037
CA060746 Heme oxygenase [ACI67681; Salmo 131(94%) 2e-52 Heme oxygenase (decyclizing) 6.821 2.258
salar] activity (GO:0004392)
[B5XAII]
Ribosomal protein S5 [BAF45893; 86(98%) leAI RNA binding; structural
Soleasenegalensis] constituent of ribosome
(GO:0003723;GO:0003735)
[A2QOSO]
CA043736 Elongation factor 2 [ACN58670; Salmo 211(100%) 2e-119 GTP binding; translation
salar] elongation factor activity
(GO:0005525;GO:0003746)
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173(99%)
163(100%)
GlutathioneS-transferaseA 101 (100%)
[AC007597; Oncorhynchus mykiss]
SelenoproteinPaprecursorputative 684(99%)
mRNA [BT072678; Salmo salar}(N)
Enolase 3-1 [ACH70930; Salmo solar] 182 (99%)
116(100%)
109(100%)
Toxin-I [AAM21198IAF363273; 50 (84%)
Oncorhynchusmykiss]
Coiled-coil transcriptional coactivatorb, 317(95%)
homeoboxproteinHoxCl3bb,
homeoboxprotein HoxC12bb,and
homeoboxproteinHoxCllbbgenes,
completecds; HoxCIObbpseudogene,
partial sequence; andhomeobox
protein HoxC9bb,homeobox protein
HoxC8bb, homeobox protein
HoxC6bb,homeoboxprotein
HoxC5bb,homeoboxprotein
HoxC4bb,andsingle-strandselective
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[COPUE5]
ATPbinding;unfoldedprotein
binding (GO:0005524;
GO:0051082) [COHAB6]
Translation elongation factor
activity (GO:0003746)
[B5XFY9]
Transferase activity
(GO:OO 16740) [C IBEZ4]
Unknown
Magnesium ion binding;
phosphopyruvatehydratase
activity (GO:0000287;
GO:0004634) [B5DGQ6]
Cellular Component: MHC class I
protein complex (GO:0042612)
[Q91966]
RNA binding; ribosome binding;
translation elongation factor
activity; translation initiation
factor activity (GO:0003723;
GO:0043022;GO:0003746;
GO:0003743) [B9EMV4]
Unknown [Q8JJ66]
Sequence-specific DNA binding;
sequence-specific DNA binding
transcription factor activity
(GO:0043565;GO:0003700)
[B3SU99]
monofunctional uracil genes, complete
cds [EU025717;Salmosalar](N)
Complement Clq-like protein 4 101(46%) 2e-18 Unknown [B9EPU5] 6.027
precursor [ACM09542; Salmo salar]
Unnamed protein product [CAG02807; 123(62%) 6e-37 Channel activity (GO:0015267) 5.938 1.818
Telraodonnigroviridis] [Q4S975]
SelenoproteinPaprecursorputative 730(99%) 0 Unknown
mRNA [BT072678; Salmo salar] (N)
Beta-2-microglobulinprecursorputative 542(99%) 0 Cellular Component: MHC class I
mRNA [BT047559; Salmo sala] (N) protein complex (GO:0042612)
[Q9DD81]
GlycinecleavagesystemHprotein, 79(100%) 4e-38 Glycine cleavage complex;
mitochondrial precursor [ACNI0330; mitochondrion (GO:0005960;
Salmosalar] GO:0005739) [COH8G I]
FBP3211 precursor [ABB29992; MOI'one 153(68%) 7e-51 Biological Process: cell adhesion
chrysops] (GO:0007155) [Q2LK87]
CA064237 Onmycontig mRNA sequence 728(95%) Unknown
[EZ784403;Oncorhynchusmykiss](N)
Heat shock protein hsp90 [AAB49983; 157(82%) 2e-39 ATPbinding;unfoldedprotein
OncorhynchuslshawYlscha] binding (GO:0005524;
GO:0051082) [P87397]
Notchlessproteinhomolog I 67(100%) 5e-33 Unknown [COPUL3]
[ACN58698;Salmosalar]
SelenoproteinPaprecursorputative 706(100%) 0 Unknown 5.659
mRNA [BT072678; Salmo salar] (N)
ComplementClq-like protein 4 117(48%) 2e-25 Unknown [B9EPU5]
precursor [ACM09542;Salmosalar]
Onmycontig mRNA sequence 491(100%)
[EZ767124; Oncorhynchusmykiss](N)
Alpha actin [AAF75784IAF267496; 137(100%) 4e-75 ATP binding; protein binding 5.609 2.048
Salmolrutta] (GO:0005524;GO:0005515)
[Q918KI]
Sec61 alpha form A-like mRNA 688(99%) 0 P-P-bortd-hydrolysis-driven
[BT044020;Salmosalar](N) protein transmembrane
transporter activity
(GO:0015450) [B5RI96]
Eukaryotic translation elongation factor 47(92%) 5e-18 GTP binding; GTPase activity; 5.473 1.651
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2 [ABK58358;Callilhrixjacchus]
411(91%)
117(86%)
(ormosanus]
213(98%)
700(96%)
534(98%)
Glutamate dehydrogenase I, 515(100%)
mitochondrial precursor putative
mRNA [BT044837; Salmo salar] (N)
Complement factor H precursor 137 (76%)
[CAF25505; Oncorhynchus mykiss]
Cytochrome P450 [AAC98961; 87 (81%)
Dicenlrarchuslabrax]
193(99%)
145(100%)
530(80%)
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translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[AOSXL6]
Unknown
Unknown [BOFFJ7]
Calcium ion binding
(GO:0005509) [COH958]
Unknown
Metal ion binding;superoxide
dismutaseactivity
(GO:0046872;GO:0004784)
[CIBFL3]
Binding; oxidoreductase activity,
acting on theCH-NH2 group of
donors, NAD or NADP as
acceptor (GO:0005488;
GO:0016639) [B5X IB8]
Unknown [Q2L4Q6]
Electron carrier activity; heme
binding;monooxygenase
activity (GO:0009055;
GO:0020037;GO:0004497)
[Q9YI34]
P-P-bond-hydrolysis-driven
protein transmembrane
transporleractivity
(GO:0015450) [B5X322]
Sugar binding (GO:0005529)
[Q4LAN6]
Unknown
CA060068 Disulfide-isomeraseA3precursor 112(100%) 2e-61 Isomerase activity (GO:0016853) 5.168 2.507
[AC134304;Salmosalar] [B5X4S3]
Serine/threonine-proteinphosphatase2A 681(99%) 0 Phosphoprotein phosphatase 5.069
catalytic subunit beta isoform putative activity (GO:000472 I)
mRNA [BT04485I ; Salmo salar] (N) [B5XID2]
Onmycontig mRNA sequence 221(94%) 7e-84 Unknown 5.044 0.605
[EZ861225; Oncorhynchus mykiss] (N)
Complement component C3 101(92%) 3e-46 Endopeptidase inhibitor activity;
[AAB05029; Oncorhynchus mykiss] protein binding (GO:0004866;
GO:0005515) [P98093]
Homo sapiens glyceraldehyde-3- 193(100%) 2e-106 Unknown
phosphate dehydrogenase
[AAP36549;Synlhelicconsfrucl]
Cold-inducible RNA-binding protein 627(99%) 0 Nucleic acid binding; nucleotide
putative mRNA [BT058753; Salmo binding (GO:0003676;
salar](N) GO:0000166) [COH8U7]
Onmycontig mRNA sequence 359(84%) le-8I Unknown 4.963
[EZ771918;Oncorhynchusmykiss](N)
HSC7I [AAB21658; Oncorhynchus 212(100%) 7e-95 ATPbinding
mykiss] (GO:0005524)[P08108]
CK990940 Unknown 4.851 0.557
CA056224 Clonessal-rgf-540-084 [BT072779; 655(100%) 0 Unknown 4.833 1.800
Salmosalar](N)
Cold-inducible RNA-binding protein 28(100%) 4e-07 Nucleic acid binding; nucleotide
[ACM09312;Salmosalar] binding (GO:0003676;
GO:0000166) [B9EP65]
Glutathione peroxidase type 2 71(85%) 4e-28 Glutathione peroxidase activity
[AA V32968; Oncorhynchus mykiss] (GO:0004602) [Q5UTE7]
K 18, simple type I keratin [CAA 74664; 73(100%) 6e-24 Structural molecule activity
Oncorhynchusmykiss] (GO:0005198) [057607]
Elongation factor I-alpha I putative 628(100%) 0 GTPbinding;GTPaseactivity; 4.600 0.630
mRNA [BT059777; Salmo salar] (N) translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COHBSI]
CB505935 SelenoproteinPaprecursorputative 511(100%) 0 Unknown 4.573 0.736
mRNA [BT072678; Salmo salar] (N)
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Membrane-spanning4-domains 200(79%) le-70 Cellular Component: integral to 4.522 0.938
subfamily A member 4A [ACI69003; membrane (GO:0016021)
Salmosalar] [B5XDT3]
Onmycontig mRNA sequence 465(99%) 0 Unknown
[EZ782390; Oncorhynchus mykiss](N)
Troponin T, slow skeletal muscle 190(100%) ge-92 Unknown [B9EPE5]
[ACM09392; Salmo solar]
40Sribosomal protein SII [ACOI5454; 105(100%) le-53 Structural constituent of ribosome 4.485 0.417
Caligusclemensi] (GO:0003735) [CIC2FI]
Actin [AAK60616IAF330142; 78(100%) 2e-37 ATPbinding;proteinbinding
Oncorhynchllsmykiss] (GO:0005524;GO:0005515)
[Q90WC5]
CB511435 Complement factor Bf-I [AAC83699; 151(76%) 4e-62 Serine-type endopeptidase 4.401 0.923
Oncorhynchus mykiss gairdneri] activity (GO:0004252)
[Q9YGE7]
Onmycontig mRNA sequence 559(95%) 0 Unknown
[EZ7649 I3; Oncorhynchlls mykiss] (N)
Lysosomal-associated transmembrane 578(100%) 0 Cellular Component: integral to
protein 4A putative mRNA membrane (GO:0016021)
[BT045705;Salmosalar](N) [B5X3T6]
Beta-2-microglobulinprecursorputative 608(99%) 0 Cellular Component: MHC class I
mRNA [BT047559; Salmo salar] (N) protein complex (GO:0042612)
[Q9DD81]
C type lectin receptor C [AAT77222; 186(94%) le-76 Receptoractivity;sugarbinding 4.334 0.692
Salmosalar] (GO:0004872;
GO:0005529)[Q68S96]
Mitochondrialcomplexlsubunit 52(100%) 6e-27 Unknown [B8YI11] 4.310
NDUFB2 [ACL68409; Oncorhynchlls
mykiss]
Glyceraldehyde-3-phosphate 112(100%) 3e-53 NAD or NADH binding;
dehydrogenase [ACI33883;Salmo glyceraldehyde-3-phosphate
salar] dehydrogenase
(phosphorylating) activity
(GO:0051287;GO:0004365)
[B5X3K2]
Glyceraldehyde-3-phosphate 116(100%) 3e-60 NAD or NADH binding;
dehydrogenase [ACI69846;Salmo glyceraldehyde-3-phosphate
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salar] dehydrogenase
(phosphorylating) activity
(GO:0051287;GO:0004365)
[B5XG76]
Beta-2-glycoprotein I precursor 211(84%) 2e-ltO Unknown [COH7UJ] 4.288 0.798
[ACNtOIIO; Salmo salar]
Onmycontig mRNA sequence 213(93%) 5e-80 Unknown 4.271 0.344
[EZ764509; Oncorhynchlls mykiss] (N)
Mitochondrialimportreceptorsubunit 387(96%) 3e-171 P-P-bond-hydrolysis-driven
TOM7 homolog putative mRNA protein transmembrane
[BT048608;Salmosalar](N) transporteractivity;receptor
activity (GO:0015450;
GO:0004872) [B5X7Q4]
S-adenosylhomocysteinehydrolase 185(99%) le-I02 Adenosylhomocysteinaseactivity;
[ACH70814; Salmo salar] binding (GO:0004013;
GO:0005488) [B5DGEO]
NACHT, LRR and PYD domains- 188(85%) 8e-38 Unknown 4.219 2.406
containing protein I putativemRNA
[BT072692;Salmosalar](N)
CK990274 Unknown 4.202 0.954
DW564611 Unnamed protein product [CAF95001; 94(94%) le-40 Unknown [Q4SWII] 4.192 0.932
Te'raodonnigroviridis]
Onmycontig mRNA sequence 760(92%)
[EZ908375; Oncorhynchllsll7ykiss](N)
CB494398 Disulfide-isomeraseA3precursor 46(94%) le-15 Isomerase activity (GO:0016853) 4.134 0.942
[ACI34304;Salll7osalar] [B5X4S3]
Eif4albprotein [AAI53508;Danio 189(92%) 2e-92 ATPbinding;ATP-dependent
rerio] helicaseactivity; nucleic acid
binding (GO:0005524;
GO:0008026;GO:0003676)
[A8E590]
Cold-inducible RNA-binding protein 83(99%) 2e-39 Nucleic acid binding; nucleotide
[ACN I0466; Salmo salar] binding (GO:0003676;
GO:0000166) [COH8U7]
Beta-2 microglobulin mRNA 505(93%) 0 Cellular Component: MHC class I 4.118 0.645
[L6353310NHB2MD Oncorhynchlls protein complex (GO:0042612)
mykiss](N) [Q91202]
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Complement factor HI protein 149(82%) le-69 Unknown [BOFFJ7] 4.113 0.491
[ABY55261; Oncorhynchlls masoll
formosanlls]
Glyceraldehyde-3-phosphate 146(99%) 6e-78 NAD or NADH binding;
dehydrogenase [ACI66269;Sa/mo glyceraldehyde-3-phosphate
sa/ar] dehydrogenase
(phosphorylating) activity
(GO:0051287;GO:0004365)
[B5X5Z9]
Cytochrome P450 3A27 [ACI33861; 205(100%) 3e-115 Electroncarrieractivity;heme 4.104 1.378
Sa/mosa/ar] binding; oxidoreductase
activity, acting on paired
donors, with incorporation or
reduction of molecular oxygen,
reduced flavin or flavoprotein
as one donor, and incorporation
of one atom of oxygen
(GO:0009055;GO:0020037;
GO:0016712) [B5X31O]
Beta-2 microglobulin type 2 24(92%) le-12 Cellular Component: MHC class I
[AAP51 056; Oncol'hynchlls mykiss] protein complex (GO:0042612)
[Q6XQIO]
Elongation factor I-alpha [ACNI0642; 148(100%) 2e-79 GTP binding; GTPase activity;
Sa/mosa/ar] translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COH9C3]
Fructose-I,6-bisphosphatase 190(97%) le-119 Fructose 1,6-bisphosphate 1-
[ACH70893; Sa/mo sa/al'] phosphatase activity
(GO:0042 I32) [B5DGL9]
CB493939 Onmycontig mRNA sequence 646(97%) 0 Unknown 3.987
[EZ763719; Oncol'hynchlls mykiss] (N)
Ferritin-H subunit 65(96%) 6e-57 Ferric iron binding; 3.972 0.540
[AAK08117IAF338763; oxidoreductase activity
Oncorhynchllsnerka] (GO:0008199;GO:0016491)
[Q98TTO]
Onmycontig mRNA sequence 542(99%) 0 Unknown 3.968
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181(62%)
513(89%)
78(100%)
273(58%)
133(99%)
ElongationfactorJ-beta[ACI68836; 164(97%)
Sa/masa/ar]
Onmycontig mRNA sequence 377 (95%)
[EZ764925; Oncarhynchus mykiss] (N)
Calmodulin 2 [AAX37095; Synthetic 143 (96%)
151(99%)
Cysteine-type endopeptidase
inhibitor activity (GO:0004869)
[CIBX66]
Unknown
Receptoractivity(GO:0004872)
[B5X5M7]
Small conjugating protein ligase
activity (GO:0019787)
[B9EPC6]
Translation elongation factor
activity (GO:0003746)
[B5XDB6]
Unknown
Unknown [B5XA YO]
RCG61927 [EDM02821; Rattus
narvegicus]
60SribosomalproteinLIOa
[AC008534; Oncarhynchus mykiss]
Cold-inducible RNA-binding protein
putative mRNA [BT056773; Sa/mo
sa/ar](Nl
165(99%)
70(43%)
179(99%)
516(99%)
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Cellular Component: MHC class I
protein complex (GO:0042612)
[B9ELZ2]
Unknown
RNA binding; structural
constituentofribosome
(GO:0003723;GO:0003735)
[CIBHN1]
Nucleic acid binding; nucleotide
binding (GO:0003676;
GO:0000166) [B5DGC5]
Onmycontig mRNA sequence 636(99%)
[EZ765170; Oncorhynchus mykiss] (N)
Extracellular matrix protein 1 precursor 97(97%) leA8 Cellular Component: extracellular
[ACN I0906; Salmo salar] space (GO:0005615) [COHA37]
Actin [AAK60616IAF330142; 102(100%) 6e-53 ATP binding; protein binding
Oncorhynchusmykiss] (GO:0005524;GO:0005515)
[Q90WC5]
139(99%) ge-77 Ferric iron binding; ferroxidase
activity (GO:0008199;
GO:0004322) [P49946]
Fish-egg lectin [ACM09206; Salmo 84(100%) 4e-44 Sugar binding (GO:0005529)
salar] [B9ENV9]
Retinol dehydrogenase 3 [ACI67927; 191(92%) le-98 Oxidoreductase activity
Salmosalar] (GO:0016491) [B5XAQ7]
Glutathione peroxidase 3 precursor 492(99%) 0 Unknown
putative mRNA [BT072794; Salmo
salar](N)
Elongation factor EFl alpha 64(99%) le-27 GTP binding; GTPase activity;
[ACP56687;Oncorhynchus translation elongation factor
tshawytscha] activity (GO:0005525;
GO:0003924;GO:0003746)
[C3VPX4]
240(99%) le-141 Electron carrier activity; iron-
sulfur cluster binding;
oxidoreductase activity
(GO:0009055;GO:0051536;
GO:OO 16491) [C IBEH2]
701(100%) 0 Cellular Component: endoplasmic
reticulum; integral to membrane
(GO:0005783;GO:0016021)
[B9EQJ2]
Lectinprecursor[ACN09984;Salmo 75(46%) 4e-11 Sugar binding (GO:0005529)
salar] [COH7G5]
Unnamed protein product [CAG05386; 186(95%) 6e-I10 Unknown [Q4SIU6]
Tetraodonnigroviridis]
Onmycontig mRNA sequence 644(99%)
[EZ764794;Oncorhynchusmykiss](N)
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78 kDa glucose-regulated protein 197(99%) 2e-106 ATP binding (GO:0005524)
precursor [ACI33778; Sa/lIlosa/ar] [B5X397]
Extracellular matrix protein I precursor 566(96%) 0 Cellular Component: extracellular 3.572 0.759
putative mRNA [BT059193; Sa/mo space (GO:0005615) [COHA37]
sa/ar](N)
40S ribosomal protein SA [AC009157; 106(79%) ge-37 Structural constituent of ribosome
Osmerusmordax] (GO:0003735) [CIBJF4]
Onmycontig mRNA sequence 433(90%) 2e-144 Unknown
[EZ764857;Oncorhynchuslllykiss](N)
Zonadhesin-likegene[AY785950; 448(85%) 5e-110 Cellular Component: membrane
Sa/lIlosa/ar](Nl (GO:0016020) [Q5S3NI]
Hemoglobinsubunitalpha-4 71(99%) ge-55 Hemebinding;oxygenbinding; 3.480 0.417
[ACN09908; Sa/mo sa/ar] oxygen transporter activity
(GO:0020037;GO:0019825;
GO:0005344) [COH789]
TransposableelementTcb2transposase 52(89%) 2e-30 Unknown [COHA75] 3.478
[ACNI0944;Sa/mosa/ar]
Cystatin precursor [ACI66376;Sa/mo 114(85%) 2e-44 Cysteine-type endopeptidase
sa/ar] inhibitor activity (GO:0004869)
[B5X6A6]
Elongation factor I-alpha [ACNI0642; 51(100%) 2e-20 GTP binding; GTPase activity;
Sa/lIlosa/ar] translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COH9C3]
Fructose-bisphosphatealdolase B 116(94%) 5e-49 Fructose-bisphosphatealdolase
[ACNIOIOO;Sa/lIlosa/ar] activity (GO:0004332)
[COH7TI]
Proteasome subunit alpha type 3 142(100%) ge-70 Threonine-type endopeptidase
[AC007671; Oncorhynchus mykiss] activity (GO:0004298)
[CIBF68]
Elongation factor I-alpha [ACNI0642; 99(100%) le-49 GTP binding; GTPase activity;
Sa/mosa/ar] translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COH9C3]
Onmycontig mRNA sequence 706(99%) 0 Unknown 3.460 0.479
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[EZ768185;Oncorhynchllsmykiss](N)
Adenylyl cyclase-associated protein I 610(99%) 0 Actin binding (GO:000377)
putative mRNA [BT0452I 0; Salmo [B5X2EI]
salar](Nl
CarboxypeptidaseNcatalyticchain 217(100%) 7e-128 Metallocarboxypeptidaseactivity;
precursor [ACN I0284; Salmo salar] zinc ion binding (GO:000418;
GO:0008270) [COH8B5]
5-aminolevulinate synthase, erythroid- 30(100%) 2e-10 5-aminolevulinatesynthase
specific, mitochondrial precursor activity; pyridoxal phosphate
[ACNI0630; Salmo salar] binding; Transferase activity,
transferring nitrogenous groups
(GO:0003870;GO:0030170;
GO:0016769) [COH9BI]
28Sribosomal protein S18a, 61(100%) 4e-30 Structural constituent of ribosome
mitochondrial precursor [AC008097; (GO:0003735) [C I BGE4]
Oncorhynchllsmykiss]
Prothymosin alpha [ACM09466; Salmo 111(99%) ge-17 Unknown [B9EPL9] 3.429 0.999
salar]
ATPsynthasesubunite,mitochondrial 71(96%) 2e-18 Hydrogen ion transmembrane
[ACI66375;Salmosalar] transporter activity
(GO:0015078) [B5X6A5]
Ferritin, middle subunit [ACI66713; 130(95%) 7e-67 Ferric iron binding (GO:0008199)
Salmosalar] [B5X793]
Cytochromeb-cl complexsubunit I, 147(100%) le-83 Metalloendopeptidaseactivity;
mitochondrial precursor [ACN58644; zinc ion binding (GO:0004222;
Salmo GO:0008270) [COPUA8]
solar]
CA054202 Delta-6fattyacyldesaturaseD6fad a 466(96%) 0 Heme binding; oxidoreductase
gene [AY736067;Salmosalar](!'J) activity,actingonpaired
donors, with oxidation ofa pair
of donors resulting in the
reduction of molecular oxygen
to two molecules of water
(GO:0020037;GO:0016717)
[Q6SESO]
Onmycontig mRNA sequence 411(93%) 2e-158 Unknown 3.395 0.607
[EZ910586; Oncorhynclllls mykiss] (N)
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Hemoglobin subunit alpha [ACN 10174; 91(91%) le-38 Heme binding; oxygen binding;
Salmasalar] oxygen transporter actIvIty
(GO:0020037;GO:0019825;
GO:0005344) [COH805]
Brain protein 44-like protein 80(100%) le-39 Unknown [B5X6D4]
[ACI66404;Salmosalar]
Solute carrier family 25-2 [ACH71015; 81(100%) ge-40 Binding; transporter activity
Salmosalar] (GO:0005488;GO:0005215)
[B5DGZl]
Cold-inducible RNA-binding protein 588(99%) 0 Unknown
putative mRNA [BTI25559; Salmo
salar](Nl
Translocon-associated protein subunit 110(100%) le-57 Cellular Component: endoplasmic
beta precursor [ACOI3626; Esox reticulum; integral to membrane
lucius] (GO:0005783;GO:0016021)
[CIBX73]
623(99%) 0 Unknown
67(74%) 4e-IO Cellular Component:
mitochondrion (GO:0005739)
[A8WE67]
Beta-2-microglobulinprecursor 68(100%) 6e-34 Cellular Component: MHC class I
[ACM08628;Salmosalar] protein complex (GO:0042612)
[B9EM81]
Hypothetical protein PANDA_002907 31(100%) 6e-09 Unknown [D2HOF9]
[EFB 16835; Ailuropoda melanoleuca]
Onmycontig mRNA sequence 466(93%)
[EZ763644; Oncorhynchus mykiss] (N)
Onmycontig mRNA sequence 340(99%)
[EZ785438; Oncorhynchus mykiss] (N)
Hepcidin-l precursor [ACI67048; Salmo 31(94%) 5e-13 Cellular Component: extracellular
salar] region (GO:0005576)
[B5X878]
Cytochrome oxidase subunit 11 226(94%) ge-I02 Copperionbinding;cytochrome-c
[AAD04736; Salmo salar] oxidase activity; electron carrier
activity;hemebinding
(GO:0005507;GO:0004129;
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GO:0009055;GO:0020037)
[Q37677]
Ribosomal protein 53-2 [ACH71009; 180(100%) le-97 RNA binding; structural
Salmosalar] constituent of ribosome
(GO:0003723;GO:0003735)
[B5DGY5]
CWC15 homolog [ACM08285; Salmo 80(100%) le-33 Cellular Component:
salar] spliceosomalcomplex
(GO:0005681) [B9EL88]
DY724400 Unknown 3.325 0.232
CB491411 ApolipoproteinC-lprecursor 87(96%) 3e-39 Cellular Component: extracellular 3.311 0.245
[ACI69086;Salmosalar] region (GO:0005576)
[B5XEI6]
Tubulin,alpha8like2 [ACH70822; 77(99%) 7e-33 GTPbinding;GTPaseactivity;
Salmosalar] structural molecule activity
(GO:0005525;GO:0003924;
GO:0005198) [B5DGE8]
Zgc: 112247 [AAH95705; Danio rerio] 92(79%) 4e-34 Pyridoxal phosphate binding;
transferase activity, transferring
nitrogenous groups
(GO:0030170;GO:0016769)
[Q502G6]
104(72%) 7e-38 Copper ion binding;
oxidoreductase activity
(GO:0005507;GO:0016491)
[Q4RPE7]
Hypothetical protein [ACH85281; 101(70%) 4e-36 Unknown [B5RI40]
Salmosalar]
Onmycontig mRNA sequence 715(97%)
[EZ909005; Oncorhynchus mykiss] (N)
Brain protein 44-like protein 72(100%) 7e-34 Unknown [B5XEV9]
[ACI69379;Salmosalar]
Ribosomal RNA methyltransferase 2 109(94%) 2e-103 RNAmethyltransferaseactivity;
[AC008707; Oncorhynchus mykiss] nucleic acid binding
(GO:0008173;GO:0003676)
[CIBI54]
Novel protein similar to vertebrate 144(97%) 2e-74 Cellular Component: integral to
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NCK-associatedprotein I membrane;lamellipodium
[CAQI4913; Danio rerio] membrane (GO:0016021;
GO:0031258) [BOS6RI]
Hypothetical protein [ACH85281; 164(79%) le-60 Unknown [B5RI40]
Salmosalar]
Chromosome 20 open reading frame 149 121(91%) 2e-49 Biological Process: cell
[ACH70875;Salmosalar] differentiation; multicellular
organismaldevelopment
(GO:0030154;GO:0007275)
[B5DGKI]
Unnamed protein product [CAF97930; 120(82%) 3e-50 Cellular Component: cytoplasm
Telraodonnigroviridis] (GO:0005737) [Q4SN52]
CB496842 C type lectin receptor B [ACM80352; 92(100%) ge-52 Receptoractivity;sugarbinding
Oncorhynchusmykiss] (GO:0004872;GO:0005529)
[COKIP4]
C-type lectin domain family 4 member 27(100%) le-08 Sugar binding (GO:0005529)
E [ACI67923;Salmosalar] [B5XAQ3]
Glyceraldehyde-3-phosphate 200(100%) 2e-110 NAD or NADH binding;
dehydrogenase [ACI69846;Salmo glyceraldehyde-3-phosphate
salar] dehydrogenase
(phosphorylating) activity
(GO:0051287;GO:0004365)
[B5XG76]
U3smallnucleolarribonucleoprotein 205(99%) 7e-113 Nucleic acid binding 3.228
protein IMP4 [ACI66547;Salmo (GO:0003676) [B5X6S7]
salar]
SJCHGC03032 protein [AAX28478; 113(46%) 5e-14 Unknown [Q5BVU7]
Schislosomajaponicum]
Disulfide-isomerase A6 precursor 229(100%) 6e-117 Isomerase activity (GO:0016853)
[ACI34364;Salmosalar] [B5X4Y3]
Transmembrane 9 superfamily member 332(99%) 6e-164 Cellular Component: integral to
2 precursor putative mRNA membrane (GO:0016021)
[BT058975;Salmosalar](N) [COH9G9]
Transmembrane protein 127 putative 434(100%) 0 Cellular Component: integral to
mRNA [BT045429; Salmo salar] (N) membrane (GO:0016021)
[B5X310]
257
CB497823 26S protease regulatory subunit 8
[AC009830; Osmerus mordax]
Unnamed protein product [CAG02814;
Tetraodonnigroviridis]
Mu-crystallin homolog [ACM08876;
Salmosalar]
Oocyte protease inhibitor-2
[AA016105; Oncorhynchus mykiss]
DEAD (Asp-G1u-Ala-Asp) box
polypeptide 21 [ACH85363; Salmo
salar]
137(99%) 2e-70 ATP binding; nucleoside-
triphosphatase activity;
peptidase activity
(GO:0005524;GO:0017111;
GO:0008233) [C 1BLC7]
221(48%) 2e-45 Unknown [Q4S968]
149(100%) le-78 Binding; catalytic activity
(GO:0005488;GO:0003824)
[B9EMX9]
159(100%) le-80 Unknown [B5X715]
105(99%) 2e-41 Structural molecule activity
(GO:0005198) [057607]
757(89%) 0 Unknown
493(99%) 0 Cellular Component: integral to
membrane (GO:0016021)
[B9EL72]
89(76%) 2e-33 Peptidase activity (GO:0008233)
[Q8AX91]
207(83%) 2e-72 ATP binding; ATP-dependent
helicaseactivity; RNA binding
(GO:0005524;GO:0008026;
GO:0003723) [B5RIC3]
664(91%) 0 Unknown
139(41%) le-14 Cellular Component: integral to
membrane (GO:0016021)
[B5XDT3]
165(87%) 3e-84 Carboxylesterase activity
(GO:0004091) [Q92149]
211(99%) ge-104 GTP binding; GTPase activity;
translation elongation factor
activity (GO:0005525;
GO:0003924;GO:0003746)
[COH9N2]
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SelenoproteinPaprecursorputative 583(99%)
mRNA [BT07222I ; Salmo salar] (N)
Pentraxin [CAA67764; Oncorhynchus 160(99%) 6e-90 Unknown [P79899]
mykiss]
Onmycontig mRNA sequence 578(98%)
[EZ763824; Oncorhynchus mykiss] (N)
THO complex I [AAH54938; Danio 201(85%) 2e-91 Protein binding (GO:0005515)
rerio] [Q7SYB2]
Hypothetical protein mRNA 639(98%) 0 Unknown [B5RI40]
[BT043964;Salmosalar](N)
Clonessal-rgf-OOI-077 [BT071827; 711(99%)
Salmosalar](N)
Onmycontig mRNA sequence 307(89%)
[EZ910931;Oncorhynchusmykiss](N)
GlutathioneS-transferase[BAA76974; 159(97%) 2e-84 Glutathione transferase activity
Oncorhynchusnerka] (GO:0004364) [Q9W647]
Onmycontig mRNA sequence 509(90%) 2e-174 Unknown
[EZ908703; Oncorhynchus mykiss] (N)
Ferritin, heavy subunit [ACNI0128; 175(99%) le-97 Ferric iron binding;
Salmosalar] oxidoreductase activity
(GO:0008199;GO:0016491)
[COH7V9]
Onmycontig mRNA sequence 168(95%) 1e-64 Unknown
[EZ907370;Oncorhynchusmykiss](N)
Calmodulin 2 [AAX37095; synthetic 149(100%)
construct]
Osteopontin-likeprotein 30(100%) 5e-08 Unknown [Q9DE42]
[AAG35656IAF204760;
Oncorhynchusmykiss]
Onmycontig mRNA sequence 595(99%) 0 Unknown
[EZ764258; Oncorhynchus mykiss](N)
GlutathioneS-transferasetheta-1 155(100%) 3e-83 Transferase activity
[ACI33850;Salmosalar] (GO:0016740) [B5X3G9]
Homeoboxprotien HoxB5ab 82(100%) 4e-41 Sequence-specific DNA binding;
[ABW77478; Salmo salar] sequence-specific DNA binding
transcription factor activity
(GO:0043565;GO:0003700)
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Onmycontig mRNA sequence 455 (95%)
[EZ768570; Oncorhynchus mykiss] (N)
Onmycontig mRNA sequence 564 (97%)
[EZ763960; Oncorhynchus mykiss] (N)
Gamma-aminobutyric acid receptor- 457 (89%)
associated protein-like 2 putative
mRNA [BT056984; Salmo solar] (N)
Ferritin,heavysubunit[AC007472; 126(100%)
Oncorhynchusmykiss]
530(95%)
Onmycontig mRNA sequence 579 (90%)
[EZ905677; Oncorhynchus mykiss] (N)
Onmycontig mRNA sequence 156 (88%)
[EZ888359; Oncorhynchus mykiss](N)
Alanine aminotransferase2-like putative 627(99%)
mRNA [BT072409; Salmo solar] (N)
Tumorprotein p53 binding protein 205(99%)
[AAV32965; Oncorhynchus mykiss]
Onmycontig mRNA sequence 438 (96%)
[EZ832254;Oncorhynchusmykiss](N)
T-complexprotein 1 subunitepsilon 109(100%)
[ACNI1333; Salmo solar]
748(99%)
Novel protein [CAX 14472; Danio rerio] 42 (79%)
141(99%)
131(100%)
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[B3TDB6]
Unknown
Receptoractivity(GO:0004872)
[B9EMV9]
Ferric iron binding;
oxidoreductase activity
(GO:0008199;GO:0016491)
[CIBEL9]
Nucleic acid binding; nucleotide
binding (GO:0003676;
GO:0000166) [COH9Z3]
Unknown
Cellular Component: intracellular
(GO:0005622) [Q5UTFO]
Unknown
ATP binding; unfolded protein
binding (GO:0005524;
GO:0051082) [COHBB4]
DNA binding; transposase
activity (GO:0003677;
GO:0004803) [B5RI68]
Methyltransferaseactivity
(GO:0008168) [B8JM82]
Unknown [P79899]
Cysteine-type endopeptidase
activity (GO:0004197)
[CIC377]
Ferritin, middle subunit [ACI67714; 138(100%) le-74 Ferric iron binding (GO:0008199) 2.969
Salmosalar] [B5XA44]
Onmycontig mRNA sequence 592(94%) 0 Unknown
[EZ772458;Oncorhynchusmykiss](N)
Nucleoside diphosphate kinase 151 (99%) 4e-82 ATP binding; nucleoside 2.957 0.510
[AA042980; Oncorhynchus mykiss] diphosphate kinase activity
(GO:0005524;GO:0004550)
[Q804YO]
Unnamed protein product [CAF92600; 211(61%) 2e-60 Serine-type endopeptidase
Telraodonnigroviridis] inhibitor activity (GO:0004867)
[Q4T3D2]
Y-boxbindingprotein[ACL31579; 71(100%) le-21 DNA binding (GO:0003677)
Oncorhynchusmykiss] [B8Y7S9]
Toxin-I [AAM21198IAF363273; 61(87%) le-26 Unknown [Q8JJ66] 2.942 0.712
Oncorhynch/lsmykiss]
Cold-inducible RNA-binding protein 593(99%) 0 Unknown 2.938 0.378
putative mRNA [BTI25559; Salmo
salar](N)
Novel protein [CAI21251;Daniorerio] 170(46%) 7e-36 Serine-type endopeptidase
inhibitor activity (GO:0004867)
[Q5RIH8]
Onmycontig mRNA sequence 509(95%) 0 Unknown
[EZ764913; Oncorhynchus mykiss] (N)
Onmycontig mRNA sequence 514(92%)
[EZ78! 0 !4; Oncorhynchus mykiss] (N)
Ovomucin alpha-subunit [BAB2148; 141(42%)
Gallusgallus]
SJCHGC03032 protein [AAX28478; 101(49%) 2e-14 Unknown [Q5BVU7] 2.906
Schislosomajaponicum]
ApolipoproteinC-1 precursor 87(99%) ge-41 Cellular Component: extracellular
[ACI69086;Salmosalar] region (GO:0005576)
[B5XEI6]
Extracellular matrix protein 568(99%) 0 Cellular Component: extracellular
I precursor putative mRNA [BT059193; space (GO:0005615) [COHA37]
SalmosalartN)
Onmycontig mRNA sequence 453(96%) 0 Unknown 2.883 0.407
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[EZ7831 17; Oncorhynchllsmykiss](N)
CTP synthase 1 [ACI34065; Salmo 133(97%) 4e-79 CTP synthase activity 2.877
salar] (00:0003883) [B5X434]
Integral membrane protein 623(99%) 0 Unknown [COH9D9]
2B putative mRNA [BT058945; Salmo
salar](N)
Transposase-like mRNA [BT043992; 714(100%) 0 DNAbinding;transposase 2.866 0.296
Salmo salar] (Nl activity (00:0003677;
00:0004803) [B5RI68]
TCR-alphaldelta locus [EF467299; 292(87%) 4e-8! Unknown 2.863 0.582
Salmo salar] (N)
OlutathioneS-transferaseA 48(98%) 3e-19 Transferase activity
[AC007597; Oncorhynchlls mykiss] (00:0016740) [CIBEZ4]
HSC71 [AAB21658; Oncorhynchlls 133(100%) 3e-48 ATPbinding(00:0005524) 2.842
mykiss] [P08108]
Onmycontig mRNA sequence 390(82%) 4e-71 Unknown
[EZ904381; Oncorhynchllsll1ykiss](N)
CA054597 Unknown 2.818 0.678
CX245969 Tdo2protein[AAI5192I;Daniorerio] 238(83%) 2e-I03 Iron ion binding; tryptophan 2,3- 2.816 0.347
dioxygenaseactivity
(00:0005506;00:0004833)
[A7MBU6]
Ferritin, heavysubunit [AC007472; 95(93%) 2e-44 Ferric iron binding; 2.815
Oncorhynchllsmykiss] oxidoreductase activity
(00:0008199;00:0016491)
[CIBEL9]
Stress-induced-phosphoproteinl 803(99%) 0 Binding (00:0005488) [B5XOZ2]
putative mRNA [BT0447 I I; Salmo
salar](N)
Ferritin, middle subunit [ACI68639; 126(100%) 5e-70 Ferric iron binding (00:0008199) 2.804
Salll1osalar] [B5XCR9]
Liver-expressed antimicrobial peptide 90(99%) 7e-47 Biological Process: defense 2.798
2B [AARI1767; Oncorhynchlls response to bacterium
mykiss] (00:0042742) [Q64JE5]
C-Cmotifchemokine20precursor 76(91%) 2e-33 Chemokineactivity
[ACI66945;Salll1osalar] (00:0008009)[B5X7X5]
Onmycontig mRNA sequence 596(94%) 0 Unknown 2.788 0.047
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[EZ763364;Oncorhynchllsmykiss](N)
40S ribosomal protein S4 [ACNI0029; 177(99%) ge-96 Structural constituent of ribosome 2.775 0.485
Salmosalar] (GO:0003735) [COH7LO]
Glyceraldehyde-3-phosphate 162(99%) 2e-85 NAD or NADH binding; 2.773
dehydrogenase [ACI69846;Salmo glyceraldehyde-3-phosphate
salar] dehydrogenase
(phosphorylating)actiYity
(GO:0051287;GO:0004365)
[B5XG76]
Onmycontig mRNA sequence 596(99%) 0 Unknown 2.768
[EZ763389;Oncorhynchllsmykiss](N)
Onmycontig mRNA sequence 602(99%)
[EZ799738; Oncorhynchlls mykiss](N)
Fructose-bisphosphate aldolase A 136(100%) 3e-74 Fructose-bisphosphatealdolase
[ACNI0700;Salmosalar] actiYity(GO:0004332)
[COH911]
DNA-directed RNA polymerases I, 11, 617(99%) 0 DNA binding; DNA-directed
and III subunit RPABC2 putative RNApolymeraseactiYity
mRNA [BT057259; Salmo salar] (N) (GO:0003677;GO:0003899)
[B9ENN4]
Adult-type muscle actin 2 [CAX48983; 52(91%) 8e-20 ATPbinding; protein binding 2.745 0.528
Botlyllllsschlosseri] (GO:0005524;GO:0005515)
[COMP46]
Zgc: 101080 [AAH78275; Danio rerio] 68(68%) 5e-11 Cellular Component: centrosome;
gamma-tubulin ring complex;
spindle (GO:0005813;
GO:OO08274;GO:0005819)
[Q6DCI7]
Beta-2-glycoprotein I precursor 132(96%) Je-71 Unknown [COH7UI]
[ACNIOIJO;Salmosalar]
Embryonicbeta-typeglobin2 131(89%) 2e-59 Hemebinding; oxygen binding; 2.736 0.328
[BAA34951; Oncorhynchlls mykiss] oxygentransporteractiYity
(GO:0020037;GO:0019825;
GO:0005344) [Q9YGF4]
Ferritin, middle subunit [ACI33572; 106(100%) 3e-56 Ferric iron binding;
Salmosalar] oxidoreductaseactiYity
(GO:0008199;GO:OOI6491)
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157(100%)
60S ribosomal protein LIOa[ACI69173; 159(99%)
Salmosalar]
Onmycontig mRNA sequence 341 (83%)
[EZ78355 I; Oncorhynchlls mykiss] (N)
Onmycontig mRNA sequence 383 (96%)
[EZ764029; Oncorhynchus mykiss](N)
Integral membrane protein 2B 108(99%)
[ACN 10658; Salmo salar]
Zgc: 85729 [AAH70008; Danio rerio] 208 (99%)
148(100%)
302(92%)
Heat shock protein 70 isoform 3 108(99%)
[ACH70704; Salmo salar]
Beta-2microglobulintype2 64(97%)
[AAP51 056; Oncorhynchus mykiss]
43(96%)
39(95%)
Brain protein 44-like protein 71 (96%)
[AC007659; Oncorhynchus mykiss]
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[B5X2PI]
NAD or NADH binding;
glyceraldehyde-3-phosphate
dehydrogenase
(phosphorylating) activity
(GO:0051287;GO:0004365)
[B5XG76]
RNA binding (GO:0003723)
[B5XEA3]
Unknown
Unknown [COH9D9]
Phosphoprotein phosphatase
activity (GO:000472 I)
[Q6NSN6;]
Lipid binding (GO:0008289)
[B5XFF2]
Ferric iron binding;
oxidoreductase activity
(GO:0008199;GO:0016491)
[COH718]
ATPbinding(GO:0005524)
[B5DG30]
Cellular Component: MHC class I
protein complex (GO:0042612)
[Q6XQIO]
Sugar binding (GO:0005529)
[Q4LAN6]
Protein binding; zinc ion binding
(GO:0005515;GO:0008270)
[Q4SJ95]
Unknown [CIBF56]
Beta-2-microglobulinprecursorputative 552(99%) 0 Unknown [B5X5Y2] 2.650 0.409
mRNA [BT04645I ; Salmo salar] (N)
CB514575 TransportproteinSec61 subunitalpha 759(99%)
isoform B putative mRNA
[BT072062;Salmosalar](N)
Onmycontig mRNA sequence 732(91%) 0 Unknown 2.619 0.516
[EZ771593; Oncorhynchus mykiss] (N)
Small EDRK-rich factor 2 [AC007539; 61(100%) 2e-26 Unknown [C I BET6]
Oncorhynchusmykiss]
Hypothetical membrane associated 29(69%) 3e-06 Unknown [QI WR24]
protein [ABE00674;Laclobacillus
salivarius
UCCI18]
Ldhbprotein[AAH44190;Daniorerio] 97(84%) 3e-41 L-Iactate dehydrogenase activity;
binding (GO:0004459;
GO:0005488) [Q803U5]
Onmycontig mRNA sequence 689(95%) 0 Unknown
[EZ765737; Oncorhynchus mykiss](N)
Onmycontig mRNA sequence 558(99%)
[EZ763364; Oncorhynchus mykiss] (N)
40S ribosomal protein S27 [ABJ98653; 87(98%) 2e-37 Metal ion binding; structural 2.605 0.573
Psellamaxima] constituent of ribosome
(GO:0046872;GO:0003735)
[AOEZY9]
Onmycontig mRNA sequence 616(99%) 0 Unknown
[EZ907372;Oncorhynchllsmykiss](N)
60S ribosomal protein L3 [ACI68315; 123(99%) 5e-68 Structural constituent of ribosome
Salmosalar] (GO:0003735) [B5XBU5]
Ribosomal protein L3-like [ACH70797; 169(100%) 4e-96 Structural constituent of ribosome
Salmosalar] (GO:0003735) [B5DGC3]
Interferon alpha I-like gene, complete 347(90%) le-114 Hormone activity (GO:0005179) 2.584
sequence; growth hormone I gene, [Q5SDSI]
complete cds; and skeletal muscle
sodium channel alphasubunit-like,
myosinalkalilightchain-like,and
microtubule-associated protein Tau-
like genes, complete sequence
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620(99%)
305(87%)
617(99%)
148(100%) 6e-80 Hemebinding; oxygen binding;
oxygenlransporteraclivily
(GO:0020037;GO:0019825;
GO:0005344) [CIBEM6]
798(99%) 0 Unknown
727(90%)
292(91%)
118(100%) 4e-60 Sugar binding (GO:0005529)
[COH8QI]
43(98%) 2e-07 Aclinbinding(GO:0003779)
[B5X6X6]
385(95%) 2e-162 Unknown
90(88%) 6e-37 Ferric iron binding (GO:0008199)
[B5XDB9]
109(100%) le-37 Unknown [B5XEG8]
subunilalpha[ACI69238;Sa/mo
sa/or]
CB496642 Microsomal glulalhione S-lransferase 3 122(100%) 2e-67 Transferaseaclivity
(GO:OO 16740) [C 1BHY4]
757(94%) 0 Unknown
36(70%) 3e-06 GTP binding (GO:0005525)
[Q4S015]
141(27%) 8e-07 CellularComponenl: inlegrallo
membrane (GO:0016021)
[B4DLP9]
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Zinc transporter 7 putative mRNA 653(99%) 0 Cation transmembrane transporter
[BT045478;Salmosalar](N) activity (GO:0008324)
[B5X359]
Brain protein 44-like protein 103(100%) 4e-54 Unknown [B5X6D4] 2.508
[ACI66404;Salmosalar]
Fructose-bisphosphatealdolaseB 48(90%) 2e-15 Fructose-bisphosphatealdolase 2.503 0.278
[ACN 10100; Salmo salar] activity (GO:0004332)
[COH7TI]
Onmycontig mRNA sequence 470(93%) 0 Unknown
[EZ764857; Oncorhynchlls mykiss] (N)
RCC2 homolog [ACI33792; Salmo 56(75%) 3e-26 DNA binding; transposase 2.498
salar] activity (GO:0003677;
GO:0004803) [B5X3BI]
Adenine nucleotide translocator s598 41(88%) 2e-23 Binding; transporter activity 2.492 0.251
[BAD86711; Takifllgll rllbripes] (GO:0005488 GO:0005215)
[Q5KSP2]
Ancient ubiquitous protein 1 precursor 38(93%) 4e-12 Acyltransferaseactivity 2.485 0.499
[ACI33926;Salmosalar] (GO:00084 I5) [B5X3P5]
Sporozoite surface protein 2 precursor 82(49%) 6e-06 Unknown [B5X2L3]
[ACI33544;Salmosalar]
EG780477 Unknown 2.467 0.397
EG898703 Beta actin isoform 1 [BAG 12566; Solea 244(96%) 2e-130 ATPbinding;proteinbinding 2.465 0.127
(GO:0005524;GO:OO05515)
[BIB560]
Hemoglobin subunit beta [ACI68762; 94(91%) ge-38 Heme binding; oxygen binding;
Salmosalar] oxygen transporter activity
(GO:0020037;GO:0019825;
GO:0005344) [B5XD42]
Ferritin, middle subunit [ACI66713; 181(99%) 8e-100 Ferric iron binding (GO:0008199)
Salmosalar] [B5X793]
ATPsynthase H+transporting 56(88%) 4e-19 ATPbinding;hydrogen ion
mitochondrialFI complex beta transporting ATP synthase
[ACH85277; Salmo salar] activity, rotational mechanism;
hydrogen-exporting ATPase
activity, phosphorylative
mechanism; proton-transporting
ATPase activity, rotational
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EG790867 Unknown
CA044962 Onmycontig mRNA sequence 571(97%)
[EZ763684; Oncorhynchus mykiss] (N)
Eukaryotictranslation initiation factor 3 106(99%)
subunit 3 [AC008262; Oncorhynchus
mykiss]
Heat shock protein 70 isoform 3 111(100%)
[ACH70704; Salmo salar]
TransportproteinSec61 subunitbeta 98(100%)
[ACI69157;Salmosalar]
Malate dehydrogenase, mitochondrial 130(100%)
precursor [ACI66104; Salmosalar]
Ferritin heavy subunit [AAB34575; 120(94%)
Salmosalar]
Membrane-spanning4-domains 67(98%)
subfamily A member 4A [ACI69003;
Salmosalar]
Onmycontig mRNA sequence 744(93%)
[EZ801426; Oncorhynchusmykiss](N)
Onmycontig mRNA sequence 675(92%)
[EZ905927; Oncorhynchus mykiss] (N)
Glutathione S-transferase P [ACI70112; 62(100%)
Salmosalar]
Onrnycontig mRNA sequence 179(98%)
[EZ774133; Oncorhynchusmykiss](N)
Chibby homolog 1 [ACI68079; Salmo 117(100%)
salar]
Beta-2-microglobulinprecursor 49(100%)
[ACM08831; Salmo salar]
88(97%)
154(79%)
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mechanism (GO:0005524;
GO:0046933;GO:0008553;
GO:0046961) [B5RI36]
Translation initiation factor
activity (GO:0003743)
[CIBGV9]
ATP binding (GO:0005524)
[B5DG30]
Unknown [B5XE87]
L-malate dehydrogenase activity
(GO:0030060) [B5X514]
Ferric iron binding; ferroxidase
activity (GO:0008199;
GO:0004322) [P49946]
Cellular Component: integral to
membrane (GO:0016021)
[B5XDT3]
Unknown
Unknown
Glutathione transferase activity
(GO:0004364) [B5XGZ2]
Unknown
Unknown [B5XB59]
Cellular Component: MHC class 1
protein complex (GO:0042612)
[B9EMT4]
Structuralmo!eculeactivity
(GO:0005198) [Q90W73]
Unknown [Q4QZ 18]
2.446 0.195
2.438 0.198
[CAJOI769;Oncorhynchllsmykiss]
Thymosin beta-12 [ACI67890; Salmo 43(100%) 2e-08 Actin binding (GO:0003779)
salar] [B5X6X6]
26Sproteasomenon-ATPaseregulatory 127(100%) le-58 Enzyme regulator activity
subunit 3 putative mRNA [BT059067; (GO:0030234) [COH9Rl]
Salmo salar] (N)
CB502821 PhvsicalmaDcontig483 fEU481821; 135(90%)
59(90%) 4e-25 Oxidoreductaseactivity,actingon
rerio] the CH-CH group of donors
(GO:0016627) [Q3B743]
CA041519 Glutathione S-transferase theta-I 157(100%) 3e-84 Transferase activity
[ACI66470;Salmosalar] (GO:0016740) [B5X6KO]
CB517969 TransposableelementTcb2transposase 74(84%) 2e-33 Unknown [B5X8Z6]
[ACI67316;Salmosalar]
Onmycontig mRNA sequence 275(95%)
[EZ763364;Oncorhynchllsmykiss](N)
GTPcyclohydrolase 1 feedback 89(100%) 4e-45 Hydrolase activity; protein
regulatory protein [ACI69203;Salmo binding (GO:0016787;
salar] GO:0005515) [B5XED3]
CA052820 Onmycontig mRNA sequence 520(87%) 6e-153 Unknown
[EZ870780;Oncorhynchllsmykiss](N)
CB509736 Eukaryotictranslationinitiationfactor3, 290(99%) 2e-147 Translation initiation factor
subunit H mRNA [BT043978; Salmo activity (GO:0003743)
salar](N) [B5RI54]
124(100%) 5e-66 Ferric iron binding;
oxidoreductase activity
(GO:0008199;GO:0016491)
[CIBFEI]
Adenosylhomocysteinase B putative 659(95%) 0 Adenosylhomocysteinaseactivity;
mRNA [BT058783; Salmo salar] (N) binding (GO:0004013;
GO:0005488) [B5DGEO]
Novel protein (zgc: 153086) 159(68%) 3e-51 Unknown [BOS713]
[CAQI3556; Danio rerio]
Hemoglobin subunit beta-I [ACN09863; 98(100%) 4e-48 Hemebinding; oxygen binding;
Salmosalar] oxygen transporter actIVIty
(GO:0020037;GO:0019825;
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46(70%)
Histone HI.O [ACNlOI92; Salmosalar] 101 (98%)
Cell-surface antigen heavy chain 584(99%)
putative mRNA [BT059429; Salmo
salar](N)
NADH dehydrogenase I alpha 94 (100%)
subcomplexsubunit2[ACI68755;
Salmosalar]
56(99%)
Catalase putative mRNA [BT045615; 763 (99%)
Salmosalar](N)
Heatshockproteinhsp90beta 85(100%)
[AAD302751AF 135117; Salmo salar]
77(84%)
Delta-5fattyacyldesaturase(D5fad) 606(100%)
gene [GU294485;Salmosalar](N)
Guanine nucleotide binding protein beta 174(99%)
polypeptide2-like I [ACH70647;
Salmosalar]
Unnamed protein product [CAG06430; 139 (66%)
Tetraodol1l1igroviridis]
Onmycontig mRNA sequence 655 (99%)
[EZ826281;Oncorhynchusnerka](N)
Onmycontig mRNA sequence 532 (99%)
[EZ906965; Oncorhynchus mykiss] (N)
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GO:0005344) [COH744]
Glycoprotein6-alpha-L-
fucosyltransferaseactivity
(GO:0008424) [Q6EV75]
DNA binding (GO:0003677)
[COH823]
Catalytic activity; cation binding
(GO:0003824;GO:0043l69)
[COHAS3]
Cellular Component:
mitochondrial inner membrane;
respiratory chain (GO:0005743;
GO:0070469) [B5XD35]
DNA binding; DNA-directed
RNA polymerase activity
(GO:0003677;GO:0003899)
[CIBXK5]
Catalase activity; heme binding
(GO:0004096;GO:0020037)
[B5X3J6]
ATP binding; unfolded protein
binding (GO:0005524;
GO:0051082) [Q9W6K6]
Purine-nucleoside phosphorylase
activity (GO:0004731)
[Q6NYGO]
Oxidoreductase activity
(GO:0016491) [D2Y360]
Unknown [B5DFX3]
Unknown [Q4RYV2]
UDPglucuronosyltransferase I family 231(74%) 6e-101 Transferase activity, transferring 2.234 0.072
polypeptidea3 isoform 1 [ADC91921; hexosyl groups (GO:0016758)
Doniol'erio] [D3XD50]
Actin [AAK60616IAF330142; 110(100%) 3e-57 ATPbinding; protein binding 2.231 0.386
Oncol'hynchusmykiss] (GO:0005524;GO:0005515)
[Q90WC5]
CA045289 Unknown 2.229 0.259
CK990503 Unknown 2.227 0.468
DY715202 Elongation factor 2 [ACN58670; Solmo 65(77%) 4e-20 GTPbinding;translation 2.216 0.356
solar] elongation factor activity
(GO:0005525;GO:0003746)
[COPVE5]
Membrane-spanning4-domains 82(100%) ge-28 Cellular Component: integral to
subfamily A member 8A [ACI70074; membrane (GO:0016021)
Solmosolor] [B5XGV4]
Onmycontig mRNA sequence 240(85%) 3e-56 Unknown 2.199
[EZ826103; Oncol'hynchusnel'ko](N)
ApolipoproteinA-lprecursor 126(100%) 3e-52 Lipid binding (GO:0008289)
[ACI68193; Solmo salol'] [B5XBH3]
Kelch repeat and BTB (POZ) domain 76(97%) 8e-35 Protein binding (GO:0005515)
containing 10 [ACH70794;Solmo [B5DGCO]
solar]
Onmycontig mRNA sequence 321(86%)
[EZ764499;Oncol'hynchusmykiss](N)
Chromosome 20 open reading frame 149 725(98%) 0 Biological Process: cell
mRNA [BT043760; Solmo solar] (N) differentiation; multicellular
organismaldevelopment
(GO:0030154;GO:0007275)
[B5DGKI]
Onmycontig mRNA sequence 398(100%) 0 Unknown
[EZ764029; Oncol'hynchus mykiss] (N)
FGF2 [ACJ02099; Solmo salol'] 27(78%) ge-06 Growth factor activity
(GO:0008083) [C6EWZ5]
Transposase-like mRNA [BT043992; 687(100%) 0 DNAbinding;transposase
Solmosolol'](N) activity (GO:0003677;
GO:0004803) [B5RI68]
BAC CHORI214-92104 [EF427384; 566(99%) 0 Threonine-type endopeptidase 2.166 0.288
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Salmo salar] (N) activity (GO:0004298)
[A7KEOI]
3-ketoacyl-CoA thiolase,mitochondrial 686(99%) 0 Acyltransferaseactivity
putative mRNA [BT045547; Salmo (GO:00084 I5) [B5X3C8]
salar](N)
Disulfide-isomeraseA3precursor 55(70%) le-ID Isomerase activity (GO:0016853)
[ACI33158;Salmosalar] [B5XIH7]
Onmycontig mRNA sequence 394(100%) 0 Unknown
[EZ764029; Oncorhynchus mykiss] (N)
Onmycontig mRNA sequence 115(85%)
[EZ826561;Oncorhynchusnerka](N)
Very long-chain acyl-CoA synthetase 120(98%) le-90 Catalytic activity (GO:0003824)
[ACI34091;Salmosalar] [B5X460]
Cytochromeb-cl complexsubunit2, 222(100%) 8e-117 Metalloendopeptidaseactivity;
mitochondrial precursor [ACNI0092; zinc ion binding (GO:0004222;
Salmosalar] GO:000827) [COH7S3]
Unnamed protein product [CAF90593; 122(73%) 3e-44 Nucleic acid binding
Tetraodonnigroviridis] (GO:0003676) [Q4T939]
Hemoglobin subunit beta-4 [AC008020; 148(99%) ge-79 Hemebinding; oxygen binding;
Oncorhynchusmykiss] oxygen transporter activity
(GO:0020037;GO:0019825;
GO:0005344) [CIBG67]
Transposase [ABV31711; Salmo solar] 59(77%) le-19 DNA binding; transposase
activity (GO:0003677;
GO:0004803) [A8C514]
TransposableelementTcb2transposase 93(78%) le-33 Unknown [B5X8Z6]
[ACI67316;Salmosalar]
Properdin P factor 2 [CAPI7612; 141(100%) 6e-87 Unknown [A8YQG4]
Oncorhynchusmykiss]
Ependymin precursor [ACI68886; 36(98%) 2e-12 Calcium ion binding
Salmosalar] (GO:0005509) [B5XDG6]
Onmycontig mRNA sequence 623(94%) 0 Unknown 2.108
[EZ826574;Oncorhynchusnerka](N)
Unnamed protein product [CAF89670; 136(45%) 6e-25 Carbohydrate binding; catalytic 2.103 0.332
Tetraodonnigroviridis] activity (GO:0030246;
GO:0003824) [Q4TBR2]
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APPE DIX XIII. Supplemental figure showing growth performance data of six diploid GH
transgenic (2NGHTg) Atlantic salmon families (ASII, AS29, AS48, AS26, AS 33 and
AS25) during a period of approximately 45 days. A. Initial and final weight; B. Initial and
final length; C Weight-specific growth rate (SGRw); D. Length-specific growth rate
(SGRd. All data are presented as means (± SE). For all growth parameters presented in
panel A-D, different letters were used to identify significant differences (cut off p = 0.05)
among the six families enrolled in this study. In panel A and B, significant differences in
both initial weight and length among families were identified by different lower case
letters and significant differences among the six families were identified by different
upper case letters. In panel C and D, significant differences in weight- and length-specific
growth rates among families were identified by different upper case letters.
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APPENDIX XIV. Supplemental figure showing experimental design and results summary
of a 32K cDNA microarray study to identify differentially expressed hepatic transcripts
between diploids (2N) and triploids (3N) in three GHTg families. Within each
comparison, microarray features with more than 2-fold higher expression in a given
comparison (e.g. ASll 2N vs. 3N) in any three (including one dye-swap) out of four
technical replicate arrays (two duplicates, two dye-swaps). The base of each arrow
represents Cy3-labeled target and the head of each arrow represents the Cy5-labeled
target.
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AS11:2N> 3N (any30ut of4 slides): 46 microarray features (Appendix VII)
3N>2N(any30utof4slid s):1]3microarrayfeatures(AppendixVlllj
AS25:2N>3N(<lny30UIO(4slides):17microarrayfealures(AppendixlX)
3N>2N(any30utO(4slides):18micro<lrr<lyfealures(AppendixX)
AS29:2N>3N(any30utof4slides):124microarrayfeatures(AppendixXI)
3N > 2N(any 3 oUlof4slides):444 microarray fealures (Appendix XII)
Cy3 CyS
---..
278
APPENDIX XV. Supplemental figure showing QPCR results for genes of interest selected
from the 32K cDNA microarray the 2N vs. 3N study. Relative quantity with associated
standard error was determined to demonstrate relative gene expression level among three
OH transgenic families: AS 11, AS25 and AS29. Difference of expression level between
families for a single gene of interest was indicated by p value with a significance cutoff of
0.05 (p < 0.05, significant difference, indicated as asterisks; p ~ 0.05, no significant
difference, indicated as values).
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